## Guidelines for the management of atrial fibrillation

Europace 12, 1360-1420 DOI: 10.1093/europace/euq350

**Citation Report** 

#	Article	IF	CITATIONS
1	Reviews : VON KNUD KRAKAU. Die Harmon Doktrin : Eine These der Vereinigten Staaten zum internationalen Flubrecht. Hamburg, Institut fļr AuswÄ <b>¤</b> ige Politik, 1966. Pp. 139. Price not indicated. International Studies, 1967, 9, 372-373.	0.5	0
2	Pharmacological attenuation of apoptosis in reoxygenated endothelial cells. Cellular and Molecular Life Sciences, 2004, 61, 3076-3086.	2.4	9
4	The pharmaceutical pipeline for atrial fibrillation. Annals of Medicine, 2011, 43, 13-32.	1.5	13
5	Role of Emerging Antithrombotic Therapy in the Prevention of Cardioembolic Complications in Patients with Atrial Fibrillation. American Journal of Cardiovascular Drugs, 2011, 11, 265-275.	1.0	12
6	New treatment options for atrial fibrillation: towards patient tailored therapy. Heart, 2011, 97, 1796-1802.	1.2	10
7	Randomized study comparing duty-cycled bipolar and unipolar radiofrequency with point-by-point ablation in pulmonary vein isolation. Heart Rhythm, 2011, 8, 1383-1390.	0.3	71
9	Effect of Lenient Versus Strict Rate Control on Cardiac Remodeling in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2011, 58, 942-949.	1.2	44
10	The Effect of Rate Control on Quality of Life in Patients With Permanent Atrial Fibrillation. Journal of the American College of Cardiology, 2011, 58, 1795-1803.	1.2	131
11	Can We Predict Thromboembolic Events in Low-Risk Patients Undergoing Catheter Ablation of Atrial Fibrillation?. Journal of the American College of Cardiology, 2011, 58, 2386-2388.	1.2	1
12	Pre-admission CHADS2 score is related to severity and outcome of stroke. Journal of the Neurological Sciences, 2011, 307, 149-152.	0.3	26
13	Edoxaban. Drugs, 2011, 71, 1503-1526.	4.9	98
14	Is Antiarrhythmic Treatment in the Elderly Different?. Drugs and Aging, 2011, 28, 617-633.	1.3	29
15	Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace, 2011, 13, 308-328.	0.7	249
16	Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. Europace, 2011, 13, 610-625.	0.7	172
17	From Guidelines to Bench: Implications of Unresolved Clinical Issues for Basic Investigations of Atrial Fibrillation Mechanisms. Canadian Journal of Cardiology, 2011, 27, 19-26.	0.8	49
18	A Proud Tradition and a New Beginning With a Theme Issue on Atrial Fibrillation. Canadian Journal of Cardiology, 2011, 27, 5-6.	0.8	0
19	Hospitalizaciones asociadas al diagnóstico de fibrilación auricular en Chile: Tendencia creciente en la última década. Revista Chilena De CardiologÃa, 2011, 30, 193-197.	0.0	1
21	Managing atrial fibrillation in the elderly: critical appraisal of dronedarone. Clinical Interventions in Aging, 2012, 7, 1.	1.3	4

#	Article	IF	CITATIONS
22	Bleeding risk assessment and management in atrial fibrillation patients. Thrombosis and Haemostasis, 2011, 106, 997-1011	1.8	234
23	Association between Variants on Chromosome 4q25, 16q22 and 1q21 and Atrial Fibrillation in the Polish Population. PLoS ONE, 2011, 6, e21790.	1.1	31
24	Delaying cardioversion following 4-week anticoagulation in case of persistent atrial fibrillation after a transcatheter ablation procedure to reduce silent cerebral thromboembolism. Journal of Cardiovascular Medicine, 2011, 12, 785-789.	0.6	14
25	Late postoperative atrial fibrillation: minor surgery complication or major cardiovascular issue?. Journal of Cardiovascular Medicine, 2011, 12, 381-382.	0.6	1
26	Clinical advances in imaging: how useful is computed tomography for guiding and evaluating cardiac interventions. Interventional Cardiology, 2011, 3, 663-678.	0.0	0
27	Role of atrioventricular nodal ablation and pacemaker therapy in elderly patients with recurrent atrial fibrillation. Interventional Cardiology, 2011, 3, 713-720.	0.0	1
28	Time in the Therapeutic Range During Warfarin Therapy in Japanese Patients With Non-Valvular Atrial Fibrillation - A Multicenter Study of Its Status and Influential Factors Circulation Journal, 2011, 75, 2087-2094.	0.7	52
29	The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events. Journal of Internal Medicine, 2011, 270, 281-290.	2.7	34
30	Bleeding risk with oral anticoagulation - new frontiers and new questions. International Journal of Clinical Practice, 2011, 65, 719-721.	0.8	1
31	Effects of Dronedarone on Clinical Outcomes in Patients with Lone Atrial Fibrillation: Pooled Post Hoc Analysis from the ATHENA/EURIDIS/ADONIS Studies. Journal of Cardiovascular Electrophysiology, 2011, 22, 770-776.	0.8	14
32	Incidence of Silent Cerebral Thromboembolic Lesions After Atrial Fibrillation Ablation May Change According to Technology Used: Comparison of Irrigated Radiofrequency, Multipolar Nonirrigated Catheter and Cryoballoon. Journal of Cardiovascular Electrophysiology, 2011, 22, 961-968.	0.8	261
33	The Impact of Dronedarone on Lone Atrial Fibrillation: Perhaps Not Such a "Benign―Arrhythmia?. Journal of Cardiovascular Electrophysiology, 2011, 22, 777-780.	0.8	1
34	New Anticoagulants for Prevention of Stroke in Patients with Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2011, 22, 948-955.	0.8	19
35	Time-Related Prevalence of Postoperative Atrial Fibrillation After Stand-Alone Minimally Invasive Radiofrequency Ablation. Journal of Cardiac Surgery, 2011, 26, 453-459.	0.3	6
36	Role of oral amiodarone in patients with atrial fibrillation and congestive heart failure. Journal of Cardiology, 2011, 58, 108-115.	0.8	17
37	Novel pharmacological targets for the rhythm control management of atrial fibrillation. , 2011, 132, 300-313.		29
38	A hybrid stimulation strategy for suppression of spiral waves in cardiac tissue. Chaos, Solitons and Fractals, 2011, 44, 633-639.	2.5	7
39	Catheter Ablation for Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 2296-2304.	13.9	82

#	Article	IF	CITATIONS
40	Is CHA2DS2-VASc score a predictor of left atrial thrombus in patients with paroxysmal atrial fibrillation?. Thrombosis and Haemostasis, 2011, 105, 1107-1109.	1.8	21
41	Risk-benefit ratio assessment for stroke prevention in intermediate risk atrial fibrillation patients: will TEE-based aspirin treatment fill the gap?. Netherlands Heart Journal, 2011, 19, 212-213.	0.3	1
42	Regenerative therapies in electrophysiology and pacing: introducing the next steps. Journal of Interventional Cardiac Electrophysiology, 2011, 31, 3-16.	0.6	10
43	Progression of new onset to established persistent atrial fibrillation: an implantable device-based analysis with implications for clinical classification of persistent atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2011, 32, 7-15.	0.6	13
44	Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14–16, 2010, São Paulo, Brazil. Journal of Thrombosis and Thrombolysis, 2011, 32, 242-266.	1.0	2
45	Atrial Fibrillation and Percutaneous Coronary Intervention: Stroke, Thrombosis, and Bleeding. Current Treatment Options in Cardiovascular Medicine, 2011, 13, 203-214.	0.4	1
46	What is the role of the cardiologist in future management of stroke prevention in atrial fibrillation?. Advances in Therapy, 2011, 28, 1-12.	1.3	5
47	Update on the Management of Atrial Fibrillation: Anticoagulation and Medical Therapy. Current Cardiology Reports, 2011, 13, 387-393.	1.3	0
48	Ranolazine versus amiodarone for prevention of postoperative atrial fibrillation. Future Cardiology, 2011, 7, 733-737.	0.5	6
49	Regulatory pathways for development of antiarrhythmic drugs for management of atrial fibrillation/flutter. Europace, 2011, 13, 1063-1076.	0.7	12
50	Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. Europace, 2011, 13, 1110-1117.	0.7	152
51	Anticoagulation in people with atrial fibrillation. BMJ: British Medical Journal, 2011, 342, d530-d530.	2.4	1
55	Prognostic importance of natriuretic peptides and atrial fibrillation in patients receiving cardiac resynchronization therapy. European Journal of Heart Failure, 2011, 13, 543-550.	2.9	28
56	Fish Oil for Secondary Prevention of Atrial Fibrillation. Circulation, 2011, 124, 1093-1096.	1.6	12
57	Incident Stroke and Mortality Associated With New-Onset Atrial Fibrillation in Patients Hospitalized With Severe Sepsis. JAMA - Journal of the American Medical Association, 2011, 306, 2248-54.	3.8	372
58	Current Ablation Strategies for Persistent and Long-Standing Persistent Atrial Fibrillation. Cardiology Research and Practice, 2011, 2011, 1-9.	0.5	12
59	Rationale and current perspective for early rhythm control therapy in atrial fibrillation. Europace, 2011, 13, 1517-1525.	0.7	55
60	Thoracoscopic Video-Assisted Pulmonary Vein Antrum Isolation, Ganglionated Plexus Ablation, and Periprocedural Confirmation of Ablation Lesions. Circulation: Arrhythmia and Electrophysiology, 2011 4, 262-270	2.1	193

#	Article	IF	CITATIONS
61	The HAS-BLED Score and Renal Failure: Response. Chest, 2011, 139, 1249-1250.	0.4	2
62	Polyunsaturated fatty acids for prevention of atrial fibrillation: a 'fishy' story. Europace, 2011, 13, 149-152.	0.7	12
63	An epidemic of atrial fibrillation?. Europace, 2011, 13, 1059-1060.	0.7	5
64	A New Landscape for Stroke Prevention in Atrial Fibrillation. Stroke, 2011, 42, 3316-3322.	1.0	26
65	Mixed treatment comparisons for atrial fibrillation: evidence network or bewildering entanglement?. Europace, 2011, 13, 295-296.	0.7	7
66	Efficacy and safety of pulmonary veins isolation by cryoablation for the treatment of paroxysmal and persistent atrial fibrillation. Europace, 2011, 13, 789-795.	0.7	48
67	Atrial fibrillation ablation: a cost or an investment?. Europace, 2011, 13, ii39-ii43.	0.7	6
68	Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. Europace, 2011, 13, 1118-1126.	0.7	33
69	Prognostic value of total atrial conduction time estimated with tissue Doppler imaging to predict the recurrence of atrial fibrillation after radiofrequency catheter ablation. Europace, 2011, 13, 1533-1540.	0.7	85
70	Invasive therapy for atrial fibrillation: recent developments in ablation, navigation and mapping technology. Heart, 2011, 97, 237-243.	1.2	12
71	Statins and atrial fibrillation: do we need a further study?. Expert Review of Cardiovascular Therapy, 2011, 9, 801-804.	0.6	5
72	Left Atrial Remodeling and Response to Valsartan in the Prevention of Recurrent Atrial Fibrillation. Circulation: Cardiovascular Imaging, 2011, 4, 721-728.	1.3	14
73	Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace, 2011, 13, 723-746.	0.7	197
74	Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. European Heart Journal, 2011, 32, 1968-1976.	1.0	61
76	Incidence and predictors of asymptomatic atrial fibrillation in patients older than 70 years with complete atrioventricular block and dual chamber pacemaker implantation. Croatian Medical Journal, 2011, 52, 61-67.	0.2	12
77	Ablation for Atrial Fibrillation in Combination With Left Atrial Appendage Closure: First Results of a Feasibility Study. Journal of the American Heart Association, 2012, 1, e002212.	1.6	85
79	Polyunsaturated Fatty Acids in Atrial Fibrillation: Looking for the Proper Candidates. Frontiers in Physiology, 2012, 3, 370.	1.3	4
80	Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) Trial. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 43-51.	2.1	147

#	Article	IF	CITATIONS
81	High Risk of QT Interval Prolongation and Torsades de Pointes Associated with Intravenous Quinidine Used for Treatment of Resistant Malaria or Babesiosis. Antimicrobial Agents and Chemotherapy, 2012, 56, 4495-4499.	1.4	17
82	Long-Term Frequency Gradients During Persistent Atrial Fibrillation in Sheep Are Associated With Stable Sources in the Left Atrium. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 1160-1167.	2.1	65
83	Improving Thromboprophylaxis Using Atrial Fibrillation Diagnostic Capabilities in Implantable Cardioverter-Defibrillators. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 182-188.	0.9	33
84	Prescribing anticoagulation medication for the elderly. Aging Health, 2012, 8, 205-216.	0.3	1
85	Catheter ablation for atrial fibrillation: who, why and does it work?. Postgraduate Medical Journal, 2012, 88, 604-611.	0.9	4
86	Effect of Sodium Nitroprusside on the Occurrence of Atrial Fibrillation after Cardiothoracic Surgery. Annals of Pharmacotherapy, 2012, 46, 785-792.	0.9	8
87	Net Clinical Benefit of Warfarin. Circulation, 2012, 125, 2285-2287.	1.6	6
89	Post-operative atrial fibrillation: a maze of mechanisms. Europace, 2012, 14, 159-174.	0.7	322
90	Arrhythmia-induced cardiomyopathies: the riddle of the chicken and the egg still unanswered?. Europace, 2012, 14, 466-473.	0.7	51
92	Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. European Journal of Heart Failure, 2012, 14, 295-301.	2.9	96
93	Lifestyle risk reduction interventions in atrial fibrillation: a systematic review. European Journal of Preventive Cardiology, 2012, 19, 1091-1100.	0.8	17
94	The importance of whether atrial fibrillation or heart failure develops first. European Journal of Heart Failure, 2012, 14, 1030-1040.	2.9	70
95	Efficacy and Safety of Vernakalant in Recentâ€Onset Atrial Fibrillation After the European Medicines Agency Approval: Systematic Review and Metaâ€Analysis. Journal of Clinical Pharmacology, 2012, 52, 1872-1878.	1.0	24
97	Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial fibrillation: a meta-analysis. Europace, 2012, 14, 1490-1497.	0.7	78
98	Accuracy of oscillometric blood pressure monitors for the detection of atrial fibrillation: a systematic review. Expert Review of Medical Devices, 2012, 9, 635-640.	1.4	23
99	Clinical evidence of the role of edoxaban in anticoagulation. Clinical Investigation, 2012, 2, 199-206.	0.0	0
100	Antiarrhythmic properties of ranolazine – from bench to bedside. Expert Opinion on Investigational Drugs, 2012, 21, 1733-1741.	1.9	9
101	Cerebral Microbleeds on Magnetic Resonance Imaging and Anticoagulant-Associated Intracerebral Hemorrhage Risk. Frontiers in Neurology, 2012, 3, 133.	1.1	84

#	Article	IF	CITATIONS
102	Better prevention of stroke through screening for atrial fibrillation. British Journal of General Practice, 2012, 62, 234-235.	0.7	2
103	Stroke Prevention in Atrial Fibrillation: Where are We Now?. Clinical Medicine Insights: Cardiology, 2012, 6, CMC.S8976.	0.6	9
104	ESC-EURObservational Research Programme: the Atrial Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm Association. Europace, 2012, 14, 1094-1103.	0.7	123
105	Chloroquine Terminates Stretch-Induced Atrial Fibrillation More Effectively Than Flecainide in the Sheep Heart. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 561-570.	2.1	38
106	Catheter Ablation to Maintain Sinus Rhythm. Circulation, 2012, 125, 1439-1445.	1.6	53
107	Minimally invasive thoracoscopic hybrid treatment of lone atrial fibrillation: early results of monopolar versus bipolar radiofrequency source. Interactive Cardiovascular and Thoracic Surgery, 2012, 14, 445-450.	0.5	47
108	Upper Normal Blood Pressures Predict Incident Atrial Fibrillation in Healthy Middle-Aged Men. Hypertension, 2012, 59, 198-204.	1.3	139
109	CardioPulse Articles. European Heart Journal, 2012, 33, 147-156.	1.0	6
110	A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation. European Heart Journal, 2012, 33, 2163-2171.	1.0	50
111	Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic optionsa report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace, 2012, 14, 8-27.	0.7	193
112	Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents. Europace, 2012, 14, 312-324.	0.7	32
113	Possible refinement of clinical thromboembolism assessment in patients with atrial fibrillation using echocardiographic parameters. Europace, 2012, 14, 36-45.	0.7	64
114	The role of echocardiography in stroke risk assessment in patients with atrial fibrillation: is it additive or does it simply echo clinical risk factors?. Europace, 2012, 14, 1-2.	0.7	7
115	Role of inflammation in early atrial fibrillation recurrence. Europace, 2012, 14, 810-817.	0.7	79
116	Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. Europace, 2012, 14, 666-674.	0.7	114
117	Pacemaker clinics and anticoagulation for atrial fibrillation. Europace, 2012, 14, 1375-1375.	0.7	2
118	Reduced connexin40 protein expression in the right atrial appendage of patients bearing the minor connexin40 allele (⒒44 G → A). Europace, 2012, 14, 1199-1205.	0.7	5
119	Mesh ablator vs. cryoballoon pulmonary vein ablation of symptomatic paroxysmal atrial fibrillation: results of the MACPAF study. Europace, 2012, 14, 1441-1449.	0.7	23

	Сітат	tion Report	
#	ARTICLE	IF	CITATIONS
120	Prognostic value of left atrial expansion index and exercise-induced change in atrial natriuretic peptide as long-term predictors of atrial fibrillation recurrence. Europace, 2012, 14, 1302-1310.	0.7	15
121	Periprocedural anticoagulation therapy for devices and atrial fibrillation ablation. Europace, 2012, 14, 741-744.	0.7	19
122	Adenosine plus dipyridamole: a novel strategy to enhance adenosine-induced conduction recovery after pulmonary vein isolation. Europace, 2012, 14, 1567-1571.	0.7	7
123	The impact of atrial fibrillation on quality of life of the elderly: the calm before the storm?. Europace, 2012, 14, 1379-1380.	0.7	0
124	Surgical and hybrid atrial fibrillation ablation procedures. Europace, 2012, 14, 939-941.	0.7	19
125	Management of ventricular and atrial arrhythmias in humans: towards a patient-specific approach. Europace, 2012, 14, v125-v128.	0.7	1
126	Individualized therapy in patients with atrial fibrillation: new look at atrial fibrillation. Europace, 2012, 14, v121-v124.	0.7	4
127	Atrial fibrillation: is there evidence to support an early ablation strategy?. Europace, 2012, 14, 613-614.	0.7	Ο
128	The role of action potential alternans in the initiation of atrial fibrillation in humans: a review and future directions. Europace, 2012, 14, v58-v64.	0.7	45
129	An Algorithm for the Practical Management of the New Onset of Atrial Fibrillation in Patients Admitted to the ICU. ICU Director, 2012, 3, 179-184.	0.2	2
130	Pacemaker clinic: an opportunity to detect silent atrial fibrillation and improve antithrombotic treatment: Response. Europace, 2012, 14, 1375-1376.	0.7	1
131	Stroke Prevention in Atrial Fibrillation: Concepts and Controversies. Current Cardiology Reviews, 2012, 8, 290-301.	0.6	12
132	Obesity, Diabetes and Atrial Fibrillation; Epidemiology, Mechanisms and Interventions. Current Cardiology Reviews, 2012, 8, 253-264.	0.6	74
133	Oral IIa and Xa Inhibitors for Prevention of Stroke in Atrial Fibrillation: Clinical Studies and Regulatory Considerations. Current Clinical Pharmacology, 2012, 7, 166-174.	0.2	3
134	Long-term Success and Follow-up After Atrial Fibrillation Ablation. Current Cardiology Reviews, 2012, 8, 354-361.	0.6	17
135	Atrial Fibrillation. Chest, 2012, 141, 290-292.	0.4	Ο
136	Pharmacokinetics of the Direct Factor Xa Inhibitor Edoxaban and Digoxin Administered Alone and in Combination. Journal of Cardiovascular Pharmacology, 2012, 60, 335-341.	0.8	29
137	Pharmacokinetics of the Direct Factor Xa Inhibitor Edoxaban and Digoxin Administered Alone and in Combination. Journal of Cardiovascular Pharmacology, 2012, Publish Ahead of Print, .	0.8	32

	CHAILON		
#	Article	IF	CITATIONS
138	Medical treatment of atrial fibrillation. Journal of Cardiovascular Medicine, 2012, 13, 97-107.	0.6	20
139	Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Thrombosis and Haemostasis, 2012, 107, 1100-1106.	1.8	30
140	Atrieflimmer, fysisk aktivitet og utholdenhetstrening. Tidsskrift for Den Norske Laegeforening, 2012, 132, 295-299.	0.2	23
143	Managing anticoagulation in patients receiving implantable cardiac devices. Future Cardiology, 2012, 8, 393-411.	0.5	1
144	Stroke and Thromboembolism in Atrial Fibrillation. Circulation Journal, 2012, 76, 2289-2304.	0.7	131
145	The long and short of antiarrhythmic drug treatment. Lancet, The, 2012, 380, 198-200.	6.3	2
146	Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study. Journal of Thrombosis and Haemostasis, 2012, 10, 1745-1751.	1.9	105
147	Increased intracardiac vascular endothelial growth factor levels in patients with paroxysmal, but not persistent atrial fibrillation. Europace, 2012, 14, 948-953.	0.7	29
148	Vitamin K antagonists. Hamostaseologie, 2012, 32, 249-257.	0.9	8
149	Management of Atrial Fibrillation: Direct Factor IIa and Xa Inhibitors or "Warfarin Shotgun�. Mount Sinai Journal of Medicine, 2012, 79, 705-720.	1.9	1
151	Adverse effects of permanent atrial fibrillation on heart failure in patients with preserved left ventricular function and chronic right apical pacing for complete heart block. Clinical Research in Cardiology, 2012, 101, 829-836.	1.5	8
152	Pharmacology of myocardial calcium-handling. Wiener Medizinische Wochenschrift, 2012, 162, 311-315.	0.5	1
153	Predictors of left atrium appendage clot detection despite on-target warfarin prevention for atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2012, 35, 151-158.	0.6	16
154	Approaching a Paradigm Shift: Endoscopic Ablation of Lone Atrial Fibrillation on the Beating Heart. Annals of Thoracic Surgery, 2012, 94, 1886-1892.	0.7	45
155	Prospective observational studies of the management and outcomes in patients with atrial fibrillation: A systematic review. Journal of the Saudi Heart Association, 2012, 24, 243-252.	0.2	8
156	Paroxysmal Supraventricular Tachycardias and Preexcitation Syndromes. Revista Espanola De Cardiologia (English Ed ), 2012, 65, 456-469.	0.4	2
159	2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design. Heart Rhythm, 2012, 9, 632-696.e21.	0.3	1,541
160	Stroke aetiology in heart failure: towards patientâ€ŧailored prevention of stroke. European Journal of Heart Failure, 2012, 14, 230-231.	2.9	2

#	Article	IF	CITATIONS
161	Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure, 2012, 14, 1171-1178.	2.9	57
162	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Europace, 2012, 14, 1385-1413.	0.7	2,319
164	Taquicardias paroxÃsticas supraventriculares y sÃndromes de preexcitación. Revista Espanola De Cardiologia, 2012, 65, 456-469.	0.6	31
165	International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). American Heart Journal, 2012, 163, 13-19.e1.	1.2	195
166	International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation. American Heart Journal, 2012, 163, 804-811.	1.2	32
167	Genetic Loci on Chromosomes 4q25, 7p31, and 12p12 Are Associated With Onset of Lone Atrial Fibrillation Before the Age of 40 Years. Canadian Journal of Cardiology, 2012, 28, 191-195.	0.8	50
168	Surgical ablation for atrial fibrillation. Europace, 2012, 14, 1545-1552.	0.7	18
169	Management of Atrial Fibrillation in Patients With Structural Heart Disease. Circulation, 2012, 125, 945-957.	1.6	106
171	Could successful cryoballoon ablation of paroxysmal atrial fibrillation prevent progressive left atrial remodeling?. Cardiovascular Ultrasound, 2012, 10, 11.	0.5	9
172	Left atrial pathological degeneration assessed by integrated backscatter transesophageal echocardiography as a predictor of progression to persistent atrial fibrillation: Results from a prospective study of three-years follow-up. Cardiovascular Ultrasound, 2012, 10, 28.	0.5	10
173	The hybrid approach for the surgical treatment of lone atrial fibrillation: One-year results employing a monopolar radiofrequency source. Journal of Cardiothoracic Surgery, 2012, 7, 71.	0.4	61
174	Cardiovascular Phenotype in Turner Syndrome—Integrating Cardiology, Genetics, and Endocrinology. Endocrine Reviews, 2012, 33, 677-714.	8.9	186
176	New Oral Anticoagulants. Drugs, 2012, 72, 1739-1753.	4.9	76
177	Burden of atrial fibrillation and poor rate control detected by continuous monitoring and the risk for heart failure hospitalization. American Heart Journal, 2012, 164, 616-624.	1.2	45
178	Does the Left Atrial Appendage Morphology Correlate With the Risk of Stroke in Patients With Atrial Fibrillation?. Journal of the American College of Cardiology, 2012, 60, 531-538.	1.2	683
179	Clinical management of atrial fibrillation: early interventions, observation, and structured follow-up reduce hospitalizations. American Journal of Emergency Medicine, 2012, 30, 1962-1969.	0.7	26
180	Rate or Rhythm Control for Atrial Fibrillation: Update and Controversies. American Journal of Medicine, 2012, 125, 1049-1056.	0.6	21
181	The role of imaging to support catheter ablation of atrial fibrillation. Cor Et Vasa, 2012, 54, e375-e385.	0.1	4

#	Article	IF	CITATIONS
182	Characterization of atrial fibrillation and the effect of pulmonary vein antrum isolation in endurance athletes. Journal of Arrhythmia, 2012, 28, 175-181.	0.5	1
184	Atrial fibrillation with a giant left atrial appendage can be successfully treated with pulmonary vein antrum isolation. Netherlands Heart Journal, 2012, 20, 179-181.	0.3	7
185	Pulmonary vein remapping: Adequate shortcut or cut too short?. Heart Rhythm, 2012, 9, 926-927.	0.3	1
186	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. European Heart Journal, 2012, 33, 2719-2747.	1.0	3,144
187	Mechanisms of Arrhythmias and Conduction Disorders in Older Adults. Clinics in Geriatric Medicine, 2012, 28, 555-573.	1.0	80
188	Initiation and Persistence with Warfarin Therapy in Atrial Fibrillation According to Ethnicity. Frontiers in Pharmacology, 2012, 3, 123.	1.6	2
189	Prescribing of Potentially Inappropriate Medications for the Elderly. Deutsches Ärzteblatt International, 2012, 109, 69-75.	0.6	73
190	Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban. Thrombosis, 2012, 2012, 1-10.	1.4	12
191	Left atrial appendage closure in secondary prevention of stroke in a patient with atrial fibrillation as well as prior stroke and iatrogenic intracranial haemorrhage. Postepy W Kardiologii Interwencyjnej, 2012, 3, 250-252.	0.1	1
192	Substrate of complex fractionated atrial electrograms: evidence by pathologic analysis. Chinese Medical Journal, 2012, 125, 4393-4397.	0.9	3
193	Early Experience Using a Left Atrial Appendage Occlusion Device in Patients with Atrial Fibrillation. Yonsei Medical Journal, 2012, 53, 83.	0.9	7
194	UP TO DAY POSSIBILITIES OF ATRIAL FIBRILLATION PREVENTION. Rational Pharmacotherapy in Cardiology, 2012, 8, 561-568.	0.3	0
195	RISK OF THROMBOEMBOLIC COMPLICATIONS AND ANTITHROMBOTIC THERAPY IN IN-PATIENTS WITH PERMANENT AND RECURRENT ATRIAL FIBRILLATION IN REAL CLINICAL PRACTICE. Rational Pharmacotherapy in Cardiology, 2012, 8, 675-680.	0.3	4
196	Spontaneous Sinus Conversion of Permanent Atrial Fibrillation During Treatment of Hyperkalemia. Korean Circulation Journal, 2012, 42, 65.	0.7	5
197	An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation. Core Evidence, 2012, 7, 49.	4.7	12
198	Apixaban: a new option for stroke prevention in atrial fibrillation?. Future Prescriber, 2012, 13, 8-13.	0.1	0
199	Treatment of lone atrial fibrillation: a look at the past, a view of the present and a glance at the future. European Journal of Cardio-thoracic Surgery, 2012, 41, 1284-1294.	0.6	31
200	Anticoagulant therapy for patients with ischaemic stroke. Nature Reviews Neurology, 2012, 8, 319-328.	4.9	28

#	Article	IF	CITATIONS
201	Novel Anticoagulants for Atrial Fibrillation. Angiology, 2012, 63, 164-170.	0.8	13
202	Cryoballoon in atrial fibrillation ablation. Herz, 2012, 37, 153-158.	0.4	2
203	Atrial fibrillation and diabetes mellitus. Herz, 2012, 37, 258-263.	0.4	4
205	Can computer tomography help predict feasibility of transseptal puncture after percutaneous closure of an interatrial septal communication?. Journal of Interventional Cardiac Electrophysiology, 2012, 34, 167-172.	0.6	9
206	N-terminal pro-B-type natriuretic peptide level at long-term follow-up after atrial fibrillation ablation: a marker of reverse atrial remodelling and successful ablation. Journal of Interventional Cardiac Electrophysiology, 2012, 34, 129-136.	0.6	24
207	Ablation for atrial fibrillation: what are acceptable levels of experience, efficacy, and complications?. Journal of Interventional Cardiac Electrophysiology, 2012, 34, 125-128.	0.6	1
208	Mutation spectrum of the GATA4 gene in patients with idiopathic atrial fibrillation. Molecular Biology Reports, 2012, 39, 8127-8135.	1.0	51
210	Planning and monitoring of patients for electrical cardioversion for atrial fibrillation. Netherlands Heart Journal, 2012, 20, 148-154.	0.3	7
211	Percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation. Netherlands Heart Journal, 2012, 20, 161-166.	0.3	10
213	An Apparent Way of Achieving Proof of Pulmonary Vein Disconnection during Cryoballoon Ablation. PACE - Pacing and Clinical Electrophysiology, 2012, 35, e337-40.	0.5	3
214	Impact of Catheter Ablation on Quality of Life in Patients with Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2012, 23, 128-129.	0.8	1
215	An Earnest Search for Atrial Fibrillation Patients Without Thromboembolic Risk. Journal of Cardiovascular Electrophysiology, 2012, 23, 714-716.	0.8	Ο
216	Slipping Through the Mini-Maze. Annals of Thoracic Surgery, 2012, 93, 361.	0.7	1
217	Diabetes, hyperglycaemia, and acute ischaemic stroke. Lancet Neurology, The, 2012, 11, 261-271.	4.9	377
218	Left Ventricular Diastolic Dysfunction in Atrial Fibrillation: Predictors and Relation with Symptom Severity. Journal of Cardiovascular Electrophysiology, 2012, 23, 1073-1077.	0.8	35
219	Do the current atrial fibrillation guidelines for stroke prevention need to be changed with the availability of new data on the new oral anticoagulants?. International Journal of Clinical Practice, 2012, 66, 422-424.	0.8	Ο
220	Novel antithrombotic agents for atrial fibrillation. , 2012, 134, 345-354.		3
223	Blood coagulation factor XII—a neglected player in stroke pathophysiology. Journal of Molecular Medicine, 2012, 90, 119-126.	1.7	19

#	Article	IF	CITATIONS
224	Clinical trials of antiarrhythmic therapies and optimizing health care resource deployment: the need for a paradigm shift. Journal of Interventional Cardiac Electrophysiology, 2012, 33, 1-3.	0.6	2
225	Population-Based Study of Acute- and Long-Term Care Costs after Stroke in Patients with AF. International Journal of Stroke, 2013, 8, 308-314.	2.9	51
226	Response of circulating heat shock protein 70 and anti-heat shock protein 70 antibodies to catheter ablation of atrial fibrillation. Journal of Translational Medicine, 2013, 11, 49.	1.8	26
227	Clinical performance of bleeding risk scores for predicting major and clinically relevant nonâ€major bleeding events in patients receiving warfarin. Journal of Thrombosis and Haemostasis, 2013, 11, 1647-1654.	1.9	32
228	Assessment of Interleukinâ€1 Gene Cluster Polymorphisms in Lone Atrial Fibrillation: New Insight into the Role of Inflammation in Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 2013, 36, 1220-1227.	0.5	28
229	Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study. Netherlands Heart Journal, 2013, 21, 354-363.	0.3	29
233	Catheter ablation of atrial fibrillation to reduce stroke risk. Herz, 2013, 38, 247-250.	0.4	3
234	Adaptive frequency tracking of the baseline ECG identifies the site of atrial fibrillation termination by catheter ablation. Biomedical Signal Processing and Control, 2013, 8, 969-980.	3.5	15
235	La presión arterial ambulatoria nocturna se asocia al remodelado auricular y la activación neurohormonal en pacientes con fibrilación auricular idiopática. Revista Espanola De Cardiologia, 2013, 66, 458-463.	0.6	9
236	Atrial fibrillation: An anesthesiologist's perspective. Acta Anaesthesiologica Taiwanica, 2013, 51, 34-36.	1.0	6
237	Estimated glomerular filtration rate is associated with major bleeding complications but not thromboembolic events, in anticoagulated patients taking warfarin. Thrombosis Research, 2013, 131, 481-486.	0.8	22
239	Navigating the mini-maze: Systematic review of the first results and progress of minimally-invasive surgery in the treatment of atrial fibrillation. International Journal of Cardiology, 2013, 166, 132-140.	0.8	68
240	Medication assessment tool to detect care issues from routine data: a pilot study in primary care. International Journal of Clinical Pharmacy, 2013, 35, 1063-1074.	1.0	9
241	The Effects of Chronic Exercise Training in Individuals WithÂPermanent Atrial Fibrillation: A Systematic Review. Canadian Journal of Cardiology, 2013, 29, 1721-1728.	0.8	47
242	Cardioversion for atrial fibrillation in current European practice: results of the European Heart Rhythm Association survey. Europace, 2013, 15, 915-918.	0.7	38
243	Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. European Heart Journal,	1.0	62
244	Dosage of statin, cardiovascular comorbidities, and risk of atrial fibrillation: A nationwide population-based cohort study. International Journal of Cardiology, 2013, 168, 1131-1136.	0.8	18
245	Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace, 2013, 15, 1540-1556	0.7	125

#	Article	IF	CITATIONS
246	The cost-utility of catheter ablation of atrial fibrillation: a systematic review and critical appraisal of economic evaluations. BMC Cardiovascular Disorders, 2013, 13, 78.	0.7	27
248	Internal cardioversion of persistent atrial fibrillation in implantable cardioverter defibrillator patients: the juice is not worth the squeeze. Netherlands Heart Journal, 2013, 21, 545-547.	0.3	1
249	Immediate and medium-term outcomes of cryoballoon-based pulmonary vein isolation in patients with paroxysmal and persistent atrial fibrillation: single-centre experience. Journal of Interventional Cardiac Electrophysiology, 2013, 38, 187-195.	0.6	39
250	Cardiac troponin I: Prothrombotic risk marker in non-valvular atrial fibrillation. International Journal of Cardiology, 2013, 167, 877-882.	0.8	24
251	Atrial fibrillation management, outcomes and predictors of stable disease in daily practice: Prospective non-interventional study. International Journal of Cardiology, 2013, 167, 750-756.	0.8	13
252	A New Catheter for Pulmonary Vein Isolation: The Hole Story?. Journal of Cardiovascular Electrophysiology, 2013, 24, 1336-1337.	0.8	6
253	Rate control in atrial fibrillation, insight into the RACE II study. Netherlands Heart Journal, 2013, 21, 199-204.	0.3	2
254	Continuous warfarin therapy is safe and feasible in catheter ablation of atrial fibrillation. Scandinavian Cardiovascular Journal, 2013, 47, 109-113.	0.4	9
255	Economic Evaluation of Percutaneous Left Atrial Appendage Occlusion, Dabigatran, and Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation. Circulation, 2013, 127, 2414-2423.	1.6	79
256	Content and distribution of discursive space in consultations between patients with atrial fibrillation and healthcare professionals. European Journal of Cardiovascular Nursing, 2013, 12, 47-55.	0.4	10
257	Ineligibility for Anticoagulation in Patients with Atrial Fibrillation. American Journal of Medicine, 2013, 126, 105-111.	0.6	10
258	CHADS2 Score, Statin Therapy, and Risks of Atrial Fibrillation. American Journal of Medicine, 2013, 126, 133-140.e1.	0.6	26
259	Dynamic remodeling of intracellular Ca2+ signaling during atrial fibrillation. Journal of Molecular and Cellular Cardiology, 2013, 58, 134-142.	0.9	46
260	Risk assessment and therapy decision in patients at low risk for stroke: CHA2DS2-VASc vs. CHADS2?. European Heart Journal, 2013, 34, 168-169.	1.0	3
261	Isolated left ventricular non-compaction controversies in diagnostic criteria, adverse outcomes and management. Heart, 2013, 99, 681-689.	1.2	68
262	Role of Late Sodium Channel Current Block in the Management of Atrial Fibrillation. Cardiovascular Drugs and Therapy, 2013, 27, 79-89.	1.3	46
264	EpidemiologÃa de la fibrilación auricular en España. Revista Espanola De Cardiologia Suplementos, 2013, 13, 3-8.	0.2	3
265	Genetic Modifier of the QTc Interval Associated With Early-Onset Atrial Fibrillation. Canadian Journal of Cardiology, 2013, 29, 1234-1240.	0.8	9

#	Article	IF	CITATIONS
266	Effectiveness of Moxonidine to Reduce Atrial Fibrillation Burden in Hypertensive Patients. American Journal of Cardiology, 2013, 112, 684-687.	0.7	22
267	Prediction of atrial fibrillation recurrence after cardioversion—Interaction analysis of cardiac autonomic regulation. Medical Engineering and Physics, 2013, 35, 376-382.	0.8	14
268	Polymorphic ventricular tachycardia after amiodarone infusion in extreme tachycardia–bradycardia-syndrome. International Journal of Cardiology, 2013, 168, e65-e67.	0.8	1
269	Prevalence of Undiagnosed Atrial Fibrillation and of That Not Being Treated With Anticoagulant Drugs: the AFABE Study. Revista Espanola De Cardiologia (English Ed ), 2013, 66, 545-552.	0.4	26
270	Role of Preablation Neutrophil/Lymphocyte Ratio on Outcomes ofÂCryoballoon-Based Atrial Fibrillation Ablation. American Journal of Cardiology, 2013, 112, 513-519.	0.7	52
271	The Ca-calmodulin dependent kinase II: A promising target for future antiarrhythmic therapies?. Journal of Molecular and Cellular Cardiology, 2013, 58, 182-187.	0.9	23
272	European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2013, 15, 625-651.	0.7	721
274	The impact of body mass index on the efficacy and safety of catheter ablation of atrial fibrillation. International Journal of Cardiology, 2013, 164, 94-98.	0.8	62
275	Atrial Fibrillation: What's New?. Journal for Nurse Practitioners, 2013, 9, 400-401.	0.4	0
276	Tiempo en rango terapéutico de los pacientes que siguen tratamiento con derivados cumarÃnicos en la práctica clÃnica diaria. Cardiocore, 2013, 48, 158-161.	0.0	0
277	Nighttime Ambulatory Blood Pressure is Associated With Atrial Remodelling and Neurohormonal Activation in Patients With Idiopathic Atrial Fibrillation. Revista Espanola De Cardiologia (English Ed ), 2013, 66, 458-463.	0.4	8
278	Treatment failure of low molecular weight heparin bridging therapy. International Journal of Cardiology, 2013, 167, e106-e107.	0.8	11
279	Pulmonary vein hematoma after atrial fibrillation cryoablation: A new complication. Heart Rhythm, 2013, 10, 1359.	0.3	5
280	Improvement of left atrial function and left atrial reverse remodeling after minimally invasive radiofrequency ablation evaluated by 2-dimensional speckle tracking echocardiography. Journal of Thoracic and Cardiovascular Surgery, 2013, 146, 72-77.	0.4	25
281	Which are the most reliable predictors of recurrence of atrial fibrillation after transcatheter ablation?: a meta-analysis. International Journal of Cardiology, 2013, 167, 1984-1989.	0.8	169
282	Actualización detallada de las guÃas de la ESC para el manejo de la fibrilación auricular de 2012. Revista Espanola De Cardiologia, 2013, 66, 54.e1-54.e24.	0.6	14
283	A proposal for a new scoring system in the prediction of catheter ablation outcomes: Promising results from the Turkish Cryoablation Registry. International Journal of Cardiology, 2013, 169, 201-206.	0.8	71
284	Abnormal troponin level as short-term predictor of poor outcome in acute atrial fibrillation. American Journal of Emergency Medicine, 2013, 31, 699-704.	0.7	25

#	Article	IF	CITATIONS
286	The type of atrial fibrillation is associated with longâ€ŧerm outcome in patients with acute ischemic stroke. International Journal of Cardiology, 2013, 167, 1519-1523.	0.8	22
287	The preventive effect of statin therapy on new-onset and recurrent atrial fibrillation in patients not undergoing invasive cardiac interventions. International Journal of Cardiology, 2013, 167, 624-630.	0.8	25
288	Atrial Fibrillation, Silent Cerebral Ischemia, and Cognitive Function. Journal of the American College of Cardiology, 2013, 62, 1998-1999.	1.2	6
289	Low stroke risk after elective cardioversion of atrial fibrillation: An analysis of the Flec-SL trial. International Journal of Cardiology, 2013, 168, 3977-3981.	0.8	17
290	Rhythm Control of Atrial Fibrillation in Heart Failure. Heart Failure Clinics, 2013, 9, 407-415.	1.0	10
291	Study Design of the Man and Machine Trial: A Prospective International Controlled Noninferiority Trial Comparing Manual with Robotic Catheter Ablation for Treatment of Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2013, 24, 40-46.	0.8	17
292	Managing anticoagulation for atrial fibrillation: current issues and future strategies. Journal of Internal Medicine, 2013, 273, 31-41.	2.7	9
293	A Systematic Review of the Health Benefits of Exercise Rehabilitation in Persons Living With Atrial Fibrillation. Canadian Journal of Cardiology, 2013, 29, 483-491.	0.8	72
294	Antithrombotic therapy in atrial fibrillation: aspirin is rarely the right choice. Postgraduate Medical Journal, 2013, 89, 346-351.	0.9	7
295	Surgical Strategies and Devices for Surgical Exclusion of the Left Atrial Appendage: A Word of Caution. Journal of Cardiac Surgery, 2013, 28, 199-206.	0.3	12
296	Hospitalization for vitamin-K-antagonist-related bleeding: treatment patterns and outcome. Journal of Thrombosis and Haemostasis, 2013, 11, 651-659.	1.9	32
297	Rate Control Efficacy in Permanent Atrial Fibrillation: Successful and Failed Strict Rate Control Against a Background of Lenient Rate Control. Journal of the American College of Cardiology, 2013, 61, 741-748.	1.2	50
298	Clinical trials with new oral anticoagulants. Hamostaseologie, 2013, 33, 62-70.	0.9	9
299	Minimally invasive surgical treatment of lone atrial fibrillation: Early results of hybrid versus standard minimally invasive approach employing radiofrequency sources. International Journal of Cardiology, 2013, 167, 1469-1475.	0.8	83
300	Atrial Fibrillation in CKD: Balancing the Risks and Benefits of Anticoagulation. American Journal of Kidney Diseases, 2013, 62, 615-632.	2.1	69
301	Assessment of stroke risk in Middle Eastern patients with atrial fibrillation: The Gulf SAFE registry. International Journal of Cardiology, 2013, 168, 1644-1646.	0.8	14
302	Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosisâ€nediated conditions. Annals of the New York Academy of Sciences, 2013, 1291, 42-55.	1.8	18
303	Transitions of care in anticoagulated patients. Journal of Multidisciplinary Healthcare, 2013, 6, 215.	1.1	18

#	Article	IF	CITATIONS
304	Fibrosis, myocardial crossings, disconnections, abrupt turns, and epicardial reflections: do they play an actual role in human permanent atrial fibrillation? A controlled necropsy study. Cardiovascular Pathology, 2013, 22, 65-69.	0.7	28
305	Cognitive function is associated with impaired heart rate variability in ageing adults: the Irish longitudinal study on ageing wave one results. Clinical Autonomic Research, 2013, 23, 313-323.	1.4	85
306	Outcomes of repeat catheter ablation using magnetic navigation or conventional ablation. Europace, 2013, 15, 1426-1431.	0.7	28
307	Minimal invasive surgery for atrial fibrillation: an updated review. Europace, 2013, 15, 170-182.	0.7	75
308	Sailing between Scylla and Charybdis: oral long-term anticoagulation in dialysis patients. Nephrology Dialysis Transplantation, 2013, 28, 534-541.	0.4	48
309	Progressive endothelial damage revealed by multilevel von Willebrand factor plasma concentrations in atrial fibrillation patients. Europace, 2013, 15, 1562-1566.	0.7	27
310	Stroke Stop Study: editorial comment. Europace, 2013, 15, 5-6.	0.7	4
311	Obesity and atrial fibrillation: the evidence is gaining weight. Europace, 2013, 15, 771-772.	0.7	2
312	The effect of integrated cardiac rehabilitation versus treatment as usual for atrial fibrillation patients treated with ablation: the randomised CopenHeart <sub>RFA</sub> trial protocol. BMJ Open, 2013, 3, e002377.	0.8	19
313	Impact of coronary atherosclerosis on the efficacy of radiofrequency catheter ablation for atrial fibrillation. European Heart Journal Cardiovascular Imaging, 2013, 14, 247-252.	0.5	15
314	A proposal for interdisciplinary, nurse-coordinated atrial fibrillation expert programmes as a way to structure daily practice. European Heart Journal, 2013, 34, 2725-2730.	1.0	71
315	The occurrence of cardiovascular disease during 5-year follow-up in patients with idiopathic atrial fibrillation. Europace, 2013, 15, 18-23.	0.7	33
316	Circumferential pulmonary vein isolation: wait or stop early after initial successful pulmonary vein isolation?. Europace, 2013, 15, 183-188.	0.7	40
317	Successful catheter ablation reduces the risk of cardiovascular events in atrial fibrillation patients with CHA2DS2-VASc risk score of 1 and higher. Europace, 2013, 15, 676-684.	0.7	64
318	Lessons from dissociated pulmonary vein potentials: entry block implies exit block. Europace, 2013, 15, 805-812.	0.7	29
319	'Patient choice' concept in AF ESC Guidelines: is the clinician giving up? Reply. Europace, 2013, 15, 460-461.	0.7	0
320	Questionable levels of evidence in new atrial fibrillation guidelines?. Europace, 2013, 15, 461-461.	0.7	1
321	Questionable levels of evidence in new atrial fibrillation guidelines? Reply. Europace, 2013, 15, 461-462.	0.7	Ο

#	Article	IF	CITATIONS
322	Temporal changes in patient characteristics and prior pharmacotherapy in patients undergoing radiofrequency ablation of atrial fibrillation: a Danish nationwide cohort study. Europace, 2013, 15, 669-675.	0.7	7
323	Uncontrolled forward motion of an ablation catheter through a recently available deflectable sheath. Europace, 2013, 15, 786-786.	0.7	0
324	Current practice of antiarrhythmic drug therapy for prevention of atrial fibrillation in Europe: The European Heart Rhythm Association survey. Europace, 2013, 15, 478-481.	0.7	19
325	Current practice for diagnosis and management of silent atrial fibrillation: results of the European Heart Rhythm Association survey. Europace, 2013, 15, 1223-1225.	0.7	35
326	Get with the guidelines. Europace, 2013, 15, 1685-1686.	0.7	0
327	Bleeding Risk Assessment in Patients With Atrial Fibrillation Who Are Taking Oral Anticoagulants. Hospital Practice (1995), 2013, 41, 71-78.	0.5	5
328	Obesity is a risk factor for atrial fibrillation among fertile young women: a nationwide cohort study. Europace, 2013, 15, 781-786.	0.7	66
329	Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open, 2013, 3, e002758.	0.8	155
330	Prevalence of unknown atrial fibrillation in patients with risk factors. Europace, 2013, 15, 657-662.	0.7	64
331	Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial. Journal of the American Heart Association, 2013, 2, e000067.	1.6	179
332	Caution over use of catheter ablation for atrial fibrillation. BMJ, The, 2013, 347, f5277-f5277.	3.0	10
333	Factors that influence awareness and treatment of atrial fibrillation in older adults. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 415-424.	0.2	49
334	Angiotensin-Converting Enzyme Inhibitors. , 2013, , 179-190.		0
335	Addressing the Controversy of Rate Versus Rhythm Control in Atrial Fibrillation. Postgraduate Medicine, 2013, 125, 7-18.	0.9	101
336	Prevalence and electrophysiological characteristics of typical atrial flutter in patients with atrial fibrillation and chronic obstructive pulmonary disease. Europace, 2013, 15, 1777-1783.	0.7	22
337	Long-term Prognostic Value of Dysglycemia and Ischemic Vascular Disease Beyond Abnormal Troponin Levels in Patients Presenting Acute Atrial Fibrillation. Critical Pathways in Cardiology, 2013, 12, 14-23.	0.2	1
338	Antithrombotic Therapy in Patients With Heart Valve Prostheses. Cardiology in Review, 2013, 21, 27-36.	0.6	13
339	Management of acute atrial fibrillation in the emergency department. European Journal of Emergency Medicine, 2013, 20, 151-159.	0.5	17

#	Article	IF	CITATIONS
340	Dronedarone for the treatment of non-permanent atrial fibrillation: National Institute for Health and Clinical Excellence guidance. Heart, 2013, 99, 1476-1480.	1.2	4
341	Atrial Fibrillation and Heart Failure: Rate Versus Rhythm Control. , 2013, , 129-144.		0
342	Atrial Fibrillation in the Intensive Care Setting. Journal of the Intensive Care Society, 2013, 14, 141-149.	1.1	6
343	Atrial Fibrillation in the Athlete. Current Sports Medicine Reports, 2013, 12, 86-92.	0.5	6
344	Surgical Minimally Invasive Pulmonary Vein Isolation for Lone Atrial Fibrillation. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2013, 8, 410-415.	0.4	14
345	Angiotensin System–Blocking Medications Are Associated with Fewer Falls over 12 Months in Communityâ€Dwelling Older People. Journal of the American Geriatrics Society, 2013, 61, 776-781.	1.3	41
346	Managing atrial fibrillation in the global community: The European perspective. Global Cardiology Science & Practice, 2013, 2013, 24.	0.3	6
347	Clinical usefulness of carotid ultrasound to improve stroke risk assessment: ten-year results from the Carotid Atherosclerosis Progression Study (CAPS). European Journal of Preventive Cardiology, 2013, 20, 837-843.	0.8	21
348	Predicting the future in patients with atrial fibrillation: who develops heart failure?. European Journal of Heart Failure, 2013, 15, 366-367.	2.9	4
349	Diagnostic Accuracy of Cardiac Magnetic Resonance Imaging in the Detection and Characterization of Left Atrial Catheter Ablation Lesions: A Multicenter Experience. Journal of Cardiovascular Electrophysiology, 2013, 24, 396-403.	0.8	65
350	Proâ€arrhythmogenic effects of atrial fibrillationâ€induced electrical remodelling: insights from the threeâ€dimensional virtual human atria. Journal of Physiology, 2013, 591, 4249-4272.	1.3	152
351	Comparison of Balloon Catheter Ablation Technologies for Pulmonary Vein Isolation: The Laser Versus Cryo Study. Journal of Cardiovascular Electrophysiology, 2013, 24, 987-994.	0.8	57
352	Novel Oral Anticoagulants and Atrial Fibrillation: Efficacy and Safety Considerations. Drug Development Research, 2013, 74, 505-509.	1.4	1
353	Revisiting the prehypertension debate: Increasing evidence for treatment yet randomized clinical trials are lacking. Blood Pressure, 2013, 22, 340-343.	0.7	1
354	Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a postâ€hoc analysis of the RACE II study. European Journal of Heart Failure, 2013, 15, 1311-1318.	2.9	88
355	The Hemorrhagic Risk: How to Evaluate It. PACE - Pacing and Clinical Electrophysiology, 2013, 36, 1191-1197.	0.5	2
356	Role of Triggering Pulmonary Veins in the Maintenance of Sustained Paroxysmal Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 2013, 36, 845-854.	0.5	5
357	EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summaryâ€. European Heart Journal, 2013, 34, 2094-2106.	1.0	356

#	Article	IF	CITATIONS
358	Left Atrial Function Assessed by Doppler Echocardiography Rather Than Left Atrial Volume Predicts Recurrence in Patients With Paroxysmal Atrial Fibrillation. Clinical Cardiology, 2013, 36, 235-240.	0.7	15
359	Patients' well-being: experience and actions in their preventing and handling of atrial fibrillation. European Journal of Cardiovascular Nursing, 2013, 12, 132-139.	0.4	41
360	Comparison of Antiplatelet and Antithrombotic Therapy for Secondary Prevention of Ischemic Stroke in Patients With Peripheral Artery Disease. Circulation Journal, 2013, 77, 1046-1052.	0.7	8
361	Effect of a Single Bolus Injection of Low-Dose Hydrocortisone for Prevention of Atrial Fibrillation Recurrence After Radiofrequency Catheter Ablation. Circulation Journal, 2013, 77, 53-59.	0.7	27
362	Optimal International Normalized Ratio for Atrial Fibrillation in Asians and Japanese. Circulation Journal, 2013, 77, 2242-2243.	0.7	13
363	Guideline Adherence of Antithrombotic Treatment Initiated by General Practitioners in Patients With Nonvalvular Atrial Fibrillation: A Danish Survey. Clinical Cardiology, 2013, 36, 427-432.	0.7	24
365	Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. Thrombosis and Haemostasis, 2013, 109, 328-336.	1.8	56
366	Human Electrophysiological and Pharmacological Properties of XEN-D0101. Journal of Cardiovascular Pharmacology, 2013, 61, 408-415.	0.8	52
367	Beneficial effects of an angiotensin-II receptor blocker on structural atrial reverse-remodeling in a rat model of ischemic heart failure. Experimental and Therapeutic Medicine, 2013, 5, 1009-1016.	0.8	16
368	Treatment patterns associated with stroke prevention in patients with atrial fibrillation in three major cities in the People's Republic of China. International Journal of General Medicine, 2013, 7, 29.	0.8	2
369	P Wave Indices to Predict Atrial Fibrillation Recurrences Post Pulmonary Vein Isolation. Arquivos Brasileiros De Cardiologia, 2013, 101, 519-27.	0.3	27
370	Current strategies to minimize the bleeding risk of warfarin. Journal of Blood Medicine, 2013, 4, 89.	0.7	27
371	Subclinical Thyroid Dysfunction and Cognitive Decline in Old Age. PLoS ONE, 2013, 8, e59199.	1.1	52
372	Frequency and Risk Factors for Under- and Over-Treatment in Stroke Prevention for Patients with Non-Valvular Atrial Fibrillation in General Practice. PLoS ONE, 2013, 8, e67806.	1.1	15
373	Educational Intervention Improves Anticoagulation Control in Atrial Fibrillation Patients: The TREAT Randomised Trial. PLoS ONE, 2013, 8, e74037.	1.1	165
374	Preventive Effects of the Angiotensin-II Receptor Blocker on Atrial Remodeling in an Ischemic Heart Failure Model of Rats. Korean Circulation Journal, 2013, 43, 686.	0.7	6
375	Mechanism of and Therapeutic Strategy for Atrial Fibrillation Associated with Diabetes Mellitus. Scientific World Journal, The, 2013, 2013, 1-6.	0.8	24
376	COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE. Rational Pharmacotherapy in Cardiology, 2013, 9, 398-403.	0.3	0

#	Article	IF	CITATIONS
377	Dental Procedures in Patients with Atrial Fibrillation and New Oral Anticoagulants. Arrhythmia and Electrophysiology Review, 2014, 3, 85.	1.3	4
378	Role of digoxin in controlling the ventricular rate during atrial fibrillation: a systematic review and a rethinking. Research Reports in Clinical Cardiology, 0, , 93.	0.2	3
379	Induction of Atrial Fibrillation by Neutrophils Critically Depends on CD11b/CD18 Integrins. PLoS ONE, 2014, 9, e89307.	1.1	43
380	A Functional Polymorphism C-509T in TGFβ-1 Promoter Contributes to Susceptibility and Prognosis of Lone Atrial Fibrillation in Chinese Population. PLoS ONE, 2014, 9, e112912.	1.1	20
381	Mechanisms of Action of Anesthetics for the Modulation of Perioperative Thrombosis: Evidence for Immune Mechanisms from Basic and Clinical Studies. Current Pharmaceutical Design, 2014, 20, 5779-5793.	0.9	3
382	ANALYSIS OF ANTITHROMBOTIC THERAPY IN IN-PATIENTS WITH PERMANENT ATRIAL FIBRILLATION (PHARMACOEPIDEMIOLOGY STUDY). Rational Pharmacotherapy in Cardiology, 2014, 10, 174-178.	0.3	6
383	Rhythm outcomes after catheter ablation of atrial fibrillation. Hamostaseologie, 2014, 34, 9-19.	0.9	7
384	Other Interventional Techniques. , 2014, , .		0
385	Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart, 2014, 100, 1506-1510.	1.2	126
386	Surgical ablation of atrial fibrillation. International Journal of Cardiology Heart & Vessels, 2014, 4, 7-11.	0.5	1
388	Is There Association Between Changes in eGFR Value and the Risk of Permanent Type of Atrial Fibrillation? - Analysis of Valvular and Non-Valvular Atrial Fibrillation Population. Kidney and Blood Pressure Research, 2014, 39, 600-608.	0.9	5
389	Quality of life in patients with atrial fibrillation: how to assess it and how to improve it. Europace, 2014, 16, 787-796.	0.7	89
390	Guideline adherence in antithrombotic treatment after concomitant ablation surgery in atrial fibrillation patients. Interactive Cardiovascular and Thoracic Surgery, 2014, 18, 313-320.	0.5	2
391	Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients. Europace, 2014, 16, 195-201.	0.7	11
392	Hemostasis and Anticoagulants. , 2014, , 479-496.		3
393	Current periprocedural management of ablation for atrial fibrillation in Europe: results of the European Heart Rhythm Association survey. Europace, 2014, 16, 378-381.	0.7	21
394	Incidence of cerebral thromboembolic events during long-term follow-up in patients treated with transcatheter ablation for atrial fibrillation. Europace, 2014, 16, 980-986.	0.7	33
395	Warfarin Use and the Risk for Stroke and Bleeding in Patients With Atrial Fibrillation Undergoing Dialysis. Circulation, 2014, 129, 1196-1203.	1.6	296

#	Article	IF	CITATIONS
396	Characterization of patients with atrial fibrillation not treated with oral anticoagulants. Scandinavian Journal of Primary Health Care, 2014, 32, 226-231.	0.6	23
397	Could Some Geriatric Characteristics Hinder the Prescription of Anticoagulants in Atrial Fibrillation in the Elderly?. Journal of Aging Research, 2014, 2014, 1-8.	0.4	16
398	Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF). Europace, 2014, 16, 6-14.	0.7	349
399	Stroke Prevention in Patients With Atrial Fibrillation and Renal Dysfunction. Stroke, 2014, 45, 2497-2505.	1.0	13
400	Hybrid thoracoscopic and transvenous catheter ablation of atrial fibrillation. European Journal of Cardio-thoracic Surgery, 2014, 45, 401-407.	0.6	79
401	latrogenic atrial septal defects following atrial fibrillation transcatheter ablation: a relevant entity?. Europace, 2014, 16, 1562-1568.	0.7	9
402	Prevention of Stroke in Patients With Atrial Fibrillation. , 2014, , 1129-1137.		0
403	Race against the clock: Overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage. Journal of Neurosurgery, 2014, 121, 1-20.	0.9	40
404	Current approaches in atrial fibrillation treatment. Dicle Medical Journal, 2014, 41, 614-622.	0.2	1
405	CHADS2 and CHA2DS2-VASc scores as predictors of left atrial ablation outcomes for paroxysmal atrial fibrillation. Europace, 2014, 16, 202-207.	0.7	72
406	Improvement of cerebral oxygen saturation after successful electrical cardioversion of atrial fibrillation. Europace, 2014, 16, 189-194.	0.7	19
407	'Preferred' management of atrial fibrillation in Europe. Europace, 2014, 16, 1-3.	0.7	38
408	Modified phased radiofrequency ablation of atrial fibrillation reduces the number of cerebral microembolic signals. Europace, 2014, 16, 341-346.	0.7	30
409	The effect of a nurse-led integrated chronic care approach on quality of life in patients with atrial fibrillation. Europace, 2014, 16, 491-499.	0.7	56
410	Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial. Europace, 2014, 16, 174-181.	0.7	29
411	Evolution and pharmacological modulation of the arrhythmogenic wave dynamics in canine pulmonary vein model. Europace, 2014, 16, 416-423.	0.7	37
412	Outcomes after atrioventricular node ablation and biventricular pacing in patients with refractory atrial fibrillation and heart failure: a comparison between non-ischaemic and ischaemic cardiomyopathy. Europace, 2014, 16, 880-886.	0.7	15
413	Dronedarone: an alternate choice to sotalol and amiodarone in the treatment of atrial fibrillation/flutter in patients who have coronary heart disease. Europace, 2014, 16, 153-155.	0.7	Ο

#	ARTICLE	IF	CITATIONS
414	Patient reported outcome measures for cardiac ablation procedures: a multicentre pilot to develop a new questionnaire. Europace, 2014, 16, 1626-1633.	0.7	15
415	Assessment of oesophageal position by direct visualization with luminal contrast compared with segmentation from pre-acquired computed tomography scanimplications for ablation strategy. Europace, 2014, 16, 1304-1308.	0.7	7
416	Predictors of hospitalization for heart failure and of all-cause mortality after atrioventricular nodal ablation and right ventricular pacing for atrial fibrillation. Europace, 2014, 16, 1772-1778.	0.7	6
417	Developing a complex intervention to improve prescribing safety in primary care: mixed methods feasibility and optimisation pilot study. BMJ Open, 2014, 4, e004153.	0.8	20
418	Long-term use and cost-effectiveness of secondary prevention drugs for heart disease in Western Australian seniors (WAMACH): a study protocol. BMJ Open, 2014, 4, e006258-e006258.	0.8	11
419	New oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. The Cochrane Library, 2014, , .	1.5	3
420	Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting. Revista Portuguesa De Cardiologia, 2014, 33, 535-544.	0.2	26
421	Non-linear regularity of arterial blood pressure variability in patient with atrial fibrillation in tilt-test procedure. Europace, 2014, 16, iv141-iv147.	0.7	7
422	The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace, 2014, 16, 965-972.	0.7	161
423	Safe, effective and durable epicardial left atrial appendage clip occlusion in patients with atrial fibrillation undergoing cardiac surgery: first long-term results from a prospective device trial. European Journal of Cardio-thoracic Surgery, 2014, 45, 126-131.	0.6	114
424	Impact of single atrial fibrillation catheter ablation on implantable cardioverter defibrillator therapies in patients with ischaemic and non-ischaemic cardiomyopathies. Europace, 2014, 16, 1322-1326.	0.7	29
425	Role of extended external loop recorders for the diagnosis of unexplained syncope, pre-syncope, and sustained palpitations. Europace, 2014, 16, 914-922.	0.7	42
426	Use of oral anticoagulants in atrial fibrillation is highly variable and only weakly associated with estimated stroke risk: Cross-sectional population database study. European Journal of General Practice, 2014, 20, 181-189.	0.9	11
427	Symptom severity is associated with cardiovascular outcome in patients with permanent atrial fibrillation in the RACE II study. Europace, 2014, 16, 1417-1425.	0.7	29
428	Effects of human atrial ionic remodelling by β-blocker therapy on mechanisms of atrial fibrillation: a computer simulation. Europace, 2014, 16, 1524-1533.	0.7	21
429	Author reply. Europace, 2014, 16, 151-152.	0.7	2
430	Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF) Tj ETQq(	00 <b>0.0</b> gBT	/Ovzenokock 10

431Predictors of Longâ€term Maintenance of Normal Sinus Rhythm After Successful Electrical0.719431Cardioversion. Clinical Cardiology, 2014, 37, 381-385.0.719

#	Article	IF	CITATIONS
432	Atrial fibrillation in patients with ischaemic stroke in the Swedish national patient registers: how much do we miss?. Europace, 2014, 16, 1714-1719.	0.7	17
433	An Unusual Case of Flecainideâ€induced <scp>QT</scp> Prolongation Leading to Cardiac Arrest. Pharmacotherapy, 2014, 34, e30-3.	1.2	9
434	Predictive value of the heart rate reserve in patients with permanent atrial fibrillation treated according to a strict rate-control strategy. Europace, 2014, 16, 1125-1130.	0.7	6
436	Practical Considerations for Using Novel Oral Anticoagulants in Patients With Atrial Fibrillation. Clinical Cardiology, 2014, 37, 32-47.	0.7	72
437	The Impact of Catheter Ablation in the Interpulmonary Isthmus on Atrial Fibrillation Ablation Outcomes: A Randomized Study. Journal of Cardiovascular Electrophysiology, 2014, 25, 709-713.	0.8	4
438	Risk of Atrial Fibrillation After Atrial Flutter Ablation: Impact of AF History, Gender, and Antiarrhythmic Drug Medication. Journal of Cardiovascular Electrophysiology, 2014, 25, 813-820.	0.8	43
439	Guidelines for the Prevention of Stroke in Women. Stroke, 2014, 45, 1545-1588.	1.0	754
440	Usefulness of Pâ€Wave Signal Averaging to Predict Atrial Fibrillation Recurrences after Electrical Cardioversion. Annals of Noninvasive Electrocardiology, 2014, 19, 266-272.	0.5	11
441	Age Dependence of Risk Factors for Stroke and Death in Young Patients With Atrial Fibrillation. Stroke, 2014, 45, 1331-1337.	1.0	25
442	Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines. Europace, 2014, 16, 162-173.	0.7	64
443	Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation. Europace, 2014, 16, 1291-1295.	0.7	115
444	Physician's Fear of Anticoagulant Therapy in Nonvalvular Atrial Fibrillation. American Journal of the Medical Sciences, 2014, 348, 513-521.	0.4	46
445	The talk test. Current Opinion in Cardiology, 2014, 29, 475-480.	0.8	89
446	CHA2DS2-VASc in the prediction of early atrial fibrillation relapses after electrical or pharmacological cardioversion. Journal of Cardiovascular Medicine, 2014, 15, 636-641.	0.6	13
447	Impact of an Emergency Department–Initiated Clinical Protocol for the Evaluation and Treatment of Atrial Fibrillation. Critical Pathways in Cardiology, 2014, 13, 43-48.	0.2	18
448	Perioperative Management of Antithrombotic Medications in Vitreoretinal Surgery. International Ophthalmology Clinics, 2014, 54, 199-213.	0.3	2
449	Relation of Red Cell Distribution Width With CHA2DS2-VASc Score in Patients With Nonvalvular Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 687-692.	0.7	24
450	New oral anticoagulant agents – general features and outcomes in subsets of patients. Thrombosis and Haemostasis, 2014, 111, 575-582.	1.8	58

#	Article	IF	CITATIONS
451	In-silico assessment of the dynamic effects of amiodarone and dronedarone on human atrial patho-electrophysiology. Europace, 2014, 16, iv30-iv38.	0.7	45
452	Treatment of Neurological Disorders. , 2014, , 301-348.		0
453	Relationship between Brain Natriuretic Peptides and Recurrence of Atrial Fibrillation after Successful Direct Current Cardioversion: A Metaâ€Analysis. PACE - Pacing and Clinical Electrophysiology, 2014, 37, 1530-1537.	0.5	13
454	Net Clinical Benefit of Warfarin Therapy in Elderly Chinese Patients With Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 300-306.	2.1	51
455	Adherence to guidelines for the prescribing of double and triple combinations of antithrombotic agents. European Journal of Preventive Cardiology, 2014, 21, 231-243.	0.8	7
456	Most Important Outcomes Research Papers on Stroke and Transient Ischemic Attack. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 191-204.	0.9	7
457	Refinement of Ischemic Stroke Risk in Patients with Atrial Fibrillation and CHA <sub>2</sub> DS <sub>2</sub> â€VASc Score of 1. PACE - Pacing and Clinical Electrophysiology, 2014, 37, 1442-1447.	0.5	48
458	Usefulness of a Low CHADS2 or CHA2DS2-VASc Score to Predict Normal Diagnostic Testing in Emergency Department Patients With an Acute Exacerbation of Previously Diagnosed Atrial Fibrillation. American Journal of Cardiology, 2014, 113, 1668-1673.	0.7	2
459	Treatment failure of low molecular weight heparin bridging therapy in atrial fibrillation after acute coronary syndrome. International Journal of Cardiology, 2014, 171, 289-291.	0.8	3
461	Single, remote-magnetic catheter approach for pulmonary vein isolation in patients with paroxysmal and non-paroxysmal atrial fibrillation. International Journal of Cardiology, 2014, 174, 18-24.	0.8	10
462	Radiotherapy and prevention of thrombosis in a patient with atrial fibrillation. International Journal of Cardiology, 2014, 173, e18-e19.	0.8	0
463	The nephrologist's anticoagulation treatment patterns/regimens in chronic hemodialysis patients with atrial fibrillation. Journal of Nephrology, 2014, 27, 187-192.	0.9	13
464	Oral Anticoagulation Therapy for Elderly Patients With Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 5-15.	0.7	5
465	The young patient with asymptomatic atrial fibrillation: what is the evidence to leave the arrhythmia untreated?. European Heart Journal, 2014, 35, 1439-1447.	1.0	20
466	Integrated pharmaceutical care in the community: (how) can we turn vision into reality?. Drugs and Therapy Perspectives, 2014, 30, 65-71.	0.3	0
467	Lone Atrial Fibrillation. Journal of the American College of Cardiology, 2014, 63, 1715-1723.	1.2	177
471	Success of electrocardioversion on the elderly. Netherlands Heart Journal, 2014, 22, 100-104.	0.3	1
472	A Randomized Controlled Trial of Catheter Ablation Versus Medical Treatment of Atrial Fibrillation in Heart Failure (The CAMTAF Trial). Circulation: Arrhythmia and Electrophysiology, 2014, 7, 31-38.	2.1	387

#	Article	IF	CITATIONS
473	The budget impact of left atrial appendage closure compared with adjusted-dose warfarin and dabigatran etexilate for stroke prevention in atrial fibrillation. Europace, 2014, 16, 1131-1136.	0.7	26
474	Atrial fibrillation from the pathologist's perspective. Cardiovascular Pathology, 2014, 23, 71-84.	0.7	90
475	Epicardial and endocardial electrophysiological guided thoracoscopic surgery for atrial fibrillation: A multidisciplinary approach of atrial fibrillation ablation in challenging patients. International Journal of Cardiology, 2014, 173, 229-235.	0.8	22
476	Rationale and design of The Intracoronary Stenting and Antithrombotic Regimenâ€"Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oraL anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study. American Heart lournal. 2014. 167. 459-465.e1.	1.2	19
477	The Current and Future Role of the Novel Oral Anticoagulants—Indications Beyond Atrial Fibrillation. Heart Lung and Circulation, 2014, 23, 2-9.	0.2	6
478	The dilemma of atrial fibrillation in intracerebral haemorrhage: how to balance the risks of ischaemia and bleeding. European Journal of Neurology, 2014, 21, 549-551.	1.7	3
479	Atrial Fibrillation Therapy. , 2014, , .		3
480	Electrophysiological and haemodynamic effects of vernakalant and flecainide in dyssynchronous canine hearts. Europace, 2014, 16, 1249-1256.	0.7	8
481	Contemporary Management of Arrhythmias During Pregnancy. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 961-967.	2.1	107
482	Atrial fibrillation: state of the art. Wiener Klinische Wochenschrift, 2014, 126, 692-704.	1.0	0
483	Usefulness of serum uric acid level to predict atrial fibrillation recurrence after cryoballoon-based catheter ablation. Europace, 2014, 16, 1731-1737.	0.7	31
484	Cost-effectiveness of cryoballoon ablation for the management of paroxysmal atrial fibrillation. Europace, 2014, 16, 652-659.	0.7	33
486	Diagnostic Evaluation and Follow-Up of Patients with Atrial Fibrillation. Cardiology Clinics, 2014, 32, 507-519.	0.9	3
487	Imaging before cryoablation of atrial fibrillation: is phrenic nerve palsy predictable?. Europace, 2014, 16, 505-510.	0.7	18
488	Age-Specific Incidence, Outcome, Cost, and Projected Future Burden of Atrial Fibrillation–Related Embolic Vascular Events. Circulation, 2014, 130, 1236-1244.	1.6	145
489	Blood pressure variability in patients with atrial fibrillation. Autonomic Neuroscience: Basic and Clinical, 2014, 185, 129-133.	1.4	7
490	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2733-2779.	1.0	3,469
491	Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation. Europace, 2014, 16, 973-979.	0.7	62

#	Article	IF	CITATIONS
492	Management of Recent-onset Sustained Atrial Fibrillation: Pharmacologic and Nonpharmacologic Strategies. Clinical Therapeutics, 2014, 36, 1151-1159.	1.1	10
494	Relationship between platelet indices and international normalized ratio in patients with non-valvular atrial fibrillation. Platelets, 2014, 25, 311-316.	1.1	15
495	Role of endo-epicardial dissociation of electrical activity and transmural conduction in the development of persistent atrial fibrillation. Progress in Biophysics and Molecular Biology, 2014, 115, 173-185.	1.4	75
496	Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting. Revista Portuguesa De Cardiologia (English Edition), 2014, 33, 535-544.	0.2	21
497	The definition of valvular and non-valvular atrial fibrillation: results of a physicians' survey. Europace, 2014, 16, 1720-1725.	0.7	60
498	Management of Chronic Kidney Disease. , 2014, , .		4
499	Cardiac Potassium Channel Subtypes: New Roles in Repolarization and Arrhythmia. Physiological Reviews, 2014, 94, 609-653.	13.1	181
500	Use of event recorders and loop recorders in clinical practice: results of the European Heart Rhythm Association Survey. Europace, 2014, 16, 1384-1386.	0.7	28
501	Association of Quality of Life, Anxiety, and Depression with Left Atrial Ablation Outcomes. PACE - Pacing and Clinical Electrophysiology, 2014, 37, 703-711.	0.5	27
502	Sex differences in stroke prevention in atrial fibrillation in French primary care. Results of the AFIGP (Atrial Fibrillation In General Practice) Database. Clinical Research in Cardiology, 2014, 103, 887-893.	1.5	21
503	Simultaneous assessment of contact pressure and local electrical coupling index using robotic navigation. Journal of Interventional Cardiac Electrophysiology, 2014, 40, 23-31.	0.6	8
504	Tissue velocity imaging of the left atrium predicts response to flecainide in patients with acute atrial fibrillation. Heart Rhythm, 2014, 11, 478-484.	0.3	9
505	Vitamin K Antagonists: Beyond Bleeding. Seminars in Dialysis, 2014, 27, 37-41.	0.7	25
506	Stroke and bleeding risk evaluation in atrial fibrillation: results of the European Heart Rhythm Association survey. Europace, 2014, 16, 698-702.	0.7	7
507	Major Bleeding With Dabigatran and Rivaroxaban in Patients With Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 665-672.	0.7	29
508	Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis. Journal of Interventional Cardiac Electrophysiology, 2014, 40, 277-284.	0.6	48
509	Practical introduction of novel oral anticoagulants through an anticoagulation nurse. The Leeuwarden model. Netherlands Heart Journal, 2014, 22, 297-300.	0.3	3
510	New Oral Anticoagulants in Practice: Pharmacological and Practical Considerations. American Journal of Cardiovascular Drugs, 2014, 14, 175-189.	1.0	71

#	Article	IF	CITATIONS
511	On the monitoring of dabigatran treatment in "real life―patients with atrial fibrillation. Thrombosis Research, 2014, 134, 783-789.	0.8	47
512	Brugada syndrome risk loci seem protective against atrial fibrillation. European Journal of Human Genetics, 2014, 22, 1357-1361.	1.4	13
513	Essentials of Atrial Fibrillation. , 2014, , .		3
514	Additional benefit of cryoballoon-based atrial fibrillation ablation beyond pulmonary vein isolation: modification of ganglionated plexi. Europace, 2014, 16, 645-651.	0.7	54
515	External Validity of the <scp>ARISTOTLE</scp> Trial in Real‣ife Atrial Fibrillation Patients. Cardiovascular Therapeutics, 2014, 32, 214-218.	1.1	15
517	Rapid slowing of the atrial fibrillatory rate after administration of AZD7009 predicts conversion of atrial fibrillation. Journal of Electrocardiology, 2014, 47, 316-323.	0.4	7
518	Prolonged QTc affects short-term and long-term outcomes in patients with normal left ventricular function undergoing cardiac surgery. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 1627-1633.	0.4	4
519	Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong. Heart Rhythm, 2014, 11, 1401-1408.	0.3	105
521	Persistent lone atrial fibrillation: Clinicopathologic study of 19 cases. Heart Rhythm, 2014, 11, 1250-1258.	0.3	47
522	Managing Novel Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Device Surgery: Canadian Survey. Canadian Journal of Cardiology, 2014, 30, 231-236.	0.8	35
523	Circulating serum levels of growth differentiation factor-15 and neuregulin-1 in patients with paroxysmal non-valvular atrial fibrillation. International Journal of Cardiology, 2014, 172, e311-e313.	0.8	25
524	Digoxin in patients with permanent atrial fibrillation: Data from the RACE II study. Heart Rhythm, 2014, 11, 1543-1550.	0.3	62
525	Anterior-posterior versus anterior-lateral electrode position for external electrical cardioversion of atrial fibrillation: A meta-analysis of randomized controlled trials. Archives of Cardiovascular Diseases, 2014, 107, 280-290.	0.7	20
526	The Predictive Ability of the CHADS2 and CHA2DS2-VASc Scores for Bleeding Risk in Atrial Fibrillation: The MAQI2 Experience. Thrombosis Research, 2014, 134, 294-299.	0.8	35
527	Clinical Characteristics and Prognostic Significance of Chronic Obstructive Pulmonary Disease in Patients With Atrial Fibrillation: Results From a Multicenter Atrial Fibrillation Registry Study. Journal of the American Medical Directors Association, 2014, 15, 576-581.	1.2	39
528	Maintenance of sinus rhythm after electrical cardioversion for recurrent atrial fibrillation following mitral valve surgery with or without associated radiofrequency ablation. International Journal of Cardiology, 2014, 175, 290-296.	0.8	4
529	Atrial Fibrillation at Mid-Term After Bioprosthetic Aortic Valve Replacement. Circulation Journal, 2014, 79, 70-76.	0.7	10
530	The role of valvular regurgitation in catheter ablation outcomes of patients with long-standing persistent atrial fibrillation. Europace, 2014, 16, 848-854.	0.7	30

	CITATION REI	PORT	
Article		IF	Citations
Differences in Quality of Life, Anxiety and Depression in Patients with Paroxysmal Atria and Common Forms of Atrioventricular Reentry Supraventricular Tachycardias. Indian F Electrophysiology Journal, 2014, 14, 250-257.		0.3	15
Use of drug-eluting versus bare-metal stents after an acute coronary syndrome in Portu EURHOBOP study. Revista Portuguesa De Cardiologia (English Edition), 2015, 34, 449-		0.2	3
Punteggi e strumenti di misura in medicina d'urgenza. EMC - Urgenze, 2015, 19, 1-	-11.	0.0	0
Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai. Chronic Diseases and Tr Medicine, 2015, 1, 203-209.		0.9	2
Can Contrast-Enhanced Multi-Detector Computed Tomography Replace Transesophag Echocardiography for the Detection of Thrombogenic Milieu and Thrombi in the Left At AÂProspective Study with 124 Patients. RoFo Fortschritte Auf Dem Gebiet Der Rontger Bildgebenden Verfahren, 2015, 188, 45-52.	rial Appendage:	0.7	14
A novel statistical model of the dual pathway atrioventricular node during atrial fibrillat $\cdot$	ion. , 2015, ,		0
Characterization of AV-nodal properties during atrial fibrillation using a multilevel mode approach. , 2015, , .	elling		1
Prediction of thromboâ $\in$ embolic risk in patients with hypertrophic cardiomyopathy ( <s< td=""><td>cp&gt;HCM) Tj ETQq1</td><td>1 0,78431 2.9</td><td>4_rgBT /Over</td></s<>	cp>HCM) Tj ETQq1	1 0,78431 2.9	4_rgBT /Over
Postoperative atrial fibrillation in nonâ€cardiac and cardiac surgery: an overview. Journa Thrombosis and Haemostasis, 2015, 13, S304-S312.	al of	1.9	130
Catheter Ablation of Atrial Fibrillation and Thromboembolic Risk. Circulation Journal, 20	015, 79, 445.	0.7	0
Left Atrial Appendage Closure Reduces the Incidence of Postoperative Cerebrovascular Patients Undergoing Cardiac Surgery. Circulation Journal, 2015, 79, 2591-2597.	Accident in	0.7	19
Incidence of Ischemic Stroke in Japanese Patients With Atrial Fibrillation Not Receiving Anticoagulation Therapy. Circulation Journal, 2015, 79, 432-438.		0.7	108
How Can We Bridge the Results of Global Clinical Trials and Region/Country Specific Cl by Region/Country Specific Registry Data?. Circulation Journal, 2015, 79, 287-288.	inical Practice	0.7	1
Age and CHADS2 Score Predict the Effectiveness of Renin-Angiotensin System Blocker	s on Primary	16	8

Prevention of Atrial Fibrillation. Scientific Reports, 2015, 5, 11442. Atrial Fibrillation in Athletes. Cardiology in Review, 2015, 23, 247-251. 546 0.6 6 Detecting and Diagnosing Atrial Fibrillation (D2AF): study protocol for a cluster randomised controlled trial. Trials, 2015, 16, 478. 548 Effect of Statins on the Incidence of Postoperative Atrial Fibrillation after Cardiac Valve Surgery. 550 1.2 7 Pharmacotherapy, 2015, 35, 998-1006. Cardiac Autoantibody Levels Predict Recurrence Following Cryoballoonâ€Based Pulmonary Vein Isolation in Paroxysmal Atrial Fibrillation Patients. Journal of Cardiovascular Electrophysiology, 2015, 26, 615-621.

#

531

534

536

537

538

540

541

542

543

544

545

#	Article	IF	CITATIONS
552	The Clinical Relevance of Microbleeds in Stroke study (CROMIS-2): rationale, design, and methods. International Journal of Stroke, 2015, 10, 155-161.	2.9	51
553	Increased arterial stiffness is an independent predictor of atrial fibrillation in hypertensive patients. Journal of Hypertension, 2015, 33, 2150-2155.	0.3	23
554	Effect of Vitamin D Replacement on Atrial Electromechanical Delay in Subjects with Vitamin D Deficiency. Journal of Cardiovascular Electrophysiology, 2015, 26, 649-655.	0.8	14
555	Triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation. Coronary Artery Disease, 2015, 26, 372-380.	0.3	19
556	Cardiovascular Events of Electrical Cardioversion Under Optimal Anticoagulation in Atrial Fibrillation: The Multicenter Analysis. Yonsei Medical Journal, 2015, 56, 1552.	0.9	11
557	Serum levels of nicotinamide-adenine dinucleotide phosphate oxidase 4 are associated with non-valvular atrial fibrillation. Biomedical Reports, 2015, 3, 864-868.	0.9	15
558	Anticoagulation in Atrial Fibrillation – Current Concepts. Arrhythmia and Electrophysiology Review, 2015, 04, 100.	1.3	13
559	AN OUTPATIENT WITH ATRIAL FIBRILLATION: KEY FEATURES. THE FIRST DATA OF REKVAZA FP - YAROSLAVL REGISTER. Rational Pharmacotherapy in Cardiology, 2015, 11, 149-152.	0.3	9
560	Stand-alone totally thoracoscopic left atrial appendage exclusion using a novel clipping system in patients with high risk of stroke – initial experience and literature review. Kardiochirurgia I Torakochirurgia Polska, 2015, 4, 298-303.	0.1	8
561	The Current Role of Omega-3 Fatty Acids in the Management of Atrial Fibrillation. International Journal of Molecular Sciences, 2015, 16, 22870-22887.	1.8	16
562	Association Between Left Atrial Appendage Morphology Evaluated by Trans-Esophageal Echocardiography and Ischemic Cerebral Stroke in Patients With Atrial Fibrillation. International Heart Journal, 2015, 56, 329-334.	0.5	11
563	Predictors of atrial fibrillation recurrence after cryoballoon ablation. Journal of Blood Medicine, 2015, 6, 211.	0.7	16
564	Managing atrial fibrillation in the very elderly patient: challenges and solutions. Vascular Health and Risk Management, 2015, 11, 555.	1.0	47
565	Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation. Vascular Health and Risk Management, 2015, 11, 317.	1.0	11
566	CHADS2 and CHA2DS2-VASc Scoring Systems for Predicting Atrial Fibrillation following Cardiac Valve Surgery. PLoS ONE, 2015, 10, e0123858.	1.1	30
567	Risk and Outcome after Ablation of Isthmus-Dependent Atrial Flutter in Elderly Patients. PLoS ONE, 2015, 10, e0127672.	1.1	14
568	Atrial Fibrillation and Chronic Kidney Disease in Hypertension: A Common and Dangerous Triad. Current Vascular Pharmacology, 2015, 13, 111-120.	0.8	8
569	Relation of Biomarkers of Inflammation and Oxidative Stress with Hypertension Occurrence in Lone Atrial Fibrillation. Mediators of Inflammation, 2015, 2015, 1-8.	1.4	16

#	ARTICLE	IF	CITATIONS
570	Comparison of health-related quality of life among patients using novel oral anticoagulants or warfarin for non-valvular atrial fibrillation. Anatolian Journal of Cardiology, 2015, 16, 474-481.	0.5	19
571	Clinical Characteristics and Impact of Diabetes Mellitus on Outcomes in Patients with Nonvalvular Atrial Fibrillation. Yonsei Medical Journal, 2015, 56, 62.	0.9	12
572	The development of AF over time in patients with permanent pacemakers: objective assessment with pacemaker diagnostics demonstrates distinct patterns of AF. Europace, 2015, 17, 864-870.	0.7	18
573	Is one month treatment with dabigatran before cardioversion of atrial fibrillation sufficient to prevent thromboembolism?: Table 1. Europace, 2015, 17, 1514-1517.	0.7	15
574	Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE‣Y trial. Journal of Thrombosis and Haemostasis, 2015, 13, 699-707.	1.9	53
575	Obesity and atrial fibrillation: A comprehensive review of the pathophysiological mechanisms and links. Journal of Cardiology, 2015, 66, 361-369.	0.8	108
576	The role of preprocedural monocyte-to-high-density lipoprotein ratio in prediction of atrial fibrillation recurrence after cryoballoon-based catheter ablation. Europace, 2015, 17, 1807-1815.	0.7	98
577	TGF-β1 and TIMP-4 regulate atrial fibrosis in atrial fibrillation secondary to rheumatic heart disease. Molecular and Cellular Biochemistry, 2015, 406, 131-138.	1.4	18
578	AF is associated with self-reported syncope and falls in a general population cohort. Age and Ageing, 2015, 44, 598-603.	0.7	33
579	Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study. Europace, 2015, 17, 1215-1222.	0.7	28
580	Effect of antihypertensive agents on risk of atrial fibrillation: a meta-analysis of large-scale randomized trials. Europace, 2015, 17, 701-710.	0.7	40
581	Systematic comparison of non-invasive measures for the assessment of atrial fibrillation complexity: a step forward towards standardization of atrial fibrillation electrogram analysis. Europace, 2015, 17, 318-325.	0.7	20
583	To treat or not to treat very elderly naÃ <sup>-</sup> ve patients with atrial fibrillation with vitamin K antagonists (VKA): results from the VENPAF cohort. Internal and Emergency Medicine, 2015, 10, 795-804.	1.0	17
584	Effect of Early Direct Current Cardioversion on the Recurrence of Atrial Fibrillation in Patients With Persistent Atrial Fibrillation. American Journal of Cardiology, 2015, 116, 225-229.	0.7	6
585	Factors predisposing to ventricular proarrhythmia during antiarrhythmic drug therapy for atrial fibrillation in patients with structurally normal heart. Heart Rhythm, 2015, 12, 1490-1500.	0.3	14
586	Stroke and Atrial Fibrillation. Stroke, 2015, 46, 605-607.	1.0	5
587	Left atrial appendage morphology is closely associated with specific echocardiographic flow pattern in patients with atrial fibrillation. Europace, 2015, 17, 539-545.	0.7	52
588	Clinical management of arrhythmias in elderly patients: results of the European Heart Rhythm Association survey. Europace, 2015, 17, 314-317.	0.7	30

#	Article	IF	CITATIONS
589	Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de EstimulaciÃ <sup>3</sup> n CardÃaca y ElectrofisiologÃa (SOLEACE). Europace, 2015, 17, 1747-1769.	0.7	119
590	Retrospective Evaluation of Oral Anticoagulant Therapy may not Reveal the Reality. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 484-485.	0.7	0
591	Post-discharge electrocardiogram Holter monitoring in recently hospitalised individuals with chronic atrial fibrillation to enhance therapeutic monitoring and identify potentially predictive phenotypes. European Journal of Cardiovascular Nursing, 2015, 14, 384-394.	0.4	4
592	The 2014 Atrial Fibrillation Guidelines Companion: AÂPractical Approach to the Use of the Canadian Cardiovascular Society Guidelines. Canadian Journal of Cardiology, 2015, 31, 1207-1218.	0.8	43
593	Echocardiography for Electrophysiology Procedures. Current Anesthesiology Reports, 2015, 5, 429-437.	0.9	0
594	The WATCHMAN device for stroke prophylaxis in atrial fibrillation: an evolving niche. Hospital Practice (1995), 2015, 43, 13-21.	0.5	1
595	Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012: a nationwide database study. Open Heart, 2015, 2, e000290.	0.9	44
596	Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ, The, 2015, 351, h5876.	3.0	120
597	Temporal evolution of treatment of patients with atrial fibrillation in a urban health care area. Medicina ClÂnica (English Edition), 2015, 144, 483-486.	0.1	0
598	Oral anticoagulation is frequently discontinued after ablation of paroxysmal atrial fibrillation despite previous stroke: data from the German Ablation Registry. Clinical Research in Cardiology, 2015, 104, 463-470.	1.5	30
599	Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation. European Heart Journal, 2015, 36, 653-656.	1.0	58
601	Troponin-I Is a Predictor of a Delayed Diagnosis of Atrial Fibrillation in Acute Ischemic Stroke and Transient Ischemic Attack. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 66-72.	0.7	8
602	Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease. Kidney International, 2015, 87, 200-209.	2.6	34
603	The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights From 2014. Journal of Cardiothoracic and Vascular Anesthesia, 2015, 29, 1-7.	0.6	3
604	Prevalence of Intracardiac Thrombi Under Phenprocoumon, Direct Oral Anticoagulants (Dabigatran) Tj ETQq0 0 Journal of Cardiology, 2015, 115, 635-640.	0 rgBT /Ov 0.7	verlock 10 Tf 35
605	A circulating biomarker risk-prediction model correlates with CHADS-2 risk score in chronic atrial fibrillation. IJC Metabolic & Endocrine, 2015, 6, 24-26.	0.5	5
606	Comparison of â€~anatomically designed' and â€~point-by-point' catheter ablations for human atrial fibrillation in terms of procedure timing and costs in German hospitals. Europace, 2015, 17, 1030.1-1037.	0.7	6
607	Non-vitamin K antagonist oral anticoagulants in the cardioversion of patients with atrial fibrillation: systematic review and meta-analysis. Clinical Research in Cardiology, 2015, 104, 582-590.	1.5	24

#	Article	IF	Citations
608	Thromboembolic Prevention in Frail Elderly Patients With Atrial Fibrillation: A Practical Algorithm. Journal of the American Medical Directors Association, 2015, 16, 358-364.	1.2	41
609	Asymptomatic Atrial Fibrillation: Clinical Correlates, Management, and Outcomes in the EORP-AF Pilot General Registry. American Journal of Medicine, 2015, 128, 509-518.e2.	0.6	242
610	Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Europace, 2015, 17, 187-193.	0.7	152
611	Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation: results on health-related quality of life and symptom burden. The MANTRA-PAF trial. Europace, 2015, 17, 215-221.	0.7	69
612	Adding Rigor to Stroke Risk Prediction in Atrial Fibrillation. Journal of the American College of Cardiology, 2015, 65, 233-235.	1.2	13
613	Long-term results of surgical minimally invasive pulmonary vein isolation for paroxysmal lone atrial fibrillation. Europace, 2015, 17, 747-752.	0.7	22
614	An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). American Heart Journal, 2015, 169, 472-478.e5.	1.2	140
615	Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace, 2015, 17, 194-206.	0.7	41
616	Short-course of ranolazine prevents postoperative atrial fibrillation following coronary artery bypass grafting and valve surgeries. Clinical Research in Cardiology, 2015, 104, 410-417.	1.5	24
617	Safety and efficacy outcomes in patients undergoing pulmonary vein isolation with second-generation cryoballoon. Europace, 2015, 17, 379-387.	0.7	86
618	Body weight and risk of atrial fibrillation in 7,169 patients with newly diagnosed type 2 diabetes; an observational study. Cardiovascular Diabetology, 2015, 14, 5.	2.7	49
619	Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. Journal of Internal Medicine, 2015, 278, 1-18.	2.7	64
620	How are patients with atrial fibrillation approached and informed about their risk profile and available therapies in Europe? Results of the European Heart Rhythm Association Survey. Europace, 2015, 17, 468-472.	0.7	27
621	The impact of cryoballoon-based catheter ablation on left atrial structural and potential electrical remodeling in patients with paroxysmal atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2015, 44, 131-139.	0.6	8
622	Reply to â€~Intervention of clinical management units of physical medicine and rehabilitation in cerebrovascular disease'. NeurologÃa (English Edition), 2015, 30, 389.	0.2	0
623	Left Atrial Appendage Closure Is Preferred to Chronic Warfarin Therapy. Cardiac Electrophysiology Clinics, 2015, 7, 403-413.	0.7	3
624	Management of the patient with an acute coronary syndrome using oral anticoagulation. Netherlands Heart Journal, 2015, 23, 407-414.	0.3	4
625	Antidepressants strongly influence the relationship between depression and heart rate variability: findings from The Irish Longitudinal Study on Ageing (TILDA). Psychological Medicine, 2015, 45, 623-636.	2.7	80

	CITATION	CITATION REPORT	
#	Article	IF	Citations
626	Atrial flutter and thromboembolic risk: a systematic review. Heart, 2015, 101, 1446-1455.	1.2	54
627	Selective Vulnerability of Cortical Border Zone to Microembolic Infarct. Stroke, 2015, 46, 1864-1869.	1.0	17
628	Gender Differences in Patients with Atrial Fibrillation Undergoing Electrical Cardioversion. Journal of Women's Health, 2015, 24, 466-470.	1.5	15
629	Clinical results of atrial fibrillation patients treated with cryoballoon ablation: A single center experience. Journal of Clinical and Experimental Investigations, 2015, 5, .	0.1	0
630	Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: Perspectives from the observational, prospective WATER Registry. Cardiology Journal, 2015, 22, 567-575.	0.5	15
631	Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording. Europace, 2015, 17, 1023-1029.	0.7	128
632	Treatment of Nonagenarians With Atrial Fibrillation: Insights From the Berlin Atrial Fibrillation (BAF) Registry. Journal of the American Medical Directors Association, 2015, 16, 969-972.	1.2	14
633	Extrapolation of acenocoumarol pharmacogenetic algorithms. Vascular Pharmacology, 2015, 74, 151-157.	1.0	5
634	Multimodality imaging in preoperative assessment of left atrial appendage transcatheter occlusion with the Amplatzer Cardiac Plug. European Heart Journal Cardiovascular Imaging, 2015, 16, 1276-1287.	0.5	40
635	Incidence and predictors of dormant conduction after cryoballoon ablation incorporating a 30-min waiting period. Europace, 2015, 17, 1383-1390.	0.7	15
636	EARLY: a pilot study on early diagnosis of atrial fibrillation in a primary healthcare centre. Europace, 2015, 17, 1688-93.	0.7	18
637	Detection and Predictors of Paroxysmal Atrial Fibrillation in Acute Ischemic Stroke and Transient Ischemic Attack Patients in Singapore. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 2122-2127.	0.7	7
638	Ventricular rate during acute atrial fibrillation and outcome of electrical cardioversion: The FinCV Study. Annals of Medicine, 2015, 47, 341-345.	1.5	5
639	Left atrial dyssynchrony time measured by tissue Doppler imaging to predict atrial fibrillation recurrences after pulmonary vein isolation. Anatolian Journal of Cardiology, 2015, 15, 115-122.	0.4	7
640	$\hat{I}^2$ blockers in patients with heart failure and atrial fibrillation. Lancet, The, 2015, 385, 1618.	6.3	4
643	Sex-related predictors for thromboembolic events after catheter ablation of atrial fibrillation: The Leipzig Heart Center AF Ablation Registry. Clinical Research in Cardiology, 2015, 104, 603-610.	1.5	15
644	History and development of surgical procedures for atrial fibrillation. Surgery Today, 2015, 45, 1475-1480.	0.7	3
645	Anticoagulant Treatment in Patients with Atrial Fibrillation and Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 1120-1125.	0.7	1

#	Article	IF	CITATIONS
646	Prevalence and antithrombotic management of atrial fibrillation in hospitalised patients. Heart, 2015, 101, 884-893.	1.2	17
647	Changes in renal function after catheter ablation of atrial fibrillation are associated with CHADS <sub>2</sub> and CHA <sub>2</sub> DS <sub>2</sub> -VASc scores and arrhythmia recurrences. Heart, 2015, 101, 126-131.	1.2	26
648	Selection for atrial fibrillation ablation: Importance of diastolic function grading. Journal of Cardiology, 2015, 65, 479-486.	0.8	7
649	A Health Economic Evaluation of Stroke Prevention in Atrial Fibrillation: Guideline Adherence Versus the Observed Treatment Strategy Prior to 2012 in Denmark. Pharmacoeconomics, 2015, 33, 967-979.	1.7	15
650	Percutaneous left atrial appendage closure: Technical aspects and prevention of periprocedural complications with the watchman device. World Journal of Cardiology, 2015, 7, 65.	0.5	39
651	SAfety of Fondaparinux in transoesophageal echocardiography-guided Electric cardioversion of Atrial Fibrillation (SAFE-AF) study: A pilot study. Archives of Cardiovascular Diseases, 2015, 108, 122-131.	0.7	8
652	Prospective National Study of the Prevalence, Incidence, Management and Outcome of a Large Contemporary Cohort of Patients With Incident Nonâ€Valvular Atrial Fibrillation. Journal of the American Heart Association, 2015, 4, e001486.	1.6	171
653	Prevention and management of stroke in women. Expert Review of Cardiovascular Therapy, 2015, 13, 403-415.	0.6	22
654	MMP-9 in atrial remodeling in patients with atrial fibrillation. Annales De Cardiologie Et D'Angeiologie, 2015, 64, 285-291.	0.3	22
655	Early detection of occult atrial fibrillation and stroke prevention. Heart, 2015, 101, 1097-1102.	1.2	37
656	Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation. Expert Opinion on Drug Safety, 2015, 14, 683-695.	1.0	9
657	Atrial Electromechanical Delay Is Impaired in Patients with Psoriasis. Medical Principles and Practice, 2015, 24, 30-35.	1.1	11
658	Dabigatran for the prevention and treatment of thromboembolic disorders. Expert Review of Cardiovascular Therapy, 2015, 13, 529-540.	0.6	6
659	Type 2 diabetes mellitus and atrial fibrillation: From mechanisms to clinical practice. Archives of Cardiovascular Diseases, 2015, 108, 269-276.	0.7	102
660	Periatrial epicardial adipose tissue thickness is an independent predictor of atrial fibrillation recurrence after cryoballoon-based pulmonary vein isolation. Journal of Cardiovascular Computed Tomography, 2015, 9, 295-302.	0.7	38
662	Edoxaban: A Review in Nonvalvular Atrial Fibrillation. American Journal of Cardiovascular Drugs, 2015, 15, 351-361.	1.0	5
663	The natural history of atrial fibrillation in patients with permanent pacemakers: is atrial fibrillation a progressive disease?. Journal of Interventional Cardiac Electrophysiology, 2015, 44, 23-30.	0.6	28
664	Quality Markers in Cardiology. Main Markers to Measure Quality of Results (Outcomes) and Quality Measures Related to Better Results in Clinical Practice (Performance Metrics). INCARDIO (Indicadores) Tj ETQq1 1 Revista Espanola De Cardiologia (English Ed ). 2015. 68. 976-995.e10.	0,78431 0,4	4 rgBT /Over

#	Article	IF	CITATIONS
666	Stroke Risk Stratification in Patients WithÂAtrial Fibrillation. Journal of the American College of Cardiology, 2015, 66, 1860-1863.	1.2	6
667	A 290 mV Sub- <formula formulatype="inline"> <tex notation="TeX">\$V_{m T}\$</tex></formula> ASIC for Real-Time Atrial Fibrillation Detection. IEEE Transactions on Biomedical Circuits and Systems, 2015, 9, 377-386.	2.7	22
668	Assessment of the CHA <sub>2</sub> DS <sub>2</sub> -VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2015, 314, 1030.	3.8	262
669	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2015, 17, 1467-1507.	0.7	951
670	Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients. Stroke, 2015, 46, 2830-2837.	1.0	6
671	Controversies in Cardiology. , 2015, , .		0
672	Rate-Control Treatment and Mortality in Atrial Fibrillation. Circulation, 2015, 132, 1604-1612.	1.6	110
673	Rate Control in Atrial Fibrillation. Circulation, 2015, 132, 1597-1599.	1.6	5
674	Discrepancy between guidelines for stroke prevention in atrial fibrillation and practice patterns in primary care. The nationwide French AFIGP survey. Archives of Cardiovascular Diseases, 2015, 108, 544-553.	0.7	17
675	Tratamiento anticoagulante en pacientes con fibrilación auricular no valvular en un centro de salud. Grado de control del INR e incidencia de episodios cardioembólicos. Medicina General Y De Familia, 2015, 4, 37-42.	0.1	0
676	Use of drug-eluting versus bare-metal stents after an acute coronary syndrome in Portugal: The EURHOBOP study. Revista Portuguesa De Cardiologia, 2015, 34, 449-456.	0.2	4
677	Severe Central Sleep Apnea Is Associated with Atrial Fibrillation in Patients with Left Ventricular Systolic Dysfunction. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 706-712.	0.5	15
678	Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. Europace, 2015, 17, 18-23.	0.7	102
679	Red blood cell distribution width predicts outcome of cryoballoon-based atrial fibrillation ablation. Journal of Interventional Cardiac Electrophysiology, 2015, 42, 51-58.	0.6	22
680	Effects of Persistent Atrial Fibrillation on Serum Galectin-3 Levels. American Journal of Cardiology, 2015, 115, 647-651.	0.7	54
681	Stroke Prophylaxis in Atrial Fibrillation: Searching for Management Improvement Opportunities in the Emergency Department: The HERMES-AF Study. Annals of Emergency Medicine, 2015, 65, 1-12.	0.3	34
682	Neutrophil–Lymphocyte Ratio May Predict Left Atrial Thrombus in Patients With Nonvalvular Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 166-171.	0.7	40
683	Transoesophageal echocardiography of aortic atherosclerosis: the additive value of three-dimensional over two-dimensional imaging. European Heart Journal Cardiovascular Imaging, 2015, 16, 389-394.	0.5	11

#	Article	IF	CITATIONS
684	Prognostic Value of Total Atrial Conduction Time Measured with Tissue Doppler Imaging to Predict the Maintenance of Sinus Rhythm after External Electrical Cardioversion of Persistent Atrial Fibrillation. Echocardiography, 2015, 32, 420-427.	0.3	14
685	The cost-effectiveness of radiofrequency catheter ablation as first-line treatment for paroxysmal atrial fibrillation: results from a MANTRA-PAF substudy. Europace, 2015, 17, 48-55.	0.7	42
688	A Prospective DEâ€MRI Study Evaluating the Role of TGFâ€Î²1 in Left Atrial Fibrosis and Implications for Outcomes of Cryoballoonâ€Based Catheter Ablation: New Insights into Primary Fibrotic Atriocardiomyopathy. Journal of Cardiovascular Electrophysiology, 2015, 26, 251-259.	0.8	40
689	Antiplatelet and anticoagulant drugs management before gastrointestinal endoscopy: Do clinicians adhere to current guidelines?. Digestive and Liver Disease, 2015, 47, 45-49.	0.4	10
690	Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation. Nephrology Dialysis Transplantation, 2015, 30, 491-498.	0.4	96
691	Improvement in Estimated Glomerular Filtration Rate in Patients with Chronic Kidney Disease Undergoing Catheter Ablation for Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2015, 26, 21-27.	0.8	26
692	Statins in Secondary Prevention of Atrial Fibrillation. Rational Pharmacotherapy in Cardiology, 2016, 12, 517-521.	0.3	0
693	THE PREDICTION OF ATRIAL FIBRILLATION RECURRENCE AT VARIOUS METHODS OF SINUS RHYTHM RECOVERY. Rational Pharmacotherapy in Cardiology, 2016, 12, 285-290.	0.3	0
694	Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true. Rational Pharmacotherapy in Cardiology, 2016, 12, 465-470.	0.3	1
695	Targeting stroke risk and improving outcomes in patients with atrial fibrillation in Latin America. Sao Paulo Medical Journal, 2016, 134, 534-542.	0.4	2
696	ATRIAL FIBRILLATION: CURRENT PROBLEMS AND PROSPECTS OF MEDICAL CARE, TREATMENT AND PREVENTION. Rational Pharmacotherapy in Cardiology, 2016, 12, 196-203.	0.3	3
698	Atrial fibrillation is associated with high levels of monocyte-platelet-aggregates and increased CD11b expression in patients with aortic stenosis. Thrombosis and Haemostasis, 2016, 115, 993-1000.	1.8	20
699	Value of Implantable Loop Recorders in Monitoring Efficacy of Radiofrequency Catheter Ablation in Atrial Fibrillation. Medical Science Monitor, 2016, 22, 2846-2851.	0.5	7
700	Atrial fibrillation: review of current treatment strategies. Journal of Thoracic Disease, 2016, 8, E886-E900.	0.6	59
702	Influence of Clinical Parameters and Anticoagulation on Intraprocedural Cerebral Microembolic Signals during Pulmonary Vein Isolation. PLoS ONE, 2016, 11, e0157886.	1.1	3
703	Evaluating the Efficacy and Safety of Internal Cardioversion with Implantable Cardioverter Defibrillator Device for Atrial Fibrillation in Systolic Heart Failure Patients. Annals of Noninvasive Electrocardiology, 2016, 21, 181-188.	0.5	7
704	Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life. European Journal of Internal Medicine, 2016, 33, 42-46.	1.0	14
705	How to manage patients on rivaroxaban in the emergency department. European Journal of Emergency Medicine, 2016, 23, 320-329.	0.5	2

#	Article	IF	CITATIONS
706	Inherited Structural Heart Diseases With Potential Atrial Fibrillation Occurrence. Journal of Cardiovascular Electrophysiology, 2016, 27, 242-252.	0.8	12
707	P-wave dispersion: What we know till now?. JRSM Cardiovascular Disease, 2016, 5, 204800401663944.	0.4	48
708	The Impact of Echocardiographic Epicardial Fat Thickness on Outcomes of Cryoballoonâ€Based Atrial Fibrillation Ablation. Echocardiography, 2016, 33, 821-829.	0.3	21
709	Documented atrial fibrillation recurrences after pulmonary vein isolation are associated with diminished quality of life. Journal of Cardiovascular Medicine, 2016, 17, 201-208.	0.6	5
710	The Total Incidence of Complications and the Impact of an Anticoagulation Regime on Adverse Events After Cryoballoon Ablation of Atrial Fibrillation: A Singleâ€Center Study of 409 Patients. Cardiovascular Therapeutics, 2016, 34, 144-151.	1.1	11
711	Episodic Left Bundle Branch Block—A Comprehensive Review of the Literature. Annals of Noninvasive Electrocardiology, 2016, 21, 117-125.	0.5	20
712	Effects of Aging on the Coagulation Fibrinolytic System in Outpatients of the Cardiovascular Department. Circulation Journal, 2016, 80, 2133-2140.	0.7	14
715	Early effects of paroxysmal atrial fibrillation on plasma markers of fibrinolysis. Medicine (United) Tj ETQq1 1 C	).784314 rgBT 0.4 rgBT	Qverlock 1
720	Impact of transesophageal echocardiography during transseptal puncture on atrial fibrillation ablation. Journal of Arrhythmia, 2016, 32, 170-175.	0.5	17
721	Innovative pacing: Recent advances, emerging technologies, and future directions in cardiac pacing. Trends in Cardiovascular Medicine, 2016, 26, 452-463.	2.3	3
722	Antithrombotic therapy in patients with non-valvular atrial fibrillation in Southern Sweden: A population-based cohort study. Thrombosis Research, 2016, 140, 94-99.	0.8	20
723	Atrial ectopy and N-terminal pro-B-type natriuretic peptide as predictors of atrial fibrillation: a population-based cohort study. Europace, 2016, 19, euw017.	0.7	16
724	Atrial fibrillation burden and atrial fibrillation type: Clinical significance and impact on the risk of stroke and decision making for long-term anticoagulation. Vascular Pharmacology, 2016, 83, 26-35.	1.0	66
725	Rates and predictors of three-year mortality in older people in rural Tanzania. Archives of Gerontology and Geriatrics, 2016, 62, 36-42.	1.4	11
726	Different evolution of atrial fibrillation after the first documented episode. Medicina ClÃnica (English Edition), 2016, 146, 183-184.	0.1	0
727	Predictive ability of HAS-BLED, HEMORR2HAGES, and ATRIA bleeding risk scores in patients with atrial fibrillation. A French nationwide cross-sectional study. International Journal of Cardiology, 2016, 217, 85-91.	0.8	33
728	Clinical experience with contact-force and flexible-tip ablation catheter designs. Journal of Interventional Cardiac Electrophysiology, 2016, 47, 75-82.	0.6	8
729	Substantial differences in initiation of oral anticoagulant therapy and clinical outcome among non-valvular atrial fibrillation patients treated in inpatient and outpatient settings. Europace, 2016, 18, 492-500.	0.7	11

	CITATION R	EPORT	
#	ARTICLE Screening for atrial fibrillation with automated blood pressure measurement: Research evidence and	IF	CITATIONS
730	practice recommendations. International Journal of Cardiology, 2016, 203, 465-473.	0.8	70
731	Catheter ablation of atrial fibrillation in patients with concomitant sinus bradycardia—Insights from the German Ablation Registry. Journal of Electrocardiology, 2016, 49, 117-123.	0.4	2
732	The combined effects of ranolazine and dronedarone on human atrial and ventricular electrophysiology. Journal of Molecular and Cellular Cardiology, 2016, 94, 95-106.	0.9	18
733	Novel ion channel targets in atrial fibrillation. Expert Opinion on Therapeutic Targets, 2016, 20, 947-958.	1.5	31
734	Perioperative Rosuvastatin in Cardiac Surgery. New England Journal of Medicine, 2016, 374, 1744-1753.	13.9	250
735	Atrial arrhythmias in inherited arrhythmogenic disorders. Journal of Arrhythmia, 2016, 32, 366-372.	0.5	17
736	South Asian ethnicity is associated with a lower prevalence of atrial fibrillation despite greater prevalence of established risk factors: a population-based study in Bradford Metropolitan District. Europace, 2017, 19, euw010.	0.7	37
737	Atrial fibrillation patients with CHA2DS2-VASc >1 benefit from oral anticoagulation prior to cardioversion. International Journal of Cardiology, 2016, 215, 360-363.	0.8	15
738	Cardiac rehabilitation versus usual care for patients treated with catheter ablation for atrial fibrillation: Results of the randomized CopenHeartRFA trial. American Heart Journal, 2016, 181, 120-129.	1.2	70
739	Prediction of atrial fibrillation in patients with supraventricular tachyarrhythmias treated with catheter ablation or not. Classical scores are not useful. International Journal of Cardiology, 2016, 220, 102-106.	0.8	4
740	Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders. British Journal of Haematology, 2016, 175, 359-364.	1.2	25
741	Cost-Effectiveness of a National Opportunistic Screening Program for Atrial Fibrillation in Ireland. Value in Health, 2016, 19, 985-995.	0.1	20
742	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2016, 50, e1-e88.	0.6	754
743	Efficacy and safety of novel anticoagulants versus vitamin K antagonists in patients with mild and moderate to severe renal insufficiency: Focus on apixaban. International Journal of Cardiology, 2016, 225, 77-81.	0.8	14
744	Late atypical atrial flutter after ablation of atrial fibrillation. Revista Portuguesa De Cardiologia (English Edition), 2016, 35, 539.e1-539.e6.	0.2	0
745	Stroke and Systemic Embolism After Successful Ablation of Typical Atrial Flutter. Clinical Cardiology, 2016, 39, 347-351.	0.7	12
746	The changing circumstance of atrial fibrillation ―progress towards precision medicine. Journal of Internal Medicine, 2016, 279, 412-427.	2.7	24
747	Tailored treatment strategies: a new approach for modern management of atrial fibrillation. Journal of Internal Medicine, 2016, 279, 457-466.	2.7	9

#	Article	IF	CITATIONS
748	Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications. Clinical Cardiology, 2016, 39, 19-23.	0.7	24
749	A tailored treatment strategy: a modern approach for stroke prevention in patients with atrial fibrillation. Journal of Internal Medicine, 2016, 279, 467-476.	2.7	13
750	Association of six CpC-SNPs in the inflammation-related genes with coronary heart disease. Human Genomics, 2016, 10, 21.	1.4	22
751	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.	1.0	5,689
752	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 2016, 18, 1609-1678.	0.7	3,523
753	Electrogram Fractionation-Guided Ablation in the Left Atrium Decreases theÂFrequency of Activation in the Pulmonary Veins and Leads to AtrialÂFibrillation Termination. JACC: Clinical Electrophysiology, 2016, 2, 732-742.	1.3	8
754	Outcomes of Patients With AtrialÂFibrillation Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2016, 68, 895-904.	1.2	65
755	A Fresh Perspective on Atrial Fibrillation â^—. Journal of the American College of Cardiology, 2016, 68, 905-907.	1.2	0
756	Rate control in atrial fibrillation. Lancet, The, 2016, 388, 818-828.	6.3	140
757	Handbook of Consult and Inpatient Gynecology. , 2016, , .		1
757 758	Handbook of Consult and Inpatient Cynecology. , 2016, , . Aging – The Great Impact on Coagulation State –. Circulation Journal, 2016, 80, 2092-2093.	0.7	1
		0.7	
758	Aging $\tilde{a} \in \tilde{a} \in \tilde{a}$ The Great Impact on Coagulation State $\hat{a} \in \tilde{a}$ . Circulation Journal, 2016, 80, 2092-2093. A new integrated strategy for direct current cardioversion in non-valvular atrial fibrillation patients using short term rivaroxaban administration: The MonaldiVert real life experience.		1
758 759	<ul> <li>Aging – The Great Impact on Coagulation State –. Circulation Journal, 2016, 80, 2092-2093.</li> <li>A new integrated strategy for direct current cardioversion in non-valvular atrial fibrillation patients using short term rivaroxaban administration: The MonaldiVert real life experience. International Journal of Cardiology, 2016, 224, 454-455.</li> <li>Impact of surround flow catheter tip irrigation in contact force ablation on the incidence of asymptomatic oesophageal lesions after atrial fibrillation ablation: a prospective comparative study.</li> </ul>	0.8	1 21
758 759 760	<ul> <li>Aging – The Great Impact on Coagulation State –. Circulation Journal, 2016, 80, 2092-2093.</li> <li>A new integrated strategy for direct current cardioversion in non-valvular atrial fibrillation patients using short term rivaroxaban administration: The MonaldiVert real life experience. International Journal of Cardiology, 2016, 224, 454-455.</li> <li>Impact of surround flow catheter tip irrigation in contact force ablation on the incidence of asymptomatic oesophageal lesions after atrial fibrillation ablation: a prospective comparative study. Europace, 2016, 19, euw119.</li> <li>Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead</li> </ul>	0.8 0.7	1 21 14
758 759 760 761	<ul> <li>Aging – The Great Impact on Coagulation State –. Circulation Journal, 2016, 80, 2092-2093.</li> <li>A new integrated strategy for direct current cardioversion in non-valvular atrial fibrillation patients using short term rivaroxaban administration: The MonaldiVert real life experience. International Journal of Cardiology, 2016, 224, 454-455.</li> <li>Impact of surround flow catheter tip irrigation in contact force ablation on the incidence of asymptomatic oesophageal lesions after atrial fibrillation: a prospective comparative study. Europace, 2016, 19, euw119.</li> <li>Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands. Europace, 2018, 20, euw285.</li> <li>Incidence of asymptomatic oesophageal lesions after atrial fibrillation ablation using an oesophageal temperature probe with insulated thermocouples: a comparative controlled study. Europace, 2016, 19,</li> </ul>	0.8 0.7 0.7	1 21 14 63
758 759 760 761 762	Aging – The Great Impact on Coagulation State –. Circulation Journal, 2016, 80, 2092-2093.         A new integrated strategy for direct current cardioversion in non-valvular atrial fibrillation patients using short term rivaroxaban administration: The MonaldiVert real life experience. International Journal of Cardiology, 2016, 224, 454-455.         Impact of surround flow catheter tip irrigation in contact force ablation on the incidence of asymptomatic oesophageal lesions after atrial fibrillation ablation: a prospective comparative study. Europace, 2016, 19, euw119.         Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands. Europace, 2018, 20, euw285.         Incidence of asymptomatic oesophageal lesions after atrial fibrillation ablation using an oesophageal temperature probe with insulated thermocouples: a comparative controlled study. Europace, 2016, 19, euw070.         Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. New England Journal of	0.8 0.7 0.7 0.7	1 21 14 63 32

ARTICLE IF CITATIONS The rs6771157 C/G polymorphism in SCN10A is associated with the risk of atrial fibrillation in a Chinese 768 1.6 2 Han population. Scientific Reports, 2016, 6, 35212. European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). Europace, 2017, 19, euw242. Elevated plasma levels of Th17-related cytokines are associated with increased risk of atrial 770 1.6 24 fibrillation. Scientific Reports, 2016, 6, 26543. Death and thrombo-embolic risk after ablation of atrial flutter compared with atrial fibrillation: a 771 nationwide cohort study. Europace, 2017, 19, euw107. Atrial Fibrillation in Dialysis Patients: Time to Abandon Warfarin?. International Journal of Artificial 772 0.7 5 Organs, 2016, 39, 99-105. A meta-analysis for efficacy and safety evaluation of transcatheter left atrial appendage occlusion in patients with nonvalvular atrial fibrillation. Medicine (United States), 2016, 95, e4382. 0.4 Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. European Heart Journal, 2017, 38, ehw058. 774 1.0 203 Long-term results of minimally invasive stand-alone bi-atrial surgical ablation with a bipolar ablation device for persistent and longstanding persistent AF: a single-center case series of 91 patients. Journal 0.4 of Cardiothoracic Surgery, 2016, 11, 23 Yield of screening for atrial fibrillation in primary care with a hand-held, single-lead 776 0.7 104 electrocardiogram device during influenza vaccination. Europace, 2016, 18, 1514-1520. Impact of Vitamin K Antagonists on Quality of Life in a Prospective Cohort of 807 Atrial Fibrillation Patients. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 388-394. Limited left atrial surgical ablation effectively treats atrial fibrillation but decreases left atrial 778 0.7 8 function. Europace, 2016, 19, euw106. Predicting the Outcomes of Acute Ischemic Stroke with Rheumatic Heart Disease: The Values of CHADS2, CHA2DS2–VASc, and HAS-BLED Scores. Journal of Stroke and Cerebrovascular Diseases, 2016, 779 25, 722-726. Self-reported physical activity and major adverse events in patients with atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General 780 0.7 32 Registry. Europace, 2017, 19, euw150. Net Clinical Benefit of Edoxaban for Stroke,ÂMortality, and Bleeding Risk. JACC: Clinical 1.3 Electrophysiology, 2016, 2, 47-54. Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and 782 0.9 43 subsequent consequences. Thrombosis Journal, 2016, 14, 14. A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme. Europace, 2016, 18, euw069. Early release of high-sensitive cardiac troponin during complex catheter ablation for ventricular tachycardia and atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2016, 47, 785 0.6 15 69-74. Clinical management and outcome of major bleeding in patients on treatment with vitamin K 786 antagonists. European Journal of Internal Medicine, 2016, 33, 47-54.

#	Article	IF	CITATIONS
787	Atrial Fibrillation After Coronary Artery Bypass Surgery: Can Ivabradine Reduce Its Occurrence?. Journal of Cardiovascular Electrophysiology, 2016, 27, 670-676.	0.8	18
788	J Wave Syndromes. , 2016, , .		1
789	Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort. Europace, 2016, 18, 1308-1318.	0.7	54
790	Non-vitamin K oral anticoagulants in patients with atrial fibrillation after cardiac surgery: the results of the European Heart Rhythm Association Survey. Europace, 2016, 18, 1113-1116.	0.7	12
791	Type of Atrial Fibrillation and Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement. Annals of Noninvasive Electrocardiology, 2016, 21, 519-525.	0.5	9
792	Catheter ablation restores decreased plasma miR-409-3p and miR-432 in atrial fibrillation patients. Europace, 2016, 18, 92-99.	0.7	41
793	Colchicine for Prevention of Post-Operative Atrial Fibrillation. JACC: Clinical Electrophysiology, 2016, 2, 78-85.	1.3	23
794	Individualized approaches to thromboprophylaxis in atrial fibrillation. American Heart Journal, 2016, 173, 143-158.	1.2	12
795	Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment. Nature Reviews Cardiology, 2016, 13, 230-237.	6.1	122
796	Major Bleeding and Hemorrhagic Stroke With Direct Oral Anticoagulants in Patients With Renal Failure. Chest, 2016, 149, 1516-1524.	0.4	43
797	Response to the letter regarding article "Atrial fibrillation is a risk marker for worse in-hospital and long-term outcome in patients with peripheral artery disease― International Journal of Cardiology, 2016, 203, 519.	0.8	0
798	Relationship between diastolic ventricular dysfunction and subclinical sleep-disordered breathing in atrial fibrillation ablation candidates. Heart and Vessels, 2016, 31, 1140-1147.	0.5	4
799	Prevalence of auricular thrombosis before atrial flutter cardioversion: a 17-year transoesophageal echocardiographic study. Europace, 2016, 18, 450-456.	0.7	28
800	The predictive role of renal function and systemic inflammation on the onset of de novo atrial fibrillation after cardiac surgery. European Journal of Preventive Cardiology, 2016, 23, 206-213.	0.8	13
801	Antithrombotic management in patients with atrial fibrillation undergoing coronary stent implantation: What is the impact of guideline adherence?. International Journal of Cardiology, 2016, 203, 987-994.	0.8	21
802	Clinical, biomarker, and genetic predictors of specific types of atrial fibrillation in a community-based cohort: data of the PREVEND study. Europace, 2016, 19, euw016.	0.7	13
803	Endocardial biventricular defibrillator implantation in a patient with superior vena cava obstruction. Europace, 2016, 18, 500-500.	0.7	0
804	Effect of fixed-rate vs. rate-RESPONSIve pacing on exercise capacity in patients with permanent, refractory atrial fibrillation and left ventricular dysfunction treated with atrioventricular junction aBLation and bivEntricular pacing (RESPONSIBLE): a prospective, multicentre, randomized, single-blind study. Europace, 2017, 19, euw035.	0.7	12

#	Article	IF	CITATIONS
805	Flecainide–metoprolol combination reduces atrial fibrillation clinical recurrences and improves tolerability at 1-year follow-up in persistent symptomatic atrial fibrillation. Europace, 2016, 18, 1698-1704.	0.7	23
806	The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. European Heart Journal, 2016, 37, 1591-1602.	1.0	296
807	EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. European Heart Journal Cardiovascular Imaging, 2016, 17, 355-383.	0.5	233
808	Thoracoscopic epicardial left atrial ablation in symptomatic patients with atrial fibrillation. Europace, 2016, 18, 1538-1544.	0.7	19
809	Are implantable cardiac monitors the â€~gold standard' for atrial fibrillation detection? A prospective randomized trial comparing atrial fibrillation monitoring using implantable cardiac monitors and DDDRP permanent pacemakers in post atrial fibrillation ablation patients. Europace, 2016, 18, 1000-1005.	0.7	48
810	â€~Real-world' management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme–Atrial Fibrillation (EORP-AF) General Pilot Registry. Europace, 2016, 18, 648.1-657.	0.7	61
811	Practical Guide to Direct New Oral Anticoagulant Use for Secondary Stroke Prevention in Atrial Fibrillation. Current Treatment Options in Cardiovascular Medicine, 2016, 18, 24.	0.4	3
812	External prolonged electrocardiogram monitoring in unexplained syncope and palpitations: results of the SYNARR-Flash study. Europace, 2016, 18, 1265-1272.	0.7	66
813	Effectiveness and safety of dabigatran versus acenocoumarol in â€~real-world' patients with atrial fibrillation. Europace, 2016, 18, 1319-1327.	0.7	32
814	First clinical trial of specific I <sub>KACh</sub> blocker shows no reduction in atrial fibrillation burden in patients with paroxysmal atrial fibrillation: pacemaker assessment of BMS 914392 in patients with paroxysmal atrial fibrillation. Europace, 2016, 18, 340-346.	0.7	38
815	Left atrial aging: a cardiac magnetic resonance feature-tracking study. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 310, H542-H549.	1.5	43
816	Diagnostic Evaluation and Follow-Up of Patients with Atrial Fibrillation. Heart Failure Clinics, 2016, 12, 179-191.	1.0	1
817	Performance of handheld electrocardiogram devices to detect atrial fibrillation in a cardiology and geriatric ward setting. Europace, 2017, 19, euw025.	0.7	115
818	Long-term efficacy of catheter ablation for paroxysmal atrial fibrillation in patients with Brugada syndrome and an implantable cardioverter-defibrillator to prevent inappropriate shock therapy. Heart Rhythm, 2016, 13, 1455-1459.	0.3	12
819	Usefulness of â€~figure-of-eight' suture to achieve haemostasis after removal of 15-French calibre femoral venous sheath in patients undergoing cryoablation. Europace, 2016, 18, 1545-1550.	0.7	63
821	Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis. Europace, 2016, 18, 508-520.	0.7	59
822	Peripheral arterial disease and atrial fibrillation and risk of stroke, heart failure hospitalization and cardiovascular death: A nationwide cohort study. International Journal of Cardiology, 2016, 203, 204-211.	0.8	31
823	Incidence and risk factors for symptomatic heart failure after catheter ablation of atrial fibrillation and atrial flutter. Europace, 2016, 18, 521-530.	0.7	16

#	Article	IF	CITATIONS
824	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace, 2016, 18, 37-50.	0.7	121
825	Atrial fibrillation and low vitamin D levels are associated with severe vascular calcifications in hemodialysis patients. Journal of Nephrology, 2016, 29, 419-426.	0.9	16
826	The effect of transesophageal echocardiography on the incidence of thromboembolism after electrical cardioversion in atrial fibrillation: A multicenter analysis. International Journal of Cardiology, 2016, 202, 880-882.	0.8	1
828	Health-related quality of life changes in patients undergoing repeated catheter ablation for atrial fibrillation. Clinical Research in Cardiology, 2016, 105, 1-9.	1.5	11
829	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial. Europace, 2016, 18, 6-11.	0.7	38
830	Vernakalant-facilitated electrical cardioversion: comparison of intravenous vernakalant and amiodarone for drug-enhanced electrical cardioversion of atrial fibrillation after failed electrical cardioversion. Europace, 2016, 18, 51-56.	0.7	16
831	Higher CHA <sub>2</sub> DS <sub>2</sub> -VASc Score Is Associated With Increased Mortality in Acute Pulmonary Embolism. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 631-637.	0.7	19
832	Evaluation of Bleeding Events Requiring Hospitalization in Patients With Atrial Fibrillation Receiving Dabigatran, Warfarin, or Antiplatelet Therapy. Journal of Pharmacy Practice, 2017, 30, 214-218.	0.5	7
833	Fat: an emerging player in the field of atrial fibrillation. European Heart Journal, 2017, 38, 62-65.	1.0	12
834	Mitral valve and mitral valve disease. BJA Education, 2017, 17, 1-9.	0.6	103
835	Anticoagulation therapy in elderly patients with atrial fibrillation. Journal of Cardiovascular Medicine, 2017, 18, 545-549.	0.6	6
837	Direct Comparison of Pointâ€byâ€Point and Rapid Ultraâ€Highâ€Resolution Electroanatomical Mapping in Patients Scheduled for Ablation of Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2017, 28, 289-297.	0.8	31
838	Genetic Variants Associated With Susceptibility to Atrial Fibrillation in a Japanese Population. Canadian Journal of Cardiology, 2017, 33, 443-449.	0.8	18
839	Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. American Heart Journal, 2017, 185, 140-149.	1.2	54
840	Sudden death and its risk factors after atrioventricular junction ablation and pacemaker implantation in patients with atrial fibrillation. Clinical Cardiology, 2017, 40, 18-25.	0.7	8
841	Oxidized Low-Density Lipoprotein Predicts the Development of Renal Dysfunction in Atrial Fibrillation. CardioRenal Medicine, 2017, 7, 31-41.	0.7	8
842	Risk Stratification Models in Atrial Fibrillation. Seminars in Thrombosis and Hemostasis, 2017, 43, 505-513.	1.5	9
843	Use of three-dimensional computed tomography overlay for real-time cryoballoon ablation in atrial fibrillation reduces radiation dose and contrast dye. Netherlands Heart Journal, 2017, 25, 388-393.	0.3	5

# 844	ARTICLE Matrix Metalloproteinase Neutrophil Gelatinase-Associated Lipocalin Complex Predicts Atrial Fibrillation Recurrence after Electrical Cardioversion in Obese Patients. CardioRenal Medicine, 2017, 7,	lF 0.7	Citations
845	11-20. Left Atrial Appendage Parameters Assessed by Real-Time Three-Dimensional Transesophageal Echocardiography Predict Thromboembolic Risk in Patients With Nonvalvular Atrial Fibrillation. Journal of Ultrasound in Medicine, 2017, 36, 1119-1128.	0.8	12
846	Left atrial appendage closure: outcomes and challenges. Netherlands Heart Journal, 2017, 25, 143-151.	0.3	14
847	Chronic obstructive pulmonary disease predicts higher incidence and in hospital mortality for atrial fibrillation. An observational study using hospital discharge data in Spain (2004–2013). International Journal of Cardiology, 2017, 236, 209-215.	0.8	18
848	Exercise-based cardiac rehabilitation for adults with atrial fibrillation. The Cochrane Library, 2017, 2, CD011197.	1.5	60
849	Management of Thyroid Nodules and Differentiated Thyroid Cancer. , 2017, , .		4
850	The search for the tipping point on when to anticoagulate patients with atrial fibrillation. Heart, 2017, 103, 181-183.	1.2	2
851	Digoxin versus placebo, no intervention, or other medical interventions for atrial fibrillation and atrial flutter: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis. Systematic Reviews, 2017, 6, 71.	2.5	5
852	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm, 2017, 14, e275-e444.	0.3	1,671
853	Screening for Atrial Fibrillation. Circulation, 2017, 135, 1851-1867.	1.6	453
856	Genetic variants of interleukin-18 are associated with reduced risk of atrial fibrillation in a population from Northeast China. Gene, 2017, 626, 269-274.	1.0	9
857	Self-Reported Stroke Risk Stratification. Stroke, 2017, 48, 1737-1743.	1.0	13
858	Premature atrial complexes in an ischemic stroke population and risk of recurrent stroke: a systematic review. Expert Review of Cardiovascular Therapy, 2017, 15, 447-455.	0.6	3
859	Aspirin in heart failure: don't throw the baby (aspirin) out with the bathwater. European Journal of Heart Failure, 2017, 19, 1089-1094.	2.9	3
861	Contemporary Atrial Fibrillation Management: A Comparison of the Current AHA/ACC/HRS, CCS, and ESC Guidelines. Canadian Journal of Cardiology, 2017, 33, 965-976.	0.8	89
862	Cardioversion of atrial fibrillation does not affect obstructive sleep apnea. Upsala Journal of Medical Sciences, 2017, 122, 114-118.	0.4	3
863	Populationâ€level incidence and monitoring of adverse drug reactions with longâ€ŧerm amiodarone therapy. Cardiovascular Therapeutics, 2017, 35, e12258.	1.1	9
864	Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life. International Journal of Cardiology, 2017, 227, 261-266.	0.8	47

#	Article	IF	CITATIONS
865	Active Atrial Function and Atrial Scar Burden After Multiple Catheter Ablations of Persistent Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 175-182.	0.5	6
866	Designing an optimal screening program for unknown atrial fibrillation: a cost-effectiveness analysis. Europace, 2017, 19, 1650-1656.	0.7	15
868	Antiarrhythmic Drug Management of Atrial Fibrillation. Cardiovascular Medicine, 2017, , 87-104.	0.0	0
869	Demographics, treatment and outcomes of atrial fibrillation in a developing country: the population-based TuRkish Atrial Fibrillation (TRAF) cohort. Europace, 2017, 19, 734-740.	0.7	7
870	Persistence With Dabigatran Therapy at 2ÂYears in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2017, 70, 1573-1583.	1.2	39
871	Clinical predictors of challenging atrioventricular node ablation procedure for rate control in patients with atrial fibrillation. International Journal of Cardiology, 2017, 245, 168-173.	0.8	2
872	Atrial fibrillation: Utility of CHADS 2 and CHA 2 DS 2 -VASc scores as predictors of readmission, mortality and resource utilization. International Journal of Cardiology, 2017, 245, 162-167.	0.8	24
873	Use of statins and adverse outcomes in patients with atrial fibrillation: An analysis from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) general registry pilot phase. International Journal of Cardiology, 2017, 248, 166-172.	0.8	9
874	Selection of Stent Type in Patients With Atrial Fibrillation Presenting With Acute Myocardial Infarction: An Analysis From the ACTION (Acute Coronary Treatment and Intervention Outcomes) Tj ETQq0 0 0 rg	gB <b>T.¢</b> Overlo	ock110 Tf 50
875	Letter by Pearman etÂal.Âregarding article "Effect of botulinum toxin on inducibility and maintenance of atrial fibrillation in ovine myocardial tissue― PACE - Pacing and Clinical Electrophysiology, 2017, 40, 1186-1186.	0.5	0
876	ANMCO Position Paper: direct oral anticoagulants for stroke prevention in atrial fibrillation: clinical scenarios and future perspectives. European Heart Journal Supplements, 2017, 19, D70-D88.	0.0	6
877	Development and Validation of the AFImpact: An Atrial Fibrillation–Specific Measure of Patient-Reported Health-Related Quality of Life. Value in Health, 2017, 20, 1355-1361.	0.1	6
878	Management of atrial fibrillation and concomitant coronary artery disease. Continuing Cardiology Education, 2017, 3, 47-55.	0.4	8
879	Interventional and surgical occlusion of the left atrial appendage. Nature Reviews Cardiology, 2017, 14, 727-743.	6.1	35
880	Effects of exercise training on exercise capacity, cardiac function, BMI, and quality of life in patients with atrial fibrillation: a meta-analysis of randomized-controlled trials. International Journal of Rehabilitation Research, 2017, 40, 193-201.	0.7	34
881	Safe administration of non-vitamin K antagonist oral anticoagulants. NursePrescribing, 2017, 15, 238-245.	0.1	0
882	Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. The Cochrane Library, 2017, 2017, CD011373.	1.5	68
883	Brain microbleeds, anticoagulation, and hemorrhage risk. Neurology, 2017, 89, 2317-2326.	1.5	90

#	Article	IF	CITATIONS
884	Implantable loop recorders in the real world: a study of two Canadian centers. Journal of Interventional Cardiac Electrophysiology, 2017, 50, 179-185.	0.6	20
885	Triple Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: a Fading Role. Cardiovascular Drugs and Therapy, 2017, 31, 319-324.	1.3	10
886	Feature subset selection and classification of intracardiac electrograms during atrial fibrillation. Biomedical Signal Processing and Control, 2017, 38, 182-190.	3.5	5
887	Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. European Heart Journal, 2017, 38, ehw658.	1.0	142
888	Prospective Assessment of Sexâ€Related Differences in Symptom Status and Health Perception Among Patients With Atrial Fibrillation. Journal of the American Heart Association, 2017, 6, .	1.6	44
889	The effects of rhythm control strategies versus rate control strategies for atrial fibrillation and atrial flutter: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis. Systematic Reviews, 2017, 6, 47.	2.5	5
890	Atrial fibrillation detection using a novel three-vector cardiac implantable monitor: the atrial fibrillation detect study. Europace, 2017, 19, 1101-1108.	0.7	31
891	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). European Journal of Preventive Cardiology, 2017, 24, 4-40.	0.8	83
892	Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. Circulation, 2017, 135, 323-333.	1.6	86
893	Older age and a higher EHRA score allow higher levels of frailty syndrome to be predicted in patients with atrial fibrillation. Aging Male, 2017, 20, 23-27.	0.9	16
894	CHA2DS2-VASC-AF2 score accurately predicts moderate-to-severe acute neurological dysfunction in the course of first ever ischaemic stroke. International Journal of Cardiology, 2017, 228, 286-288.	0.8	1
895	Registries in Atrial Fibrillation: From Trials to Real-Life Clinical Practice. American Journal of Medicine, 2017, 130, 135-145.	0.6	40
896	Prognosis in patients with atrial fibrillation and a presumed "temporary cause―in a community-based cohort study. Clinical Research in Cardiology, 2017, 106, 202-210.	1.5	24
897	Atrial fibrillation in New Zealand primary care: Prevalence, risk factors for stroke and the management of thromboembolic risk. European Journal of Preventive Cardiology, 2017, 24, 311-319.	0.8	28
898	Oral anticoagulation in patients with atrial fibrillation and medical non-neoplastic disease in a terminal stage. Internal and Emergency Medicine, 2017, 12, 53-61.	1.0	9
899	Relationship between vitamin D level and left atrial fibrosis in patients with lone paroxysmal atrial fibrillation undergoing cryoballoon-based catheter ablation. Journal of Cardiology, 2017, 69, 16-23.	0.8	15
900	Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis. British Journal of Clinical Pharmacology, 2017, 83, 642-652.	1.1	39
901	Performance of short ECG recordings twice daily to detect paroxysmal atrial fibrillation in stroke and transient ischemic attack patients. International Journal of Stroke, 2017, 12, 192-196.	2.9	21

#	Article	IF	CITATIONS
902	Immediate discontinuation of ablation during pulmonary vein isolation remarkably decreases the incidence of esophageal thermal lesions even when using steerable sheaths. Journal of Arrhythmia, 2017, 33, 23-27.	0.5	1
903	Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective. American Journal of Cardiovascular Drugs, 2017, 17, 123-133.	1.0	14
904	Defining the role of perioperative statin treatment in patients after cardiac surgery: A meta-analysis and systematic review of 20 randomized controlled trials. International Journal of Cardiology, 2017, 228, 958-966.	0.8	37
905	Antiarrhythmic effects of dantrolene in human diseased cardiomyocytes. Heart Rhythm, 2017, 14, 412-419.	0.3	53
906	Automated Differentiation between Normal Sinus Rhythm, Atrial Tachycardia, Atrial Flutter and Atrial Fibrillation during Electrophysiology. , 2017, , .		2
907	Device-detected subclinical atrial tachyarrhythmias: definition, implications and management—an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación CardÃaca y ElectrofisiologÃa (SOLEACE). Europace, 2017, 19, 1556-1578.	0.7	186
908	Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de EstimulaciÃ <sup>3</sup> n CardÃaca y ElectrofisiologÃa (SOLAECE). Europace, 2017, 19, 1589-1623.	0.7	208
909	document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de	0.7	107
910	EstimulaciA <sup>3</sup> n CardAaca y. Europace, 2017, 19, 1757-1758. Chinese herbal medicine for patients with atrial fibrillation. Medicine (United States), 2017, 96, e9228.	0.4	5
911	Incidence of Atrial Tachyarrhythmias in Patients With Early Repolarization Syndrome. International Heart Journal, 2017, 58, 43-49.	0.5	11
914	Enhanced Late Na and Ca Currents as Effective Antiarrhythmic Drug Targets. Frontiers in Pharmacology, 2017, 8, 36.	1.6	30
915	Oral Anticoagulants Initiation in Patients with Atrial Fibrillation: Real-World Data from a Population-Based Cohort. Frontiers in Pharmacology, 2017, 8, 63.	1.6	30
916	Discovery and Development of Calcium Channel Blockers. Frontiers in Pharmacology, 2017, 8, 286.	1.6	141
917	Antithrombotic prophylaxis of atrial fibrillation in an Italian real-world setting: a retrospective study. Vascular Health and Risk Management, 2017, Volume 13, 239-246.	1.0	3
918	Remote Magnetic versus Manual Navigation for Radiofrequency Ablation of Paroxysmal Atrial Fibrillation: Long-Term, Controlled Data in a Large Cohort. BioMed Research International, 2017, 2017, 1-6.	0.9	14
919	Serum glycated hemoglobin level as a predictor of atrial fibrillation: A systematic review with meta-analysis and meta-regression. PLoS ONE, 2017, 12, e0170955.	1.1	44
920	Measuring the effect of nurse practitioner (NP)-led care on health-related quality of life in adult patients with atrial fibrillation: study protocol for a randomized controlled trial. Trials, 2017, 18, 364.	0.7	7
921	Mobile phones in cryptogenic strOke patients Bringing sIngle Lead ECCs for Atrial Fibrillation detection (MOBILE-AF): study protocol for a randomised controlled trial. Trials, 2017, 18, 402.	0.7	26

#	Article	IF	CITATIONS
922	Implantable Cardiac Rhythm and Hemodynamic Monitors. , 2017, , 602-628.		0
923	Staged hybrid ablation for persistent and longstanding persistent atrial fibrillation effectively restores sinus rhythm in long-term observation. Archives of Medical Science, 2017, 1, 109-117.	0.4	30
924	Incidence, type of atrial fibrillation and risk factors for stroke: a population-based cohort study. Clinical Epidemiology, 2017, Volume 9, 53-62.	1.5	19
925	Cardiac Rhythm Classification from a Short Single Lead ECG Recording via Random Forest. , 0, , .		26
926	The significance of the left atrial volume index in prediction of atrial fibrillation recurrence after electrical cardioversion. Journal of Cardiovascular and Thoracic Research, 2017, 9, 54-59.	0.3	35
927	High Incidence of Occult Atrial Fibrillation in Asian Patients with Cryptogenic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 2182-2186.	0.7	9
928	The New 2016 European Society of Cardiology/European Association for Cardio-Thoracic Surgery Guidelines: Enough Guidance? Enough Evidence?. European Journal of Cardio-thoracic Surgery, 2018, 53, i9-i13.	0.6	1
929	Frequent atrial premature complexes during exercise: A potent predictor of atrial fibrillation. Clinical Cardiology, 2018, 41, 458-464.	0.7	2
930	Does an interdisciplinary outpatient atrial fibrillation ( <scp>AF</scp> ) clinic affect the number of acute <scp>AF</scp> admissions? A retrospective cohort study. Journal of Clinical Nursing, 2018, 27, 2684-2690.	1.4	5
931	Long-term outcomes and predictors of recurrence after pulmonary vein isolation with multielectrode ablation catheter in patients with atrial fibrillation. Journal of Cardiovascular Medicine, 2018, 19, 148-154.	0.6	6
932	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace, 2018, 20, e1-e160.	0.7	767
933	Antiarrhythmic drugsa€ clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP).	0.7	144
934	Europace, 2016, 20, 701-702an. Effect of Rehabilitation on Sleep Quality After Ablation for Atrial Fibrillation. Journal of Cardiovascular Nursing, 2018, 33, 261-268.	0.6	6
935	Valoración del tratamiento anticoagulante en pacientes diagnosticados de fibrilación auricular no valvular en una zona básica de salud. ClÃnica E Investigación En Arteriosclerosis, 2018, 30, 56-63.	0.4	Ο
936	DL-3-n-Butylphthalide reduces atrial fibrillation susceptibility by inhibiting atrial structural remodeling in rats with heart failure. Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, 391, 323-334.	1.4	21
937	Fibrilación auricular de novo en el paciente crÃtico: ¿en dónde estamos?. Acta Colombiana De Cuidado Intensivo, 2018, 18, 22-30.	0.1	0
938	Concomitant atrial fibrillation surgery: worth the effort?. European Journal of Cardio-thoracic Surgery, 2018, 53, i14-i18.	0.6	2
939	Clinical effectiveness of a systematic "pill-in-the-pocket―approach for the management of paroxysmal atrial fibrillation. Heart Rhythm, 2018, 15, 9-16.	0.3	30

#	Article	IF	CITATIONS
940	Atrial fibrillation type matters: greater infarct volume and worse neurological defects seen in acute cardiogenic cerebral embolism due to persistent or permanent rather than paroxysmal atrial fibrillation. Europace, 2018, 20, 1591-1597.	0.7	19
941	Individually tailored vs. standardized substrate modification during radiofrequency catheter ablation for atrial fibrillation: a randomized study. Europace, 2018, 20, 1766-1775.	0.7	121
942	Ablation Outcomes and Predictors of Mortality Following Catheter Ablation for Ventricular Tachycardia: Data From the German Multicenter Ablation Registry. Journal of the American Heart Association, 2018, 7, .	1.6	19
943	Major knowledge gaps and system barriers to guideline implementation among European physicians treating patients with atrial fibrillation: a European Society of Cardiology international educational needs assessment. Europace, 2018, 20, 1919-1928.	0.7	37
944	Frequent atrial extrasystolic beats predict atrial fibrillation in patients with congenital heart defects. Europace, 2018, 20, 25-32.	0.7	12
945	Concerns about the European society of cardiology atrial fibrillation guidelines. Europace, 2018, 20, 215-216.	0.7	0
946	Left atrial anatomy, atrial fibrillation burden, and P-wave duration—relationships and predictors for single-procedure success after pulmonary vein isolation. Europace, 2018, 20, 271-278.	0.7	26
947	Diagnosis-to-ablation time as a predictor of success: early choice for pulmonary vein isolation and long-term outcome in atrial fibrillation: results from the Middelheim-PVI Registry. Europace, 2018, 20, 589-595.	0.7	36
948	Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation. Europace, 2018, 20, 243-252.	0.7	33
949	Does atrial fibrillation cause cognitive decline and dementia?. Europace, 2018, 20, 408-419.	0.7	99
950	The change in circulating galectin-3 predicts absence of atrial fibrillation after thoracoscopic surgical ablation. Europace, 2018, 20, 764-771.	0.7	17
951	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion. Europace, 2018, 20, 565-568.	0.7	27
952	Temporal pattern/episode duration-based classification of atrial fibrillation as paroxysmal vs. persistent: is it time to develop a more integrated prognostic score to optimize management?. Europace, 2018, 20, f288-f298.	0.7	14
953	Association of left atrial low-voltage area and thromboembolic risk in patients with atrial fibrillation. Europace, 2018, 20, f359-f365.	0.7	37
954	Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention. Europace, 2018, 20, 1-11.	0.7	80
955	Anticoagulant Use and Risk of Ischemic Stroke and Bleeding in Patients With Secondary Atrial Fibrillation Associated With Acute Coronary Syndromes, AcuteÂPulmonary Disease, or Sepsis. JACC: Clinical Electrophysiology, 2018, 4, 386-393.	1.3	36
956	Prevention of Stroke in Atrial Fibrillation. , 2018, , 1092-1100.		0
957	THROMBOSIS OF LEFT ATRIAL APPENDAGE DURING THERAPY WITH DIRECT ORAL ANTICOAGULANT. CLINICAL CASE. Rational Pharmacotherapy in Cardiology, 2018, 14, 350-355.	0.3	1

#	Article	IF	CITATIONS
958	Role of Hypertension and Other Clinical Variables in Prognostication of Patients Presenting to the Emergency Department With Major Bleeding Events. Critical Pathways in Cardiology, 2018, 17, 139-146.	0.2	8
959	Increased Vulnerability to Atrial Fibrillation Is Associated With Increased Susceptibility to Alternans in Old Sheep. Journal of the American Heart Association, 2018, 7, e009972.	1.6	14
960	A Beat-to-Beat Atrial Fibrillation Detecting System. Journal of Cardiovascular Diseases & Diagnosis, 2018, s2, .	0.0	2
961	Glomerular Filtration Rate is Associated with Hemorrhagic Transformation in Acute Ischemic Stroke Patients without Thrombolytic Therapy. Chinese Medical Journal, 2018, 131, 1639-1644.	0.9	9
962	Echocardiography in Transcatheter Structural Heart Disease Interventions. Progress in Cardiovascular Diseases, 2018, 61, 423-436.	1.6	8
963	Supraventricular Arrhythmias: Clinical Framework and Common Scenarios for theÂlnternist. Mayo Clinic Proceedings, 2018, 93, 1825-1841.	1.4	8
964	Implementing vernakalant: a novel approach to cardioversion. Emergency Nurse, 2018, 27, 14-20.	0.1	0
965	Conundrum of Using Real-World Observational Data to Inform Real-World Conclusions About Safety and Efficacy. Journal of the American College of Cardiology, 2018, 72, 1801-1803.	1.2	0
966	Incidence of subclinical atrial fibrillation in a South Asian population. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 1600-1605.	0.5	7
967	Cost Saving Potential of an Early Detection of Atrial Fibrillation in Patients after ICD Implantation. BioMed Research International, 2018, 2018, 1-12.	0.9	4
968	Cardiac Structural or Functional Changes Associated with CHA <sub>2</sub> DS <sub>2</sub> -VASc Scores in Nonvalvular Atrial Fibrillation: A Cross-Sectional Study Using Echocardiography. Journal of Cardiovascular Imaging, 2018, 26, 135.	0.2	7
969	Catheter ablation of paroxysmal atrial fibrillation using highâ€density mappingâ€guided substrate modification. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 1630-1634.	0.5	6
970	Combination of catheter ablation for non‑valvular atrial fibrillation and left atrial appendage occlusion in a single procedure. Experimental and Therapeutic Medicine, 2018, 16, 2094-2100.	0.8	5
971	Embolic and Other Adverse Outcomes in Symptomatic Versus Asymptomatic Patients With Atrial Fibrillation (from the ORBIT-AF Registry). American Journal of Cardiology, 2018, 122, 1677-1683.	0.7	13
972	Dental management of patients on anti-thrombotic agents. Journal of the Korean Association of Oral and Maxillofacial Surgeons, 2018, 44, 143.	0.3	9
973	Patient characteristics and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban or vitamin K antagonists: real-world evidence from Italian administrative databases. Journal of Comparative Effectiveness Research, 2018, 7, 1063-1071.	0.6	5
974	Prestroke and Poststroke Antithrombotic Therapy in Patients With Atrial Fibrillation. JAMA Network Open, 2018, 1, e180171.	2.8	25
975	Obesity is associated with impaired long-term success of pulmonary vein isolation: a plea for risk factor management before ablation. Open Heart, 2018, 5, e000771.	0.9	25

#	Article	IF	CITATIONS
976	Atrial fibrillation in athletes: From epidemiology to treatment in the novel oral anticoagulants era. Journal of Cardiology, 2018, 72, 269-276.	0.8	8
977	Global longitudinal strain corrected by RR-interval is a superior echocardiographic predictor of outcome in patients with atrial fibrillation. International Journal of Cardiology, 2018, 263, 42-47.	0.8	15
978	Anxiety and Depression in Patients with Permanent Atrial Fibrillation: Prevalence and Associated Factors. Cardiology Research and Practice, 2018, 2018, 1-9.	0.5	47
979	Atrial fibrillation in aging population. Aging Medicine (Milton (N S W)), 2018, 1, 67-74.	0.9	11
980	Rationale and design of the improving Care for Cardiovascular Disease in China (CCC) project: a national registry to improve management of atrial fibrillation. BMJ Open, 2018, 8, e020968.	0.8	16
981	Assessment of anticoagulation treatments in non-valvular atrial fibrillation patients diagnosed in a basic health area. ClÃnica E Investigación En Arteriosclerosis (English Edition), 2018, 30, 56-63.	0.1	0
982	Rivaroxaban does not influence hemorrhagic transformation in a diabetes ischemic stroke and endovascular thrombectomy model. Scientific Reports, 2018, 8, 7408.	1.6	11
983	Multiscaled Fusion of Deep Convolutional Neural Networks for Screening Atrial Fibrillation From Single Lead Short ECG Recordings. IEEE Journal of Biomedical and Health Informatics, 2018, 22, 1744-1753.	3.9	218
984	External electrical cardioversion in patients with cardiac implantable electronic devices: Is it safe and is immediate device interrogation necessary?. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 1336-1340.	0.5	9
985	Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation: The Triple Trouble. Drugs, 2018, 78, 1309-1319.	4.9	1
986	Risk factors for heart failure hospitalizations among patients with atrial fibrillation. PLoS ONE, 2018, 13, e0191736.	1.1	9
987	Safety and effectiveness of rivaroxaban and warfarin in moderate-to-advanced CKD: real world data. Journal of Nephrology, 2018, 31, 751-756.	0.9	32
988	Mechanisms and Drug Development in Atrial Fibrillation. Pharmacological Reviews, 2018, 70, 505-525.	7.1	67
989	European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). Europace, 2019, 21, 7-8.	0.7	72
990	Regional collaboration to improve atrial fibrillation care: Preliminary data from the Netherlands heart network. Journal of Arrhythmia, 2019, 35, 604-611.	0.5	3
991	Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. Europace, 2019, 21, 1459-1467.	0.7	45
992	Does Chronic Kidney Disease Result in High Risk of Atrial Fibrillation?. Frontiers in Cardiovascular Medicine, 2019, 6, 82.	1.1	2
993	Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation. Europace, 2019, 21, 1764-1775.	0.7	20

		CITATION RE	PORT	
#	Article		IF	CITATIONS
994	Recognising and treating arrhythmias in primary care. Practice Nursing, 2019, 30, 270-	275.	0.1	1
995	Influence of risk factors in the ESCâ€EHRA EORP atrial fibrillation ablation longâ€ŧerm Pacing and Clinical Electrophysiology, 2019, 42, 1365-1373.	registry. PACE -	0.5	15
996	Effect of novel oral anticoagulants on Hospital Anxiety and Depression Scale scores. H 743-749.	erz, 2019, 44,	0.4	5
997	Frequent drinking is a more important risk factor for new-onset atrial fibrillation than b drinking: a nationwide population-based study. Europace, 2020, 22, 216-224.	inge	0.7	49
998	Clinical implication of disturbed left atrial phasic functions in the heterogeneous popu associated with hypertension or atrial fibrillation. Cardiovascular Ultrasound, 2019, 17		0.5	4
999	Non-vitamin K antagonist oral anticoagulants (NOACs) post-percutaneous coronary in network meta-analysis. The Cochrane Library, 0, , .	tervention: a	1.5	2
1000	Direct Current Cardioversion of AtrialÂFibrillation in Patients With LeftÂAtrial Appenda Devices. Journal of the American College of Cardiology, 2019, 74, 2267-2274.	ge Occlusion	1.2	15
1001	ECG Classification Using Artificial Neural Networks. Journal of Physics: Conference Seri 012062.	es, 2019, 1221,	0.3	5
1002	Novel Models for the Prediction of Left Atrial Appendage Thrombus in Patients with Ch Nonvalvular Atrial Fibrillation. Cardiology Research and Practice, 2019, 2019, 1-7.	ironic	0.5	8
1003	Very late arrhythmia recurrences in patients with sinus rhythm within the first year after ablation: The Leipzig Heart Center AF Ablation Registry. Europace, 2019, 21, 1646-165	er catheter 2.	0.7	2
1004	New Oral Anticoagulants: An Update. Journal of Bangladesh College of Physicians & Su 135-150.	rgeons, 2019, 37,	0.0	0
1005	Usefulness of Red Cells Distribution Width to Predict Worse Outcomes in Patients Wi Fibrillation. American Journal of Cardiology, 2019, 124, 1561-1567.	th Atrial	0.7	13
1006	Long-Term Implications of Atrial Fibrillation in Patients With Degenerative Mitral Regu Journal of the American College of Cardiology, 2019, 73, 264-274.	gitation.	1.2	54
1007	Sympathetic Nervous System Activation and Its Modulation: Role in Atrial Fibrillation. Neuroscience, 2018, 12, 1058.	Frontiers in	1.4	40
1008	Appropriateness of direct oral anticoagulant dosing and its relation to drug levels in at fibrillation patients. Journal of Thrombosis and Thrombolysis, 2019, 47, 550-557.	rial	1.0	14
1009	Catheter Ablation of Long-standing Persistent Atrial Fibrillation: a Reckless Challenge c Real Cure?. Korean Circulation Journal, 2019, 49, 134.	r a Way to	0.7	7
1010	Oral Manifestations of Systemic Diseases and Their Treatments. , 2019, , 1523-1639.			1
1011	Patients aged 90†years or older with atrial fibrillation treated with oral anticoagulant multicentre observational study. International Journal of Cardiology, 2019, 281, 56-61		0.8	23

#	Article	IF	CITATIONS
1012	Personalized Medicine in the Treatment of Atrial Fibrillation: Myth or Reality?. Rational Pharmacotherapy in Cardiology, 2019, 15, 90-94.	0.3	2
1013	Obesity Surgery and Anesthesiology Risks: a Review of Key Concepts and Related Physiology. Obesity Surgery, 2019, 29, 2670-2677.	1.1	38
1014	Association of Preoperative Renin-Angiotensin System Inhibitors With Prevention of Postoperative Atrial Fibrillation and Adverse Events. JAMA Network Open, 2019, 2, e194934.	2.8	13
1015	Residual flow may increase the risk of adverse events in patients received combined catheter ablation and transcatheter left atrial appendage closure for nonvalvular atrial fibrillation: a meta-analysis. BMC Cardiovascular Disorders, 2019, 19, 138.	0.7	4
1016	Acute management of atrial fibrillation with rapid ventricular response. British Journal of Hospital Medicine (London, England: 2005), 2019, 80, C82-C85.	0.2	1
1017	Cost-Effectiveness of Cryoballoon Ablation Versus Radiofrequency Ablation for Paroxysmal Atrial Fibrillation in China: Results Based on Real-World Data. Value in Health, 2019, 22, 863-870.	0.1	7
1018	Posterior box isolation as an adjunctive ablation strategy during repeat ablation with the second-generation cryoballoon for recurrence of persistent atrial fibrillation: 1-year follow-up. Journal of Interventional Cardiac Electrophysiology, 2019, 56, 1-7.	0.6	18
1019	Noninvasive peripheral vascular function and atrial fibrillation in the general population. Journal of Hypertension, 2019, 37, 928-934.	0.3	11
1021	Predictors of Left Atrial Thrombi and Spontaneous Echocardiographic Contrast in the Acute Phase After Cardioembolic Stroke in Patients With Atrial Fibrillation. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 1571-1577.	0.7	4
1022	Interaction of obesity and atrial fibrillation: an overview of pathophysiology and clinical management. Expert Review of Cardiovascular Therapy, 2019, 17, 209-223.	0.6	36
1023	PREDICTORS OF MAJOR BLEEDING AMONG ATRIAL FIBRILLATION PATIENTS ON WARFARIN. Asian Journal of Pharmaceutical and Clinical Research, 2019, , 547-550.	0.3	1
1024	Features of Atrial Fibrillation in Patients with Arterial Hypertension and Extracardial Disorders. Rational Pharmacotherapy in Cardiology, 2019, 15, 368-373.	0.3	2
1025	Incidence of atrial fibrillation in different major cancer subtypes: a Nationwide population-based 12 year follow up study. BMC Cancer, 2019, 19, 1105.	1.1	68
1026	Optical Mapping. Cardiac Electrophysiology Clinics, 2019, 11, 495-510.	0.7	10
1027	Non-vitamin K antagonist oral anticoagulants (NOACs) post-percutaneous coronary intervention: a network meta-analysis. The Cochrane Library, 2021, 2021, CD013252.	1.5	8
1028	Pacemaker Lead Endocarditis Investigated with Intracardiac Echocardiography: Factors Modulating the Size of Vegetations and Larger Vegetation Embolic Risk during Lead Extraction. Antibiotics, 2019, 8, 228.	1.5	16
1029	Influence of heart rate control on exercise capacity and quality of life in patients with permanent atrial fibrillation. BMC Cardiovascular Disorders, 2019, 19, 308.	0.7	4
1030	Radiofrequency Catheter Ablation Versus Cryoballoon Ablation in the Treatment of ParoxysmalÂAtrial Fibrillation: A Cost-effectiveness Analysis in China. Clinical Therapeutics, 2019, 41, 78-91.	1.1	12

#	Article	IF	Citations
1031	Cost Implications of Anticoagulation Strategies After Percutaneous Coronary Intervention Among Patients With Atrial Fibrillation (A PIONEER-AF PCI Analysis). American Journal of Cardiology, 2019, 123, 355-360.	0.7	6
1032	Atrial fibrillation history impact on catheter ablation outcome. Findings from the ESCâ€EHRA Atrial Fibrillation Ablation Longâ€Term Registry. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 313-320.	0.5	9
1033	Cardiac valve calcification and use of anticoagulants: Preliminary observation of a potentially modifiable risk factor. International Journal of Cardiology, 2019, 278, 243-249.	0.8	41
1034	Frequent premature atrial contractions are associated with atrial fibrillation, brain ischaemia, and mortality: a systematic review and meta-analysis. Europace, 2019, 21, 698-707.	0.7	38
1035	In-hospital and 12-month follow-up outcome from the ESC-EORP EHRA Atrial Fibrillation Ablation Long-Term registry: sex differences. Europace, 2020, 22, 66-73.	0.7	33
1036	Amyloidosis in surgically resected atrial appendages: a study of 345 consecutive cases with clinical implications. Modern Pathology, 2020, 33, 764-774.	2.9	7
1037	Burden of Premature Atrial Complexes and Risk of Recurrent Stroke and Death in Patients with Mild to Moderate Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104490.	0.7	3
1038	Trends in preadmission oral anticoagulant use and clinical outcome in atrial fibrillation patients admitted with acute stroke in Denmark. European Heart Journal Quality of Care & Clinical Outcomes, 2020, 6, 112-120.	1.8	4
1039	Genome-wide profiling reveals atrial fibrillation-related circular RNAs in atrial appendages. Gene, 2020, 728, 144286.	1.0	28
1040	Atrial Fibrillation: Current Evidence and Management Strategies During the Perioperative Period. Anesthesia and Analgesia, 2020, 130, 2-13.	1.1	18
1041	D-dimer and C-reactive Protein as Potential Biomarkers for Diagnosis of Trousseau's Syndrome in Patients with Cerebral Embolism. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104534.	0.7	24
1042	Protocol, rationale and design of DAbigatran for Stroke PreVention In Atrial Fibrillation in MoDerate or Severe Mitral Stenosis (DAVID-MS): a randomised, open-label study. BMJ Open, 2020, 10, e038194.	0.8	10
1043	The Potential Effects of Aliskiren on Atrial Remodeling Induced by Chronic Intermittent Hypoxia in Rats. Drug Design, Development and Therapy, 2020, Volume 14, 3755-3764.	2.0	2
1044	Clinical classification and the subclinical atrial fibrillation challenge: a position paper of the European Cardiac Arrhythmia Society. Journal of Interventional Cardiac Electrophysiology, 2020, 59, 495-507.	0.6	6
1045	CHA2DS2-VASc Score as a Predictor for Left Atrial Thrombus or Spontaneous Echo Contrast in Patients with Nonvalvular Atrial Fibrillation: A Meta-Analysis. BioMed Research International, 2020, 2020, 1-8.	0.9	5
1046	Increased mortality in patients with secondary diagnosis of atrial fibrillation: Report from Chinese AF registry. Annals of Noninvasive Electrocardiology, 2020, 25, e12774.	0.5	2
1047	Prescription of oral anticoagulants and antiplatelets for stroke prophylaxis in atrial fibrillation: nationwide time series ecological analysis. Europace, 2020, 22, 1311-1319.	0.7	21
1048	Paradigm shifts in pathophysiology and management of atrial fibrillation—aÂtale of the RACE trials in the Netherlands. Netherlands Heart Journal, 2020, 28, 3-12.	0.3	5

#	Article	IF	CITATIONS
1049	Clinically Meaningful Change in Quality of Life and Associated Factors Among Older Patients With Atrial Fibrillation. Journal of the American Heart Association, 2020, 9, e016651.	1.6	4
1050	Atrial fibrillation detection using photoplethysmographic signal: the effect of the observation window. , 2020, 2020, 906-909.		0
1051	Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. New England Journal of Medicine, 2020, 383, 1305-1316.	13.9	1,071
1052	Assessment of the Modified CHA2DS2VASc Risk Score in Predicting Mortality in Patients Hospitalized With COVID-19. American Journal of Cardiology, 2020, 135, 143-149.	0.7	24
1053	What do we do about atrial high rate episodes?. European Heart Journal Supplements, 2020, 22, O42-O52.	0.0	29
1054	Detection of AF and I-AVB combined with RR interval and P wave. , 2020, , .		0
1055	Ten-year follow-up after endocardial point-by-point cryoablation for paroxysmal atrial fibrillation. Acta Cardiologica, 2020, 76, 1-6.	0.3	0
1056	Heterogeneity in Conduction Underlies Obesity-Related Atrial Fibrillation Vulnerability. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008161.	2.1	18
1057	Reduced Stroke Risk among Patients with Atrial Fibrillation Receiving Chinese Herbal Medicines Treatment: Analysis of Domestic Data in Taiwan. Medicina (Lithuania), 2020, 56, 282.	0.8	0
1058	Plasma D-Dimer Level as a Subclinical Marker of Thrombotic Risk in Elderly Patients with Atrial Fibrillation. Advances in Gerontology, 2020, 10, 73-78.	0.1	0
1059	Genetic Burden of Birthweight on Atrial Fibrillation. Circulation Genomic and Precision Medicine, 2020, 13, e002987.	1.6	0
1060	An expert consensus document on the management of cardiovascular manifestations of Fabry disease. European Journal of Heart Failure, 2020, 22, 1076-1096.	2.9	96
1061	Health-Related Quality of Life in Patients With Atrial Fibrillation Treated With Catheter Ablation or Antiarrhythmic Drug Therapy: A Systematic Review and Meta-analysis. CJC Open, 2020, 2, 286-295.	0.7	8
1062	Impact of stand-alone minimally invasive radiofrequency ablation with left atrial appendectomy on left atrial function assessed by echocardiography. Quantitative Imaging in Medicine and Surgery, 2020, 10, 970-978.	1.1	2
1063	Serum uric acid and incident atrial fibrillation: A systematic review and dose–response metaâ€analysis. Clinical and Experimental Pharmacology and Physiology, 2020, 47, 1774-1782.	0.9	14
1064	Dantrolene reduces CaMKIIδC-mediated atrial arrhythmias. Europace, 2020, 22, 1111-1118.	0.7	17
1065	Diagnostic Efficacy of Cardiac Scintigraphy with <sup>99m</sup> Tc-Pyrophosphate for Latent Myocardial Inflammation in Patients with Atrial Fibrillation. Cardiology Research and Practice, 2020, 2020, 1-11.	0.5	4
1066	Dose-response analysis between hemoglobin A1c and risk of atrial fibrillation in patients with and without known diabetes. PLoS ONE, 2020, 15, e0227262.	1.1	12

CITATION REPORT	Сіт	ATION	I Re	PORT
-----------------	-----	-------	------	------

#	Article	IF	CITATIONS
1067	Fiveâ€year outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2020, 31, 621-628.	0.8	14
1068	Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden. European Journal of Clinical Pharmacology, 2020, 76, 525-537.	0.8	3
1069	Thromboembolic and bleeding risk of periprocedural bridging anticoagulation: A systematic review and metaâ€analysis. Clinical Cardiology, 2020, 43, 441-449.	0.7	32
1070	Mortality in patients with intracerebral hemorrhage associated with antiplatelet agents, oral anticoagulants or no antithrombotic therapy. European Journal of Internal Medicine, 2020, 75, 35-43.	1.0	17
1072	Predictors of Postoperative Atrial Fibrillation After Abdominal Surgery and Insights from Other Surgery Types. Research Reports in Clinical Cardiology, 2020, Volume 11, 31-38.	0.2	0
1073	Impact of re-definition of paroxysmal and persistent atrial fibrillation in the 2012 and 2016 European Society of Cardiology atrial fibrillation guidelines on outcomes after pulmonary vein isolation. Journal of Interventional Cardiac Electrophysiology, 2021, 60, 115-123.	0.6	4
1074	Frailty to predict unplanned hospitalization, stroke, bleeding, and death in atrial fibrillation. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 42-51.	1.8	33
1075	Age threshold for anticoagulation in patients with atrial fibrillation: A Swedish nationwide observational study. International Journal of Cardiology, 2021, 326, 92-97.	0.8	1
1076	Automated Atrial Fibrillation Detection using a Hybrid CNN-LSTM Network on Imbalanced ECG Datasets. Biomedical Signal Processing and Control, 2021, 63, 102194.	3.5	158
1077	Biatrial ablation vs. Pulmonary vein isolation in atrial fibrillation patients undergoing cardiac surgery: a retrospective study. Scandinavian Cardiovascular Journal, 2021, 55, 116-121.	0.4	3
1078	Concomitant Use of Direct Oral Anticoagulants and Antiepileptic Drugs: A Prospective Cohort Study in Patients with Atrial Fibrillation. Clinical Drug Investigation, 2021, 41, 43-51.	1.1	18
1079	Costâ€effectiveness of rivaroxaban versus warfarin in nonâ€valvular atrial fibrillation patients with chronic kidney disease in China. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 658-668.	0.7	2
1080	Thromboembolism in Patients with Hypertrophic Cardiomyopathy. International Journal of Medical Sciences, 2021, 18, 727-735.	1.1	5
1081	CHADS2, CHA2DS2-VASc, ATRIA, and Essen stroke risk scores in stroke with atrial fibrillation. Medicine (United States), 2021, 100, e24000.	0.4	7
1082	Perioperative Management of the Cancer Patient. , 2021, , 113-126.		0
1083	Comparison of CryoMaze With Cut-and-Sew Maze Concomitant With Mitral Valve Surgery: A Randomized Noninferiority Trial. Seminars in Thoracic and Cardiovascular Surgery, 2021, 33, 680-688.	0.4	3
1084	Association of the CHA2D(S2)-VASc Score and Its Components With Overt and Silent Ischemic Brain Lesions in Patients With Atrial Fibrillation. Frontiers in Neurology, 2020, 11, 609234.	1.1	2
1085	Alcohol consumption and risk of cardiovascular outcomes and bleeding in patients with established atrial fibrillation. Cmaj, 2021, 193, E117-E123.	0.9	4

#	Article	IF	CITATIONS
1086	Left atrial fibrosis in atrial fibrillation: Mechanisms, clinical evaluation and management. Journal of Cellular and Molecular Medicine, 2021, 25, 2764-2775.	1.6	42
1087	Cost Analysis of a Dedicated Outpatient Clinic in Patients With Newly Diagnosed Atrial Fibrillation. Journal of Cardiovascular Nursing, 2021, Publish Ahead of Print, .	0.6	1
1088	Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation. Europace, 2021, 23, 1033-1041.	0.7	106
1089	Is Screening for Atrial Fibrillation and Its Risk Factors Useful and Cost-Effective?. Cardiac Electrophysiology Clinics, 2021, 13, 235-241.	0.7	1
1090	Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Diagnosis, Clinical Course and Therapy. , 0, , .		0
1091	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation: what is new for neurologists?. Arterial Hypertension (Russian Federation), 2021, 27, 7-15.	0.1	0
1092	Joint Associations Between Body Mass Index and Waist Circumference With Atrial Fibrillation in Men and Women. Journal of the American Heart Association, 2021, 10, e019025.	1.6	11
1093	Association of cardiovascular health and incident atrial fibrillation in elderly population. Heart, 2021, 107, 1206-1212.	1.2	8
1094	Predictors of sinus rhythm 6 weeks after cardioversion of atrial fibrillation: a pre-planned post hoc analysis of the X-VeRT trial. Europace, 2021, 23, 1539-1547.	0.7	1
1096	Giant androgen-producing adrenocortical carcinoma with atrial flutter: A case report and review of the literature. World Journal of Clinical Cases, 2021, 9, 5575-5587.	0.3	1
1097	Serum Beta-2 Microglobulin: A Possible Biomarker for Atrial Fibrillation. Medical Science Monitor, 2021, 27, e932813.	0.5	1
1098	2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology, 2021, 26, 4594.	0.4	89
1099	Evolution of Antithrombotic Management of Atrial Fibrillation After Percutaneous Coronary Intervention Over 10 Years and Guidelines Uptake. CJC Open, 2021, 3, 1025-1032.	0.7	3
1100	Smartwatch monitoring for atrial fibrillation after stroke—The Pulsewatch Study: Protocol for a multiphase randomized controlled trial. Cardiovascular Digital Health Journal, 2021, 2, 231-241.	0.5	14
1101	Clinical value of the combined use of P-wave dispersion and troponin values to predict atrial fibrillation recurrence in patients with paroxysmal atrial fibrillation. Revista Portuguesa De Cardiologia, 2021, 40, 679-684.	0.2	2
1102	Current Recommendations on Atrial Fibrillation: A Comparison of the Recent European and Canadian Guidelines. Cardiology, 2022, 147, 81-89.	0.6	1
1103	Factors associated with poor prognosis in patients with atrial fibrillation: An emergency department perspective the EMERG-AF study. American Journal of Emergency Medicine, 2021, 50, 270-277.	0.7	3
1104	Initial rhythm control with cryoballoon ablation vs drug therapy: Impact on quality of life and symptoms. American Heart Journal, 2021, 242, 103-114.	1.2	10

#	Article	IF	CITATIONS
1105	Oral Manifestations of Systemic Diseases and their Treatments. , 2018, , 1-117.		4
1106	Considerations in Thyrotropin-Stimulating Hormone Suppression in Individuals with Differentiated Thyroid Cancer. , 2017, , 223-232.		1
1108	Publisher's note. European Heart Journal, 2015, 36, 2880-5.	1.0	25
1109	Long-term observation of catheter ablation vs. pharmacotherapy in the management of persistent and long-standing persistent atrial fibrillation (CAPA study). Europace, 2021, 23, 731-739.	0.7	19
1110	A thrombus of the right upper pulmonary vein: detection by the use of a 64-MDCT. BMJ Case Reports, 2012, 2012, bcr1220115446-bcr1220115446.	0.2	18
1111	New European guidelines on atrial fibrillation. BMJ: British Medical Journal, 2011, 342, d897-d897.	2.4	4
1112	Management of tachyarrhythmias in pregnancy – A review. Obstetric Medicine, 2020, 13, 159-173.	0.5	5
1113	Catheter ablation of atrial fibrillation in the elderly. Journal of Geriatric Cardiology, 2014, 11, 291-5.	0.2	16
1114	Prevalence of atrial fibrillation in Thai elderly. Journal of Geriatric Cardiology, 2016, 13, 270-3.	0.2	16
1115	Dual versus single antiplatelet therapy for patients with long-term oral anticoagulation undergoing coronary intervention: a systematic review and meta-analysis. Journal of Geriatric Cardiology, 2017, 14, 725-736.	0.2	2
1116	Doxycycline Attenuates Atrial Remodeling by Interfering with MicroRNA-21 and Downstream Phosphatase and Tensin Homolog (PTEN)/Phosphoinositide 3-Kinase (PI3K) Signaling Pathway. Medical Science Monitor, 2018, 24, 5580-5587.	0.5	16
1117	The Association Between the Use of Antiarrhythmic Drugs in Non-Valvular Atrial Fibrillation and Patient Prognosis Using Data from the China Atrial Fibrillation (China-AF) Registry. Medical Science Monitor, 2019, 25, 4856-4868.	0.5	3
1118	Considerations for routine coagulation monitoring with rivaroxaban: A case report and review of the literature. World Journal of Clinical Cases, 2019, 7, 382-388.	0.3	1
1119	Continuation of Dabigatran Therapy in "Real-World―Practice in Hong Kong. PLoS ONE, 2014, 9, e101245.	1.1	36
1120	Effects of Radiofrequency Catheter Ablation of Atrial Fibrillation on Soluble P-Selectin, Von Willebrand Factor and IL-6 in the Peripheral and Cardiac Circulation. PLoS ONE, 2014, 9, e111760.	1.1	18
1121	Effect of Chronic Kidney Diseases on Mortality among Digoxin Users Treated for Non-Valvular Atrial Fibrillation: A Nationwide Register-Based Retrospective Cohort Study. PLoS ONE, 2016, 11, e0160337.	1.1	26
1122	Atrial Fibrillation and Cardiovascular Comorbidities, Survival and Mortality: A Real-Life Observational Study. Cardiology Research, 2014, 5, 12-22.	0.5	4
1123	Use of the CHA 2 DS 2 VASc score to reduce utilisation of transoesophageal echocardiography prior to ablation for atrial fibrillation. Journal of Animal Science and Technology, 2017, 4, 45-52.	0.8	4

#	Article	IF	CITATIONS
1124	A Survey of Direct Oral Anticoagulant Cessation in General Surgery and Outcomes in Patients with Nonvalvular Atrial Fibrillation. International Heart Journal, 2020, 61, 905-912.	0.5	6
1125	The Role of Continuous Monitoring in Atrial Fibrillation Management. Arrhythmia and Electrophysiology Review, 2014, 3, 48-50.	1.3	10
1126	Anticoagulation in Atrial Fibrillation. Arrhythmia and Electrophysiology Review, 2012, 1, 12.	1.3	2
1127	Catheter Ablation of Atrial Fibrillation – Techniques and Technology. Arrhythmia and Electrophysiology Review, 2012, 1, 29.	1.3	4
1128	Relevance of Monitoring Atrial Fibrillation in Clinical Practice. Arrhythmia and Electrophysiology Review, 2012, 1, 54.	1.3	5
1129	The Future of Pulmonary Vein Isolation – Single-shot Devices, Remote Navigation or Improving Conventional Radiofrequency Delivery by Contact Monitoring and Lesion Characterisation?. Arrhythmia and Electrophysiology Review, 2013, 2, 59.	1.3	2
1130	Natriuretic Peptides as Predictors of Atrial Fibrillation Recurrences Following Electrical Cardioversion. Arrhythmia and Electrophysiology Review, 2013, 2, 109.	1.3	12
1131	The European Heart Rhythm Association Practical Guide on the Use of New Oral Anticoagulants in Patients with Non-valvular Atrial Fibrillation – A Brief Summary. Arrhythmia and Electrophysiology Review, 2013, 2, 115.	1.3	2
1132	Current Predictors of Atrial Fibrillation Progression. Rational Pharmacotherapy in Cardiology, 2019, 15, 149-158.	0.3	4
1133	Which Method to Use for Surgical Ablation of Atrial Fibrillation Performed Concomitantly with Mitral Valve Surgery: Radiofrequency Ablation versus Cryoablation. Brazilian Journal of Cardiovascular Surgery, 2018, 33, 542-552.	0.2	6
1134	Biomarkers Associated with Stroke Risk in Atrial Fibrillation. Current Medicinal Chemistry, 2019, 26, 803-823.	1.2	11
1135	Biomarkers Associated with Bleeding Risk in the Setting of Atrial Fibrillation. Current Medicinal Chemistry, 2019, 26, 824-836.	1.2	4
1136	Biomarkers in Atrial Fibrillation and Heart Failure. Current Medicinal Chemistry, 2019, 26, 873-887.	1.2	46
1137	Dual-chamber pacemakers for treating symptomatic bradycardia due to sick sinus syndrome without atrioventricular block: a systematic review and economic evaluation. Health Technology Assessment, 2015, 19, 1-210.	1.3	15
1138	Atrial fibrillation in the elderly. Journal of Geriatric Cardiology, 2012, 9, 91-100.	0.2	14
1139	2018 KHRS Guidelines for Stroke Prevention Therapy in Korean Patients with Nonvalvular Atrial Fibrillation. Korean Journal of Medicine, 2018, 93, 87-109.	0.1	8
1141	Left atrial appendage exclusion-Where do we stand?. Journal of Thoracic Disease, 2014, 6 Suppl 1, S70-7.	0.6	13
1142	Effectiveness and safety of simultaneous hybrid thoracoscopic and endocardial catheter ablation of lone atrial fibrillation. Annals of Cardiothoracic Surgery, 2014, 3, 38-44.	0.6	68

#	Article	IF	CITATIONS
1143	Structured care of patients with atrial fibrillation improves guideline adherence. Journal of Atrial Fibrillation, 2016, 9, 1498.	0.5	2
1144	Effects of Computerized Decision Support Systems on Management of Atrial Fibrillation: A Scoping Review. Journal of Atrial Fibrillation, 2017, 10, 1579.	0.5	7
1145	Beating-heart Thoracoscopic Left Atrial Appendage Exclusion in a Patient with Left atrial Thrombus. Journal of Atrial Fibrillation, 2017, 10, 1630.	0.5	2
1146	Atrial fibrillation in heart failure: The sword of damocles revisited. World Journal of Cardiology, 2013, 5, 215.	0.5	21
1147	Left atrial appendage occlusion: A better alternative to anticoagulation?. World Journal of Cardiology, 2017, 9, 139.	0.5	8
1148	Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland. Swiss Medical Weekly, 2013, 143, w13732.	0.8	20
1149	Recent Progress in Antithrombotic Therapy for Atrial Fibrillation. Journal of Atherosclerosis and Thrombosis, 2011, 18, 257-273.	0.9	3
1150	Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome in the real world: Data from the Berlin AFibACS Registry. Cardiology Journal, 2014, 21, 465-473.	0.5	12
1151	Left atrial appendage closure with the Amplatzerâ,,¢ Cardiac Plug: Rationale for a higher degree of device oversizing at implantation. Cardiology Journal, 2015, 22, 201-205.	0.5	5
1152	Management of patients with valvular and non-valvular atrial fibrillation in Poland: Results from Reference Cardiology University Center. Cardiology Journal, 2015, 22, 296-305.	0.5	3
1154	Contemporary echocardiographic assessment of atrial appendages in non-valvular atrial fibrillation. Kardiologia Polska, 2015, 73, 701-710.	0.3	4
1155	Prediction of mid-term outcome after cryo-balloon ablation of atrial fibrillation using post-procedure high-sensitivity troponin level. Cardiovascular Journal of Africa, 2015, 26, 165-170.	0.2	18
1156	Predictors of Atrial Fibrillation Recurrence in Hyperthyroid and Euthyroid Patients. Arquivos Brasileiros De Cardiologia, 2016, 106, 84-91.	0.3	7
1157	Novel GATA5 loss-of-function mutations underlie familial atrial fibrillation. Clinics, 2012, 67, 1393-1399.	0.6	30
1158	Association of Left Atrial Appendage Voltage with Ischemic Stroke in Patients with Atrial Fibrillation. Acta Cardiologica Sinica, 2019, 35, 592-599.	0.1	5
1159	Screening for paroxysmal atrial fibrillation in primary care using Holter monitoring and intermittent, ambulatory single-lead electrocardiography. International Journal of Cardiology, 2021, 345, 41-46.	0.8	9
1160	Acidente Vascular Encefálico: uma revisão de escopo. Research, Society and Development, 2021, 10, e33101319904.	0.0	1
1161	Hypertensive Heart Failure in Asia. Pulse, 2021, 9, 47-56.	0.9	5

	CITATION REI	PORT	
#	Article	IF	CITATIONS
1162	éžè−¬ç‰©ç™,法ã«ã,^ã,‹å¿fæ^;ç°å‹•æ¹æ²»ã®é‡è¦æ€§. Japanese Journal of Electrocardiology, 2011, 31, 134-1:	300.0	0
1163	2.åįfä,ů¨ã«ä¼´ã†åįfæ^;ç°å«ã®æ²»ç™,æ^¦ç•¥. Japanese Journal of Electrocardiology, 2011, 31, 346-355.	0.0	0
1164	Explorations électrophysiologiques. , 2011, , 299-309.		0
1166	Antiarrhythmic drugs for maintaining of sinus rhythm. Interventional Medicine & Applied Science, 2011, 3, 116-119.	0.2	0
1169	Prevention of thromboembolic complications of atrial fibrillation: Current aspects and perspective. Srce I Krvni Sudovi, 2012, 31, 68-76.	0.1	1
1171	13 Atriumfibrilleren. , 2013, , 167-176.		0
1172	Digitalis. Journal of the Nihon University Medical Association, 2013, 72, 252-253.	0.0	0
1173	Plasma natriuretic peptides during supraventricular tachycardia: A study in patients with atrioventricular nodal reentry tachycardia. World Journal of Cardiovascular Diseases, 2013, 03, 471-475.	0.0	0
1174	Evaluation of factors affecting persistence of atrial fibrillation in patients with concomitant atrial flutter treated with percutaneous radiofrequency current ablation of the right atrial cavotricuspid isthmus. Kardiologia Polska, 2013, 71, 247-252.	0.3	1
1176	Surgical Minimally Invasive Pulmonary Vein Isolation for Lone Atrial Fibrillation. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2013, 8, 410-415.	0.4	0
1177	Atrial Fibrillation Ablation: From Guidelines to Clinical Reality. , 2014, , 419-438.		0
1180	Diabetische Folgeerkrankungen. , 2014, , 239-296.		0
1181	Atrial Fibrillation in Decompensated Heart Failure: Associated Factors and In-Hospital Outcome. Arquivos Brasileiros De Cardiologia, 2014, 103, 315-22.	0.3	12
1182	Anticoagulant Treatment Strategies for Atrial Fibrillation. , 2014, , 37-47.		0
1184	Atrial Fibrillation and Related Disorders. , 2015, , 227-239.		1
1187	Atrial Arrhythmias Associated with J Wave Syndromes. , 2016, , 245-258.		0
1188	Initial outcome following invasive cardiac electrophysiologic studies and radiofrequency ablation of atrial fibrillation. International Journal of Applied & Basic Medical Research, 2016, 6, 90.	0.2	0
1189	Common Postoperative and Inpatient Issues. , 2016, , 343-370.		0

#	ARTICLE Procedural arrhythmia termination during beating-heart, stand-alone surgical ablation and long-term	IF	CITATIONS
1190	outcome in patients with persistent atrial fibrillation. Seminars in Cardiovascular Medicine, 2016, 22, 1-6.	0.3	0
1195	Chapter 3. The culture of Japanese medicine. , 2016, , 23-28.		0
1197	Chapter 8. Characteristics of the Japanese healthcare system. , 2016, , 69-82.		0
1199	Treatment of Neurological Disorders. , 2017, , 291-327.		1
1200	Arrhythmias in Special Populations. Cardiovascular Medicine, 2017, , 287-297.	0.0	0
1201	Tachyarrhythmien. , 2017, , 239-254.		0
1202	Kardiologie. , 2017, , 61-143.		0
1203	Surveillance of Treated Thyroid Cancer Patients and Thyroid Hormone Replacement and Suppression. , 2017, , 331-350.		0
1206	EFFICIENCY AND SAFETY OF RADIOFREQUENCY CATHETER ABLATION OF ATRIAL FIBRILLATION IN ELDERLY PATIENTS. Journal of Clinical Practice, 2017, 8, 34-41.	0.2	0
1207	GYDYMO VARFARINU SITUACIJA PIRMINĖS SVEIKATOS PRIEŽIŪROS GRANDYJE. Health Sciences, 2017, 27, 43	- <b>4</b> 80	1
1208	Non-medication Treatment of Atrial Fibrillation. International Journal of Arrhythmia, 2017, 18, 143-147.	0.3	0
1209	Mid-Term Results of Surgical Treatment of Atrial Fibrillation in Valvular Heart Disease Assesed by Speckle Tracking Echocardiography. Arquivos Brasileiros De Cardiologia, 2018, 110, 312-320.	0.3	0
1210	Incidence and characteristics of major bleeding among rivaroxaban users with renal disease and nonvalvular atrial fibrillation. Clinical and Experimental Emergency Medicine, 2018, 5, 43-50.	0.5	1
1211	Atrial Fibrillation a Benign Condition? Quality of Life Approach. Central European Journal of Clinical Research, 2018, 1, 67-75.	0.3	0
1212	Vitamin D as a predictor of arrhythmia recurrence after balloon cryoablation. Gazzetta Medica Italiana Archivio Per Le Scienze Mediche, 2018, 177, .	0.0	0
1213	Akut miyokard infarktÃ1⁄4sÃ1⁄4nde yeni geliÅŸen atriyal fibrilasyon ile SYNTAX skoru arasındaki iliÅŸki. SdÜ SaÄ Bİlİmlerİ Dergİsİ, 2018, 9, 7-14.	žlik 0.1	1
1214	Correlations between acute atrial fibrillation and local earth magnetic field strength. Journal of Complexity in Health Sciences, 2018, 1, 31-41.	0.5	2
1215	Association Between Chromosome 4Q25 Polymorphism RS2200733 and the Incidence of Atrial Fibrillation in Bulgarian Patients. Journal of Biomedical and Clinical Research, 2018, 11, 118-122.	0.1	0

#	Article	IF	CITATIONS
1216	Arrhythmia. , 2019, , 185-200.		0
1217	Optimal choice of pharmacological therapy – Prevention of stroke and assessment of bleeding risk in patients with atrial fibrillation. International Journal of Preventive Medicine, 2019, 10, 85.	0.2	0
1218	Clinical Significance of Skin Autofluorescence in Elderly Patients With Long-Standing Persistent Atrial Fibrillation. Cardiology Research, 2019, 10, 181-187.	0.5	2
1220	Haldun Muderrisoglu 2 1 Department of Cardiology, BaÅŸkent University School of Medicine, Ankara Hospital, Ankara, Turkey 2 Department of Cardiology, BaÅŸkent University School of Medicine, Ankara Hospital, Ankara, Turkey 3 Department of Cardiology, BaÅŸkent University School of Medicine, Adana Hospital, Adana, Turkey Eurasian I Med 2019: 51: 164-170 DOI: 10.5152/eurasianimed.2019.18342 Key Word.	0.2	3
1221	Eurasian Journal of Medicine, 2019, 51, 164-170. Antiarrhythmic Medications. , 2020, , 305-333.		0
1222	Antiarrhythmic drug therapy after atrial fibrillation ablation: data of the ESC-EHRA registry. Russian Journal of Cardiology, 2020, 25, 3874.	0.4	3
1223	THROMBUS OF LEFT ATRIUM AND/OR ITS APPENDAGE IN CASE OF NONVALVULAR ATRIAL FIBRILLATION: FREQUENCY OF DETECTION AND CLINICAL RISK FACTORS. Atherothrombosis, 2020, , 68-79.	0.1	5
1224	Association between acute heart failure and major cardiovascular events in atrial fibrillation patients presenting at the emergency department: an EMERG-AF ancillary study. European Journal of Emergency Medicine, 2021, 28, 210-217.	0.5	0
1225	ASSOCIATION OF RS2200733 POLYMORPHISM WITH ANTIARRHYTHMIC THERAPY AND PROGRESSION OF ATRIAL FIBRILLATION IN THE UZBEK POPULATIO. Eurasian Heart Journal, 2020, , 30-37.	0.2	0
1226	The Effect of Atrial Fibrillation on Inpatient Outcomes of Patients with Acute Pancreatitis: A Two-year National Inpatient Sample Database Study. Journal of Innovations in Cardiac Rhythm Management, 2020, 11, 4338-4344.	0.2	6
1227	NEW METHODS FOR PREDICTING OUTCOMES AND COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION. Journal of Arrhythmology, 2019, 26, 45-50.	0.1	0
1228	Devices for continuous embolic protection. , 2020, , 979-1005.		0
1229	Arrhythmias During Pregnancy and Postpartum. Contemporary Cardiology, 2020, , 645-669.	0.0	0
1230	Kardiologie. , 2020, , 71-157.		0
1231	To Study the Risk Factors for Atrial Fibrillation and the Relation Between Cardiac Symptoms with Left Atrial Area on Echocardiography. Journal of Evidence Based Medicine and Healthcare, 2020, 7, 455-459.	0.0	0
1232	Right Atrial Thrombosis and Pulmonary Embolism: A Narrative Review. Seminars in Thrombosis and Hemostasis, 2020, 46, 895-907.	1.5	7
1233	New approaches for predicting outcomes in patients with atrial fibrillation. Journal of Arrhythmology, 0, 27, 28-32.	0.1	0
1234	Unsuitable Comparison. Deutsches Ärzteblatt International, 2020, 117, 752-753.	0.6	Ο

#	Article	IF	CITATIONS
1235	A CHADS(2) score of zero is not necessarily associated to a low risk of thromboembolic events. American Journal of Cardiovascular Disease, 2012, 2, 150-1.	0.5	0
1236	Anticoagulants for stroke prevention in nonvalvular atrial fibrillation: new agents and an updated understanding. Texas Heart Institute Journal, 2012, 39, 517-25.	0.1	1
1237	Heart failure in elderly: progress in clinical evaluation and therapeutic approach. Journal of Geriatric Cardiology, 2013, 10, 165-77.	0.2	9
1238	Atrial fibrillation anticoagulation care in a large urban family medicine practice. Canadian Family Physician, 2014, 60, e173-9.	0.1	6
1239	Major themes for 2013 in cardiothoracic and vascular anaesthesia and intensive care. Heart, Lung and Vessels, 2014, 6, 79-87.	0.4	1
1240	Atrial fibrillation (acute onset). Clinical Evidence, 2014, 2014, .	0.2	0
1241	Inappropriate use of digoxin in patients presenting with digoxin toxicity. Journal of Geriatric Cardiology, 2015, 12, 143-6.	0.2	3
1242	Is dabigatran efficacy enough to prevent stroke in atrial fibrillation patient with high CHADS2 score during peri-procedural catheter radiofrequency ablation? A case report with literature review. International Journal of Clinical and Experimental Medicine, 2015, 8, 6592-600.	1.3	1
1243	KCNA5 gene polymorphism associate with idiopathic atrial fibrillation. International Journal of Clinical and Experimental Medicine, 2015, 8, 9890-6.	1.3	4
1244	The Effects of Ranolazine on Paroxysmal Atrial Fibrillation in Patients with Coronary Artery Disease: A Preliminary Observational Study. Journal of Atrial Fibrillation, 2014, 6, 940.	0.5	2
1245	Atrial Fibrillation in Athletes: The Role of Exercise. Journal of Atrial Fibrillation, 2014, 6, 1004.	0.5	1
1246	EHRA(European Heart Rhythm Association) EP-Wires Surveys: What Is Common Practice In Device Management?. Journal of Atrial Fibrillation, 2014, 7, 1115.	0.5	0
1247	Emergency Department Readmission in Elderly Patients After Acute Rhythm or Rate Control Treatment for Atrial Fibrillation. Journal of Atrial Fibrillation, 2016, 9, 1387.	0.5	0
1248	Efficacy And Safety Of Implantable Loop Recorder: Experience Of A Center. Journal of Atrial Fibrillation, 2016, 9, 1425.	0.5	7
1249	Systolic and Diastolic Function by Tissue Doppler Imaging Predicts Mortality in Patients with Atrial Fibrillation. Journal of Atrial Fibrillation, 2015, 8, 1241.	0.5	1
1250	Complications From Left Atrial Appendage Exclusion Devices. Journal of Atrial Fibrillation, 2014, 7, 1034.	0.5	13
1251	Atrioventricular Junction Ablation In Atrial Fibrillation: Choosing The Right Patient And Pacing Device. Journal of Atrial Fibrillation, 2015, 8, 1253.	0.5	1
1252	Elimination Of Triggers Without An Additional Substrate Modification Is Not Sufficient In Patients With Persistent Atrial Fibrillation. Journal of Atrial Fibrillation, 2015, 7, 1207.	0.5	2

#	ARTICLE Comparing Safety and Efficacy of Irrigated Radiofrequency Catheter Ablation Versus Combined	IF	CITATIONS
1253	Cryoballoon and Catheter Ablation for Persistent Atrial Fibrillation. Journal of Atrial Fibrillation, 2013, 6, 924.	0.5	1
1254	Quinidine for Pharmacological Cardioversion of Long-lasting Atrial Fibrillation. Journal of Atrial Fibrillation, 2011, 4, 350.	0.5	0
1255	Catheter Ablation of Atrial Fibrillation in Patients with Hardware in the Heart - Septal Closure Devices, Mechanical Valves and More. Journal of Atrial Fibrillation, 2013, 6, 851.	0.5	0
1256	Comparing Antiarrhythmic Drugs and Catheter Ablation for Treatment of Atrial Fibrillation. Journal of Atrial Fibrillation, 2013, 6, 861.	0.5	1
1257	Catheter Ablation of Atrial Fibrillation in Females. Journal of Atrial Fibrillation, 2013, 6, 893.	0.5	1
1258	Cost-Effective Medicines for Stroke Prophylaxis in Patients with Atrial Fibrillation. Journal of Atrial Fibrillation, 2012, 5, 470.	0.5	0
1259	Transient ST Elevation in Vagally Mediated Atrial Fibrillation. Journal of Atrial Fibrillation, 2012, 5, 487.	0.5	2
1260	Prevention of Stroke in Patients With Atrial Fibrillation. Journal of Atrial Fibrillation, 2011, 4, 447.	0.5	0
1261	Catheter Ablation of Atrial Fibrillation in Overweight and Obese Patients. Journal of Atrial Fibrillation, 2011, 4, 1216.	0.5	2
1262	Primary Prevention of Atrial Fibrillation - The Path Untread. Journal of Atrial Fibrillation, 2013, 5, 567.	0.5	0
1263	Catheter Ablation of Long Standing Persistent Atrial Fibrillation: Lessons Learned. Journal of Atrial Fibrillation, 2013, 5, 680.	0.5	1
1264	Primary Prevention of Atrial Fibrillation where are we in 2012?. Journal of Atrial Fibrillation, 2012, 5, 608.	0.5	3
1265	Atrial Remodelling : Role in Atrial Fibrillation Ablation. Journal of Atrial Fibrillation, 2012, 5, 691.	0.5	1
1266	Post-operative Atrial Fibrillation - Pathophysiology, Treatment and Prevention. Journal of Atrial Fibrillation, 2013, 5, 781.	0.5	7
1267	Atrial Fibrillation and Oral Anticoagulation in Chronic Kidney Disease. Journal of Atrial Fibrillation, 2012, 4, 445.	0.5	1
1268	Diabetes, Obesity and Atrial Fibrillation: Epidemiology, Mechanisms and Interventions. Journal of Atrial Fibrillation, 2013, 6, 869.	0.5	3
1269	The Association between CHADS-VASc Score and Mortality in Patients with Heart Failure with Reduced Ejection Fraction. Acta Cardiologica Sinica, 2017, 33, 429-435.	0.1	8
1270	Should atrial fibrillation patients with hypertension as an additional risk factor of the CHA2DS2-VASc score receive oral anticoagulation?. Journal of Geriatric Cardiology, 2018, 15, 229-234.	0.2	2

	С	CITATION REPORT	
#	Article	IF	CITATIONS
1271	Lichen extracts regulate the expression of BMP7 via miR-194-5p targeting to decrease the risk atrial fibrillation. International Journal of Clinical and Experimental Pathology, 2017, 10, 9092-9103.	0.5	0
1272	Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis. JACC: CardioOncology, 2021, 3, 619-634.	1.7	49
1274	Atrial Fibrillation Ablation Using Robotic Magnetic Navigation Reduces the Incidence of Silent Cerebral Embolism. Frontiers in Cardiovascular Medicine, 2021, 8, 777355.	1.1	5
1275	Risk of atrial fibrillation in patients with pneumonia. Heart and Lung: Journal of Acute and Critical Care, 2022, 52, 110-116.	0.8	2
1276	Leukocyte Telomere Length Predicts Progression From Paroxysmal to Persistent Atrial Fibrillation in the Long Term After Catheter Ablation. Frontiers in Cardiovascular Medicine, 2021, 8, 813390.	1.1	5
1277	2019 Chinese expert consensus statement on left atrial appendage closure in patients with atrial fibrillation. PACE - Pacing and Clinical Electrophysiology, 2022, 45, 535-555.	0.5	6
1278	Arrhythmias in Pregnancy. JACC: Clinical Electrophysiology, 2022, 8, 120-135.	1.3	31
1279	Low-voltage potentials contribute to postoperative atrial fibrillation development in obese patients. Heart Rhythm, 2022, 19, 710-718.	0.3	2
1280	Sex-specific differences in adverse outcome events among patients with atrial fibrillation. Heart, 2022 108, 1445-1451.	2, 1.2	3
1281	Ischemic Stroke Severity and Mortality in Patients With and Without Atrial Fibrillation. Journal of the American Heart Association, 2022, 11, e022638.	1.6	16
1284	Association between red blood cell distribution width and non-valvular atrial fibrillation in hemodialysis patients: a single-center Chinese population study. Renal Failure, 2022, 44, 62-69.	0.8	1
1285	Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry. European Journal of Internal Medicine, 2022, 99, 45-56.	1.0	5
1286	Socioeconomic and geographic differences in ablation of atrial fibrillation in Norway - a national cohort study. BMC Public Health, 2022, 22, 303.	1.2	9
1287	Association Between Inappropriately Dosed Anticoagulation Therapy With Stroke Severity and Outcomes in Patients With Atrial Fibrillation. Journal of the American Heart Association, 2022, 11, e024402.	1.6	1
1288	Evoked and transmitted culture models: Using bayesian methods to infer the evolution of cultural traits in history. PLoS ONE, 2022, 17, e0264509.	1.1	1
1289	Worldwide trends in oral anticoagulant use in patients with atrial fibrillation from 2010 to 2018: a systematic review and meta-analysis. Europace, 2022, 24, 887-898.	0.7	40
1290	NT Proâ€BNP can be used as a risk predictor of clinical atrial fibrillation with or without left atrial enlargement. Clinical Cardiology, 2022, 45, 68-74.	0.7	11
1291	Association of pulmonary vein isolation and major cardiovascular events in patients with atrial fibrillation. Clinical Research in Cardiology, 2022, , 1.	1.5	1

#	Article	IF	CITATIONS
1319	Temporal Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients between 2004 and 2019. International Journal of Environmental Research and Public Health, 2022, 19, 5584.	1.2	1
1320	Novel-Dataset Based Electrocardiogram Diagnosis of Atrial Fibrillation with Deep Learning: A Prospective Study. SSRN Electronic Journal, 0, , .	0.4	0
1323	Use of heart rate for guiding exercise training in patients with atrial fibrillation. Journal of Sports Medicine and Physical Fitness, 0, , .	0.4	0
1324	Length of stay and cost of care associated with admissions for atrial fibrillation among patients with cancer. BMC Cardiovascular Disorders, 2022, 22, .	0.7	1
1325	Atrial Fibrillation and Stroke. , 0, , .		0
1326	Review of Processing Pathological Vectorcardiographic Records for the Detection of Heart Disease. Frontiers in Physiology, 0, 13, .	1.3	7
1327	AFA-Recur: an ESC EORP AFA-LT registry machine-learning web calculator predicting atrial fibrillation recurrence after ablation. Europace, 2023, 25, 92-100.	0.7	12
1328	Ventilatory efficiency is superior to peak oxygen uptake for prediction of lung resection cardiovascular complications. PLoS ONE, 2022, 17, e0272984.	1.1	6
1329	Wenn das Auto den Arzt ersetzt: Medizinisches und ökonomisches Potential von Automotive Health. , 2022, , 73-82.		0
1330	Impact of anti-arrhythmic drugs and catheter ablation on the survival of patients with atrial fibrillation: a population study based on 199 433 new-onset atrial fibrillation patients in the UK. Europace, 2023, 25, 351-359.	0.7	5
1331	Hospital outcomes of patients receiving catheter ablation of atrial fibrillation, left atrial appendage closure, or both. Journal of Interventional Cardiac Electrophysiology, 0, , .	0.6	0
1332	Bilateral Renal Artery Thromboembolism During Thrombolytic Therapy for Embolism-Induced Acute Limb Ischemia. JACC: Case Reports, 2022, 4, 1256-1262.	0.3	0
1334	Does types of atrial fibrillation matter in the impairment of global and regional left ventricular mechanics and intra-ventricular dyssynchrony?. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
1335	Visit-to-visit SBP variability and risk of atrial fibrillation in middle-aged and older populations. Journal of Hypertension, 2022, 40, 2521-2527.	0.3	1
1336	Foreword to this edition. , 2022, , xxix-xxxii.		0
1337	External cardioversion of atrial fibrillation and flutter in patients with cardiac implantable electrical devices. PACE - Pacing and Clinical Electrophysiology, 0, , .	0.5	1
1338	Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST-AFNET 4 trial. Lancet Neurology, The, 2023, 22, 45-54.	4.9	15
1339	Gastrointestinal bleeding during anticoagulation with direct oral anticoagulants compared to vitamin K antagonists. Global Cardiology Science & Practice, 2022, 2022, .	0.3	0

;	#	Article	IF	CITATIONS
	1340	Gender Differences in Atrial Fibrillation: From the Thromboembolic Risk to the Anticoagulant Treatment Response. Medicina (Lithuania), 2023, 59, 254.	0.8	0
	1341	Matrix Metalloproteinases in Cardioembolic Stroke: From Background to Complications. International Journal of Molecular Sciences, 2023, 24, 3628.	1.8	3
:	1342	High prevalence of incidental endoscopic findings at routine endoscopy after atrial fibrillation ablation: Do we need a screening endoscopy for the upper gastrointestinal tract in the general population?. European Journal of Internal Medicine, 2023, 111, 54-62.	1.0	0
	1343	Remodeling of the Left Atrium and the Possibility of Predicting Recurrences of Atrial Fibrillation in Various Variants of Sinus Rhythm Restoration. , 2023, 2, 29-42.		1
:	1344	Maskeli Hipertansiyon ve P Dalga Dispersiyonu Arasındaki İlişkinin Değerlendirilmesi. Harran Üniversitesi Tıp Fakültesi Dergisi, 0, , 25-30.	0.1	0
	1356	Management of Cardiovascular Disease in Chronic Kidney Disease. , 2023, , 171-197.		0